

# BMJ Open

## Conflicts of interest and bias in reviews of psychological therapies: A systematic review

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2015-010606
Article Type:	Research
Date Submitted by the Author:	19-Nov-2015
Complete List of Authors:	Lieb, Klaus; University Medical Center Mainz, Psychiatry and Psychotherapy Osten Sacken, Jan; University Medical Center Mainz, Psychiatry and Psychotherapy Stoffers-Winterling, Jutta; University Medical Center Mainz, Psychiatry and Psychotherapy Reiss, Neele; Goethe University, Differential Psychology and Psychological Assessment Barth, Juergen; University of Bern,
<b>Primary Subject Heading</b>:	Medical publishing and peer review
Secondary Subject Heading:	Ethics, Medical publishing and peer review, Research methods, Pharmacology and therapeutics
Keywords:	Bias, psychotherapy, conflict of interest, systematic review

SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5 **Conflicts of interest and bias in reviews of psychological therapies: A systematic**  
6 **review**  
7

8  
9  
10 Submission to BMJ Open  
11

12  
13  
14 Klaus Lieb, Jan von der Osten-Sacken, Jutta Stoffers-Winterling, Neele Reiss, Jürgen  
15 Barth  
16

17  
18  
19 Department of Psychiatry and Psychotherapy, University Medical Center Mainz, Untere Zahlbacher Str. 8,  
20 55131 Mainz, Germany Klaus Lieb full professor, Jan von der Osten-Sacken cand. med., Jutta Stoffers-  
21 Winterling psychologist Department of Psychiatry and Psychotherapy, University Medical Center Mainz,  
22 Untere Zahlbacher Str. 8, 55131 Mainz, Germany Neele Reiss assistant professor, Department of  
23 Differential Psychology and Psychological Assessment, Goethe-University Frankfurt, Theodor-W.-Adorno-  
24 Platz 1, 60629 Frankfurt am Main, Germany Jürgen Barth research director Institute for Complementary  
25 and Integrative Medicine, University Hospital Zurich and University Zurich, Sonneggstr. 6, 8006 Zurich,  
26 Switzerland  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36

37 **Corresponding author:**

38 Univ.-Prof. Dr. Klaus Lieb

39 klaus.lieb@unimedizin-mainz.de

40 Phone +49 6131 17-7335

41 Fax +49 6131 229974

42 www.unimedizin-mainz.de/psychiatrie  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Abstract

**Objective** To explore conflicts of interest (COI) and their reporting in systematic reviews of psychological therapies and to evaluate whether these COI are reflected in biased conclusions of the reviews.

**Design** Cohort study of systematic Reviews, searched in MEDLINE and PsycINFO.

**Methods** Databases were searched for systematic reviews that assessed effects of psychological therapies for anxiety, depressive or personality disorders, included at least one randomized controlled trial (RCT) and were published between 2010 and 2013. Required COI disclosure by journal, disclosed COI by review authors and the inclusion of own primary studies by review authors were extracted. Researcher allegiance as well as bias in review conclusions were rated by two independent raters.

**Results** 936 references were retrieved, and 95 reviews fulfilled eligibility criteria. 59 compared psychological therapies with other forms of psychological therapies, and 36 compared psychological therapies with pharmacological interventions. In total, financial, non-financial, and personal COI were disclosed in 22, 4, and 1 review, respectively. Two of 86 own primary studies of review authors included in 34 reviews were disclosed by review authors. In 15 of the reviews, authors showed an allegiance effect to the evaluated psychological therapy that was never disclosed. Bias in review conclusions was found in 27 of 95 reviews. Reviews with a conclusion in favour of psychological therapies (vs. pharmacological interventions) were at high risk for biased conclusions (OR = 8.31 [1.41 to 49.05]). Bias was explained in trend by the inclusion of own primary studies in the systematic review (OR = 2.08 [CI 0.83 to 5.18]  $p = .11$ ) and researcher allegiance (OR = 2.63 [0.84 to 8.16]  $p = 0.16$ ).

**Conclusions** Non-financial COI, especially the inclusion of own primary studies into reviews and researcher allegiance, are frequently seen in systematic reviews of psychological therapies and need more transparency and better management.

## Article summary

### Strengths and limitations of this study

- This study addresses a widely neglected research topic, i.e. bias introduced by non-financial conflicts of interest, e.g. the researcher allegiance to a specific therapy, in reviews on psychological therapies.
- Although authors of reviews of psychological therapies frequently show COI (which mainly are not declared), the relationship to bias is less clear and has to be interpreted with caution.
- The selection of studies up to 2013 does not reflect possible changes in COI declarations in recent years. However, the authors are not aware of changes in COI declaration requirements regarding non-financial COI in 2014 or 2015.

## Introduction

Conflicts of interest (COI) are defined as a set of circumstances that creates a risk that a professional judgement or action regarding a primary interest will be unduly influenced by a secondary interest<sup>1 2</sup>. Research on COI has so far mainly focused on financial COI such as close financial relationships between researchers or medical doctors and pharmaceutical companies or the financing of drug trials by pharmaceutical companies<sup>3-7</sup>. Such research has shown that studies funded by pharmaceutical companies more often yield results or conclusions in favour of the sponsoring company as compared to non-industry-funded trials<sup>8 9</sup>, that close relationships of researchers to pharmaceutical companies are linked to biased assessments of drug safety and efficacy<sup>10 11</sup>, that positive trials are more likely to be published than trials unfavourable to sponsors<sup>12</sup>, and that COI are underreported in meta-analyses of pharmacological treatments<sup>13 14</sup>.

The influence of non-financial COI, however, on the framing of research questions, the data analysis and interpretation of results, or the decision which results are being published, has been much less extensively studied<sup>15</sup>. With respect to outcome research of psychological therapies, researcher allegiance constitutes an important non-financial COI. Allegiance covers the belief of a researcher in the superiority of a treatment<sup>16 17</sup>. Allegiance may be due to a special training in one specific psychological therapy, the involvement in previous efficacy research about this psychological therapy or the involvement in development of etiological models via basic research.<sup>18-20</sup> Empirical studies showed a strong impact of researcher allegiance on outcome in psychotherapy studies: A recent meta-meta-analysis showed a robust and moderate allegiance outcome association ( $r = .26$ )<sup>21</sup>, and such an association is also present in equally effective treatments<sup>22</sup>. Taking allegiance into account for the explanation of effect differences between two active treatments studies with balanced allegiance for two different treatments show no difference in the effectiveness<sup>23</sup>.

Since nothing is known about the extent and nature of non-financial COI in systematic reviews of psychological therapies, the aim of this study was to investigate how often non-

1  
2  
3 financial COI are present and disclosed in systematic reviews of psychological therapies and to  
4  
5 analyze whether these COI increase the risk of biased conclusions of the reviews.  
6  
7  
8  
9

## 10 11 **Methods**

### 12 13 14 15 **Search strategy and eligibility criteria of systematic reviews**

16  
17 We searched the MEDLINE and PsycINFO databases for systematic reviews or meta-analyses  
18 of randomised controlled trials (RCT) on psychological therapies. Reviews were selected if they  
19 fulfilled the following inclusion criteria: 1) Inclusion of psychological therapies to treat patients  
20 with anxiety disorders, personality disorders and/or major depressive disorders in adults, 2)  
21 Active control groups with either other forms of psychological therapy or pharmacological  
22 interventions, 3) Inclusion of at least one randomised study, 4) English language. Searches  
23 were last run on February 3<sup>rd</sup> 2014, covering the publication period of January 2010 to  
24 December 2013. For exact MEDLINE and PsycINFO search strategies, confer supplement  
25 tables 1 and 2.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37

### 38 39 **Screening and inclusion of systematic reviews and primary studies**

40 Retrieved references were initially screened for inclusion by title and abstract by two  
41 independent researchers. In a second step, full texts of relevant reviews were retrieved and  
42 assessed for inclusion by two independent researchers. These reviews were used to rate  
43 conflicts of interest and their disclosure (see below).  
44  
45  
46  
47

48 Primary studies included in these reviews were identified from the reference list of the  
49 systematic reviews and retrieved if one of the co-authors of the review was an author of the  
50 respective primary study. These primary studies were then used to rate researcher allegiance  
51 (see below).  
52  
53  
54  
55  
56  
57  
58  
59  
60

### Assessment of disclosed and undisclosed COI

All disclosed COI were extracted: financial COI (honoraria e.g. for consulting, lectures, scientific articles, training courses or money for research projects), non-financial COI (e.g. researcher allegiance to a psychological therapy, special qualification in a psychological therapy, enthusiasm for a psychological therapy in scientific publications, lectures and research, or inclusion of own primary studies in reviews), and personal COI (e.g. employee or private relationship to an employee of a company - regularly addressed as relationships to pharmaceutical companies). If no COI was reported, the websites of the respective journals as well as the guidelines for authors were screened for requirements of COI disclosures at the time of the publication of the review. In addition, we assessed whether review authors included own studies on psychological therapies into their review and whether this inclusion was disclosed.

### Rating of researcher allegiance

In case that a review author included at least one own primary study (which he or she co-authored) into the review, we retrieved these primary studies and rated the researcher allegiance according to information presented in the primary study (note that a rating of researcher allegiance was not possible in the reviews since these do not provide essential information to rate researcher allegiance according to established standards.<sup>18-20</sup>). Researcher allegiance was rated in 73 of the 86 included primary studies since 13 reviews did not compare psychological therapies to other treatments and were therefore excluded.

Researcher allegiance was defined to be present, if the author a) recommended the respective psychological therapy over another therapy and was b) either involved in the development of the respective psychological therapy or c) was involved in research of/development of the etiological model of the psychological therapy. Two independent researchers (JOS, JB) assessed allegiance in the primary studies and disagreements were resolved with a third rater (KL). If researcher allegiance was rated to be present in at least one of the primary studies included in a review, this review was rated as afflicted by researcher allegiance. Kappa statistics showed substantial inter-rater reliability ( $k = 0.62$ ; agreement 82%).

### Assessment of bias in reviews

To assess bias (or “spin”) in review conclusions, we evaluated whether the conclusion of the review as expressed in the abstract or the discussion section was inconsistent or consistent to the empirical results described in the results section of the review. If the conclusion was consistent with the empirical results, the review was considered as unbiased. If it was inconsistent, the review was rated as biased. Two researchers (KL, JOS) independently assessed review conclusions and results and rated the review as biased or unbiased. If no consensus was achieved, disagreements were resolved by a third person (JB). Kappa statistics showed substantial inter-rater reliability ( $k = 0.70$ ; agreement 87%).

### Statistical analyses

The percentage of disclosed COI, researcher allegiance and biased reviews was calculated. For the first two indicators, the number of reviews was the denominator, the latter indicator was calculated with the number of studies as denominator. The association of researcher allegiance with a biased conclusion of reviews is presented as Odds ratio with 95% confidence interval. The same procedure was used for the association of the inclusion of own primary studies of the authors in the review and the disclosure of COI with a biased review.

### Results

Our search yielded 936 references. After screening and retrieving full text articles, 95 reviews remained which met our inclusion criteria. A detailed flow chart with a schedule of the reasons for exclusions is found in Figure 1. The reviews and meta-analyses addressed anxiety disorders ( $n = 42$ ), depressive disorders ( $n = 48$ ), and/or personality disorders ( $n = 13$ ) and allowed conclusions about the following interventions: 59 reviews compared psychological therapies



1  
2  
3 with other forms of psychological therapies, and 36 compared psychological therapies with  
4 pharmacological interventions.  
5  
6  
7

### 8 9 **Required COI disclosure by journal and disclosed COI**

10 The references of the 95 reviews included in this study are listed in Supplement Table 3.  
11 Supplement Table 4 gives an overview how many reviews were published per year in which  
12 journal. 40 of the 50 journals regularly requested a disclosure of COI at the time of publication of  
13 the respective review. Supplement Table 5 demonstrates which journal asked for which kind of  
14 COI disclosure in the respective year of publication of the review article. In sum: Of the 50  
15 publishing journals, 40 requested a disclosure of financial COI (80%), 28 of personal COI (56%),  
16 and 17 of non-financial COI (34%).  
17  
18

19 In 37 of 95 reviews (38.9%), the authors disclosed that no competing interests exist. Authors in  
20 25 of 95 reviews (26.3%) made COI statements as follows: Own study included in the review (n  
21 = 2), research activities in relation to one psychological therapy (n = 2), research support (n =  
22 18), author has served as consultant (n = 4), served as speaker on congresses (n = 1), get  
23 honoraria (n = 5), have holdings (n = 2), have patents (n = 1), served as a trainer for a  
24 psychological therapy (n = 1), being influenced as employer (n = 1). In other words, financial,  
25 non-financial, and personal COI were disclosed in 22 reviews (23.1%), 4 reviews (4.2%), and 1  
26 review (1%), respectively. In 33 of 95 reviews (34.7%) no COI statement was made.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43

### 44 **Inclusion of own studies into the reviews and researcher allegiance**

45 We also looked at the frequency of the inclusion of own primary studies into the review and the  
46 allegiance of the researcher. 34 of 95 reviews (35.8%) included at least one primary study of  
47 one of the review authors. In sum, 86 primary studies were identified which were included in 34  
48 reviews (see Supplement Table 6 for references of these included studies). 20 reviews included  
49 1 study, 4 reviews 6 studies, 4 reviews 3 studies, 4 reviews 2 studies, 1 review 4 studies and 1  
50 review 18 studies. In 15 of the 34 reviews which included at least one own primary study, we  
51 found a researcher allegiance.  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Two reviews disclosed that they included studies of review authors in their review (2.1%). In  
4 none of the reviews any involvement of an author in the development of a psychological therapy  
5 under study was disclosed. Also the conduct of experimental studies about the etiological model  
6 of a psychological therapy or the recommendation for a certain reason was never disclosed.  
7  
8  
9

### 10 11 12 **Bias in reviews**

13  
14 Bias in the interpretation of review results was rated to be present in 27 of 95 reviews (28%).  
15 Within the 36 reviews comparing psychological therapies to pharmacological interventions, 9  
16 (25%) were biased. In reviews comparing psychological therapies and pharmacological  
17 interventions, bias in favour of a specific psychological therapy was more often present as  
18 compared to bias in favour of a pharmacological intervention (Fig. 2). Reviews with a favourable  
19 conclusion about psychological therapies (vs. pharmacological interventions) are at high risk for  
20 biased conclusions (OR = 8.31 [1.41 to 49.05]), whereas favourable conclusions about effects  
21 of pharmacological interventions were not biased in our sample (OR = 1.00 [0.16 to 6.14]. Also  
22 the conclusion of equal effects of psychological therapies and pharmacological interventions  
23 does not face a risk to be biased (OR = 0.12 [0.01 to 1.08]). The conclusion of the equality of  
24 effects of psychological therapies, however, is at risk to be biased (trend), which means that for  
25 the primary outcome of interest the review more often states equality despite inequality of  
26 treatment effects (OR = 2.69 [0.86 to 8.41]).  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43

44 We further explored whether bias in review conclusions is associated with a disclosed COI, the  
45 inclusion of own primary studies of the authors or the researcher allegiance of the authors. To  
46 do so, we first investigated these associations in all 95 reviews (Tab. 1). Biased conclusions  
47 were not explained by disclosed COI. However, biased conclusions were explained in trend by  
48 the inclusion of own studies in the systematic review. Reviews with inclusion of own primary  
49 studies were more often biased than reviews without inclusion of own primary studies of the  
50 review authors (OR = 2.08 [CI 0.83 to 5.18]  $p = .11$ ; Tab. 1). The odds for biased conclusions in  
51 systematic reviews including studies with researcher allegiance was similarly increased, but  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 statistically non-significant (OR = 2.63  
4  
5 [0.84 to 8.12],  $p = .16$ ; Tab. 1).  
6  
7  
8

9 Since we were especially interested in bias in favour of psychological therapies, we also  
10 investigated whether bias in review conclusions in favour of psychological therapies is  
11 associated with a disclosed COI, the inclusion of own primary studies of the authors or the  
12 researcher allegiance of the authors (Tab. 2). However, none of the associations were  
13 statistically significant or showed trends.  
14  
15  
16  
17  
18

## 19 Discussion

20 This study is – at least to our knowledge - the first that systematically assessed the extent and  
21 nature of reporting of financial and non-financial COI in systematic reviews of psychological  
22 therapies and that investigated how often these conflicts are disclosed and whether they may  
23 lead to bias in review conclusions. Financial and non-financial COI were disclosed only in 23.1%  
24 and 4.2% of the reviews, respectively, although non-financial COI were much more often  
25 detectable: Review authors had included 86 own studies in approximately 1/3<sup>rd</sup> of the reviews  
26 and authors of at least 16% of the reviews had allegiance for the evaluated psychological  
27 therapy. Bias in review conclusions was found in 27 of 95 reviews (28%) and was explained in  
28 trend by a non-financial COI, i.e. the inclusion of own primary studies in the systematic review.  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45

### 46 Disclosure of financial, non-financial and personal COI

47 The disclosure of financial COI was requested by 80% of the journals which published the  
48 reviews in our study, but only 22 reviews (23.2%) disclosed any financial COI. This may be  
49 explained by two reasons: Firstly, systematic reviews focussing on effectiveness of  
50 psychological therapies are most often written by psychologists who have rather seldom  
51 financial ties to pharmaceutical companies as compared to physicians who often show these  
52 relationships<sup>3-7</sup>, and secondly, the minority of reviews (36 of 95 reviews) compared  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 psychological therapies to pharmacological interventions (in 10 of those reviews, financial COI  
4 were disclosed). Although psychologists may mostly judge themselves as free of financial COI,  
5  
6 however, researcher allegiance as well as the inclusion of own studies into a review (which we  
7  
8 both rated as non-financial COI) may well lead to financial gains indirectly.<sup>15</sup> Since psychologists  
9  
10 who develop new psychological treatments are often the ones who distribute and train other  
11  
12 psychologists in those therapies, the demonstration of effectiveness of a specific psychotherapy  
13  
14 in a review may potentially lead to high financial incentives. The promotion of the respective  
15  
16 therapy might be easier and the number of trained psychotherapists with high course fee  
17  
18 increases. Showing the effectiveness of a treatment can be also an important step for patents  
19  
20 and for the implementation in treatment guidelines.  
21

22  
23 Non-financial COI were disclosed only in a very small number of reviews (4.2%) although non-  
24  
25 financial COI such as the inclusion of own primary studies of the review authors (in 34 of 95  
26  
27 reviews) and researcher allegiance (in 15 of 95 reviews) were detectable in a considerable  
28  
29 number of them. This low disclosure rate may be explained by three factors: Firstly, only a  
30  
31 minority of journals (34% at the time of assessment) requests a disclosure of non-financial COI;  
32  
33 secondly, only two journals (Perm J, Cochrane Database Syst Rev) specifically asked the  
34  
35 authors for the inclusion of own primary studies and only two others (Psychol Trauma, J  
36  
37 Psychiatr Res) asked for circumstances related to the presence of researcher allegiance at the  
38  
39 point of our assessment; thirdly, researchers may not see the necessity to declare such COI  
40  
41 although present and requested to be disclosed by the journal, which we have seen in one  
42  
43 review article. We conclude from this finding that the necessity to declare non-financial COI  
44  
45 should be made more transparent in journal articles. The following strategies may be effective:  
46  
47 Journals should consequently ask their authors to disclose any non-financial COI, should  
48  
49 exactly define such conflicts and should include examples of common causes of non-financial  
50  
51 COI such as the inclusion of own primary studies into review articles or researcher allegiance.  
52  
53 Even the prestigious INTERNATIONAL COMMITTEE OF MEDICAL JOURNAL EDITORS  
54  
55 (ICMJE) mainly focusses on financial COI and their disclosure but gives little emphasis on and  
56  
57 advice to the disclosure of non-financial COI.  
58  
59  
60

1  
2  
3 Similar to non-financial COI, also personal COI were very seldom disclosed (only in one review).  
4  
5 This is probably due to the common definition of personal COI meaning any relationship to a  
6  
7 person working in a pharmaceutical company. This of course is a less relevant COI for  
8  
9 psychotherapist assessing treatment effects of psychological therapies. However,  
10  
11 psychotherapists, especially the ones who develop new therapies, are very often personally  
12  
13 involved in institutes promoting the distribution and training of new psychological therapies.  
14  
15 Such personal COI may indirectly lead to considerable financial gains.  
16  
17  
18  
19

### 20 **Bias in review conclusions**

21 Previous research of our group and others has identified different risks increasing the likelihood  
22  
23 of bias in psychotherapeutic outcome research.<sup>21 24</sup> In our study, we investigated whether  
24  
25 researcher allegiance, an important risk factor of moderate effect size<sup>21</sup>, the inclusion of own  
26  
27 primary studies into the review or any declared COI may explain bias, which we found in 27 of  
28  
29 the 95 reviews. Both reviews with inclusion of own primary studies and reviews with researcher  
30  
31 allegiance were more often biased (statistical trend). Since researcher allegiance has been  
32  
33 shown to be significantly related to outcome of psychological therapies<sup>21</sup>, authors should be  
34  
35 transparent in disclosing their own psychotherapeutic training background and the inclusion of  
36  
37 own outcome studies in systematic reviews to make an assessment of COI and allegiance  
38  
39 easier. The allegiance indicators of our study might be an initial step for such a statement  
40  
41 (development of treatment or basic research on the etiological model for a specific treatment).  
42  
43  
44  
45

### 46 **Shortcomings**

47 This study has several shortcomings. Firstly, we restricted our search to systematic reviews and  
48  
49 meta-analyses of anxiety disorders, personality disorders and major depressive disorders. This  
50  
51 may limit the generalizability of our findings. Secondly, our study is limited to published reports  
52  
53 from 2010 onwards. This limits generalizability to earlier reviews, but is justified since COI  
54  
55 reporting has become more regular nowadays and authors might not have been asked for a  
56  
57 COI statement in earlier submissions. Thirdly, our indicators of COI and allegiance are based on  
58  
59  
60

1  
2  
3 publications and reporting quality on some indicators was rather low. The inter-rater reliability of  
4  
5 both ratings might be much better if reporting standards in journals would be implemented.  
6  
7

## 8 9 **Conclusions**

10 We conclude that non-financial COI, especially the inclusion of own primary studies into reviews  
11  
12 and researcher allegiance, are frequently seen in systematic reviews of psychological therapies  
13  
14 and need more transparency. If biasing effects of non-financial COI in psychotherapy outcome  
15  
16 research are confirmed in further studies, journals should do more than simply providing  
17  
18 transparency of COI in order to better manage the impact of COI on research outcomes and  
19  
20 publications <sup>15</sup>. One such strategy to be considered might be the exclusion of studies from  
21  
22 authors in reviews evaluating the effectiveness of a certain psychological therapy on which the  
23  
24 author has published key studies and/or for which he or she shows a researcher allegiance in  
25  
26 sensitivity analyses.  
27  
28  
29  
30

## 31 **Acknowledgements**

32  
33 The study was funded by intramural funds from the University Medical Center Mainz, Department of  
34  
35 Psychiatry and Psychotherapy, Mainz, Germany; there was no extramural funding. We thank V.  
36  
37 Stancheva for helping in study extraction.  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### Contributorship statement

KL designed the study, analysed data, monitored study extraction, data analysis and interpretation, and drafted and revised the paper. He is guarantor. JOS and NR extracted and analysed data and revised the draft of the manuscript, JSW analysed data and revised the draft of the manuscript. JB analysed data, monitored study extraction, data analysis and interpretation, and revised the paper. All authors gave final approval of the version to be published. All authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

### Transparency declaration

The guarantor affirms that the manuscript is an honest, accurate, and transparent account of the study being reported and that no important aspects of the study have been omitted.

### Declaration of competing interests

All authors have completed the ICMJE uniform disclosure form at [www.icmje.org/coi\\_disclosure.pdf](http://www.icmje.org/coi_disclosure.pdf) and declare: no support from any organisation for the submitted work; KL and JB are active in research on conflicts of interest in medicine and psychology, and JB was involved in the development of indicators of allegiance. All authors declare that they had no financial or personal relationships with pharmaceutical companies within the last 3 years. KL, NR, JSW and JB are psychotherapists trained in CBT, KL and NR also in schematherapy. NR and JB, but not KL and JSW, did receive money from institutes providing training in schematherapy and CBT within the last three years. JSW and KL are coauthors on two reviews included into the study (Gibbon et al., 2010 and Stoffers et al., 2012), and NR and KL are coauthors on one primary study (Reiss et al., 2014) included in one of the reviews.



**License for publication statement**

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, a worldwide licence to the Publishers and its licensees in perpetuity, in all forms, formats and media (whether known now or created in the future), to i) publish, reproduce, distribute, display and store the Contribution, ii) translate the Contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or, abstracts of the Contribution, iii) create any other derivative work(s) based on the Contribution, iv) to exploit all subsidiary rights in the Contribution, v) the inclusion of electronic links from the Contribution to third party material where-ever it may be located; and, vi) licence any third party to do any or all of the above.

**Data sharing statement**

Extra data is available by emailing [Klaus.lieb@unimedizin-mainz.de](mailto:Klaus.lieb@unimedizin-mainz.de).



## References

1. Thompson DF. The Challenge of Conflict of Interest in Medicine. *Z Evid Fortbild Qual Gesundheitswes* 2009;**103**(3):136-40.
2. Lo B, Fields (ed.) *Conflict of Interest in Medical Research, Education, and Practice*, Institute of Medicine 2009.
3. Campbell EG. Doctors and drug companies - scrutinizing influential relationships. *N Engl J Med* 2007;**357**(18):1796-7.
4. Campbell EG, Rao SR, DesRoches CM, et al. Physician professionalism and changes in physician-industry relationships from 2004 to 2009. *Arch Intern Med* 2010;**170**(20):1820-6.
5. Campbell EG, Weissman JS, Ehringhaus S, et al. Institutional academic industry relationships. *JAMA* 2007;**298**(15):1779-86.
6. Lieb K, Brandtönes S. A survey of german physicians in private practice about contacts with pharmaceutical sales representatives. *Dt Arztebl Int* 2010;**107**(22):392.
7. Lieb K, Scheurich A. Contact between Doctors and the Pharmaceutical Industry, Their Perceptions, and the Effects on Prescribing Habits. *PloS one* 2014;**9**(10):e110130.
8. Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. *JAMA* 2003;**289**(4):454-65.
9. Schott G, Pacht H, Limbach U, et al. The financing of drug trials by pharmaceutical companies and its consequences. Part 1: a qualitative, systematic review of the literature on possible influences on the findings, protocols, and quality of drug trials. *Dt Arztebl Int* 2010;**107**(16):279-85.
10. Wang AT, McCoy CP, Murad MH, et al. Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review. *BMJ* 2010;**340**:c1344.
11. Dunn AG, Arachi D, Hudgins J, et al. Financial conflicts of interest and conclusions about neuraminidase inhibitors for influenza: an analysis of systematic reviews. *Ann Intern Med* 2014;**161**(7):513-8.
12. Roest AM, de Jonge P, Williams CD, et al. Reporting Bias in Clinical Trials Investigating the Efficacy of Second-Generation Antidepressants in the Treatment of Anxiety Disorders: A Report of 2 Meta-analyses. *JAMA psychiatry* 2015;**72**(5):500-10.
13. Roseman M, Milete K, Bero LA, et al. Reporting of conflicts of interest in meta-analyses of trials of pharmacological treatments. *JAMA* 2011;**305**(10):1008-17.
14. Roseman M, Turner EH, Lexchin J, et al. Reporting of conflicts of interest from drug trials in Cochrane reviews: cross sectional study. *BMJ* 2012;**345**:e5155.
15. Clark AM, Choby A, Ainsworth K, et al. Addressing conflict of interest in non-pharmacological research. *Int J Clin Pract*. 2015;**69**(3):270-2.
16. Leykin Y, DeRubeis RJ. Allegiance in Psychotherapy Outcome Research: Separating Association From Bias. 2009.
17. Lambert MJ. Are differential treatment effects inflated by researcher therapy allegiance? Could Clever Hans count? *Clinical Psychology: Science and Practice* 1999;**6**(1):127-30.
18. Gaffan EA, Tsaousis I, Kemp-Wheeler SM. Researcher allegiance and meta-analysis: the case of cognitive therapy for depression. *J Consult Clin Psychol*. 1995;**63**(6):966-80.
19. Munder T, Gerger H, Trelle S, et al. Testing the allegiance bias hypothesis: a meta-analysis. *Psychother Res* 2011;**21**(6):670-84.
20. Miller S, Wampold B, Varhely K. Direct comparisons of treatment modalities for youth disorders: a meta-analysis. *Psychother Res* 2008;**18**(1):5-14.
21. Munder T, Brutsch O, Leonhart R, et al. Researcher allegiance in psychotherapy outcome research: an overview of reviews. *Clin Psychol Rev* 2013;**33**(4):501-11.

- 1  
2  
3 22. Munder T, Fluckiger C, Gerger H, et al. Is the allegiance effect an epiphenomenon of true  
4 efficacy differences between treatments? a meta-analysis. *J Couns Psychol*  
5 2012;**59**(4):631-7.  
6 23. Cuijpers P, Driessen E, Hollon SD, et al. The efficacy of non-directive supportive therapy for  
7 adult depression: a meta-analysis. *Clin Psychol Rev* 2012;**32**(4):280-91.  
8 24. Cuijpers P, van Straten A, Bohlmeijer E, et al. The effects of psychotherapy for adult  
9 depression are overestimated: a meta-analysis of study quality and effect size. *Psychol*  
10 *Med* 2010;**40**(2):211-23.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## Figures

Figure 1: Flow chart of study selection





Figure 2: Risk of bias in conclusions in comparisons of different treatments (Tx1 vs. Tx2).



BMJ Open: first published as 10.1136/bmjopen-2015-010606 on 26 April 2016. Downloaded from <http://bmjopen.bmj.com/> on October 31, 2024 by guest. Protected by copyright.

View only

## Tables

Tab. 1 Association between disclosed COI and other forms of COI (i.e. inclusion of primary studies in reviews, researcher allegiance) and bias in review conclusions in all 95 reviews.

	Review with biased conclusion	Review with unbiased conclusion	Odds Ratio [95% confidence interval]
Inclusion of own primary study	13	21	2.08 [0.83 to 5.18]
No inclusion of own primary study	14	47	
Researcher allegiance	7	8	2.63 [0.84 to 8.16]
No researcher allegiance	20	60	
COI disclosed	9	16	1.63 [0.61 to 4.32]
No COI disclosed	18	52	
Inclusion of own primary study, researcher allegiance and/or COI declared	16	31	1.74 [0.70 to 4.29]
None of the three	11	37	

Tab. 2: Association between disclosed COI and other forms of COI (i.e. inclusion of primary studies in reviews, researcher allegiance) and bias in review conclusions in the reviews rated as biased in favour of psychological therapies as compared to all other reviews.

	Review rated as “biased” in favour of psychological therapies	Review rated as “unbiased” or “biased” against psychological therapies	Odds Ratio [95% confidence interval]
Inclusion of own primary study	6	28	1.24 [0.40 to 3.83]
No inclusion of own primary study	9	52	
Researcher allegiance	2	13	0.79 [0.16 to 3.94]
No researcher allegiance	13	67	
COI disclosed	4	21	1.02 [0.29 to 3.56]
No COI disclosed	11	59	
Inclusion of own primary study, researcher allegiance and/or COI disclosed	7	40	0.88 [0.29 to 2.64]
None of the three	8	40	

## Conflicts of interest and bias in systematic reviews of psychological therapies

Submission to BMJ Open

Klaus Lieb, Jan von der Osten-Sacken, Jutta Stoffers-Winterling, Neele Reiss,  
Jürgen Barth

## Supplements

Supplement Table 1: MEDLINE EBSCO exact search strategy (last run on February 3<sup>rd</sup>, 2014)

#	
S1	(MH "Psychotherapy+")
S2	(MH "Anxiety Disorders+")*
S3	(S1 AND S2)
S4	(S1 AND S2) – Date of publication: 20100101-20131231; Publication Type: Meta-Analysis, Review

\* This search is exemplary for anxiety disorders. Separate searches were done for depressive and personality disorders, using controlled vocabulary (MH "Depressive Disorders+") or (MH "Personality Disorders+"), resp.

Supplement Table 2: PsycINFO EBSCO exact search strategy (last run on February 3<sup>rd</sup>, 2014)

#	
S1	DE "Psychotherapy" OR DE "Adlerian Psychotherapy" OR DE "Adolescent Psychotherapy" OR DE "Analytical Psychotherapy" OR DE "Autogenic Training" OR DE "Behavior Therapy" OR DE "Brief Psychotherapy" OR DE "Brief Relational Therapy" OR DE "Child Psychotherapy" OR DE "Client Centered Therapy" OR DE "Cognitive Behavior Therapy" OR DE "Conversion Therapy" OR DE "Eclectic Psychotherapy" OR DE "Emotion Focused Therapy" OR DE "Existential Therapy" OR DE "Experiential Psychotherapy" OR DE "Expressive Psychotherapy" OR DE "Eye Movement Desensitization Therapy" OR DE "Feminist Therapy" OR DE "Geriatric Psychotherapy" OR DE "Gestalt Therapy" OR DE "Group Psychotherapy" OR DE "Guided Imagery" OR DE "Humanistic Psychotherapy" OR DE "Hypnotherapy" OR DE "Individual Psychotherapy" OR DE "Insight Therapy" OR DE "Integrative Psychotherapy" OR DE "Interpersonal Psychotherapy" OR DE "Logotherapy" OR DE "Narrative Therapy" OR DE "Network Therapy" OR DE "Persuasion Therapy" OR DE "Primal Therapy" OR DE "Psychoanalysis" OR DE "Psychodrama" OR DE "Psychodynamic Psychotherapy" OR DE "Psychotherapeutic Counseling" OR DE "Rational Emotive Behavior Therapy" OR DE "Reality Therapy" OR DE "Relationship Therapy" OR DE "Solution Focused Therapy" OR DE "Supportive Psychotherapy" OR DE "Transactional Analysis"
S2	DE "Anxiety Disorders" OR DE "Acute Stress Disorder" OR DE "Castration Anxiety" OR DE "Death Anxiety" OR DE "Generalized Anxiety Disorder" OR DE "Obsessive Compulsive Disorder" OR DE "Panic Disorder" OR DE "Phobias" OR DE "Posttraumatic Stress Disorder" OR DE "Separation Anxiety"
S3	(S1 AND S2)
S4	(S1 AND S2) – Published date: 20100101-20131231; Methodology: -Systematic Review, -Meta Analysis

\* This search is exemplary for anxiety disorders. Separate searches were done for depressive and personality disorders, using controlled vocabulary (DE "Major Depression" OR DE "Anaclitic Depression" OR DE "Dysthymic Disorder" OR DE "Endogenous Depression" OR DE "Postpartum Depression" OR DE "Reactive Depression" OR DE "Recurrent Depression" OR DE "Treatment Resistant Depression") or (DE "Personality Disorders" OR DE "Antisocial Personality Disorder" OR DE "Avoidant Personality Disorder" OR DE "Borderline Personality Disorder" OR DE "Dependent Personality Disorder" OR DE "Histrionic Personality Disorder" OR DE "Narcissistic Personality Disorder" OR DE "Obsessive Compulsive Personality Disorder" OR DE "Paranoid Personality Disorder" OR DE "Passive Aggressive Personality Disorder" OR DE "Sadomasochistic Personality" OR DE "Schizoid Personality Disorder" OR DE "Schizotypal Personality Disorder"), resp.



## Supplement Table 3: References of the 95 reviews included in this study

Abbass A, Town J, Driessen E. Intensive short-term dynamic psychotherapy: A systematic review and meta-analysis of outcome research. *Harv Rev Psychiatry* 2012;20(2):97-108.

Abbass A, Town J, Driessen E. The efficacy of short-term psychodynamic psychotherapy for depressive disorders with comorbid personality disorder. *Psychiatry* 2011;74(1):58-71.

Baardseth TP, Goldberg SB, Pace BT, et al. Cognitive-behavioral therapy versus other therapies: Redux. *Clin Psychol Rev* 2013;33(3):395-405.

Barker-Collo S, Starkey N, Theadom A. Treatment for depression following mild traumatic brain injury in adults: A meta-analysis. *Brain Inj* 2013;27(10):1124-1133.

Bartley CA, Hay M, Bloch MH. Meta-analysis: Aerobic exercise for the treatment of anxiety disorders. *Prog Neuropsychopharmacol Biol Psychiatry* 2013;45:34-39.

Barrera TL, Mott JM, Hofstein RF, et al. A meta-analytic review of exposure in group cognitive behavioral therapy for posttraumatic stress disorder. *Clin Psychol Rev* 2013;33(1):24-32.

Beltman MW, Oude Voshaar RC, Speckens AE. Cognitive-behavioural therapy for depression in people with a somatic disease: meta-analysis of randomized controlled trials. *Br J Psychiatry* 2010;197(1):11-19.

Bomyea J, Lang AJ. Emerging interventions for PTSD: Future directions for clinical care and research. *Neuropharmacology* 2012;62:607-616.

Bontempo A, Panza KE, Bloch MH. Meta-Analysis: D-cycloserine Augmentation of Behavioral Therapy for the Treatment of Anxiety Disorders. *J Clin Psychiatry* 2012;73(4):533-537.

Budge SL, Moore JT, Del Re AC, et al. The effectiveness of evidence-based treatments for personality disorders when comparing treatment-as-usual and bona fide treatments. *Clin Psychol Rev* 2013;33:1057-1066.

Busch FN, Sandberg LS. Combined treatment of depression. *Psychiatr Clin North Am* 2012;35:165-179.

Casement MD, Swanson LM. A meta-analysis of imagery rehearsal for post-trauma nightmares: Effects on nightmare frequency, sleep quality, and posttraumatic stress. *Clin Psychol Rev* 2012;32:566-574.

Chard KM, Ricksecker EG, Healy ET, et al. Dissemination and experience with cognitive processing therapy. *J Rehabil Res Dev* 2012;49(5):667-78.

Chen KW, Berger CC, Manheimer E, et al. Meditative therapies for reducing anxiety: A systematic review and meta-analysis of randomized controlled trials. *Dedress Anxiety* 2012;29:545-562.

Chugh-Gupta N, Baldassarre FG, Vrkljan BH. A systematic review of yoga for state anxiety: Considerations for occupational therapy. *Can J Occup Ther* 2013;80(3):150-170.

Cody RA, Drysdale K. The Effects of Psychotherapy on Reducing Depression in Residential Aged Care: A Meta-Analytic Review. *Clin Gerontol* 2013;36(1):46-69.

Cuijpers P, Andersson G, Donker T, et al. Psychological treatment of depression: Results of a series of meta-analyses. *Nord J Psychiatry* 2011;65(6):354-364.

Cuijpers P, Berking M, Andersson G, et al. A Meta-Analysis of Cognitive-Behavioral Therapy for Adult Depression, Alone and in Comparison With Other Treatments. *Can J Psychiatry* 2013;58(7):376-385.

- 1  
2  
3 Cuijpers P, Clignet F, van Meijel B, et al. Psychological treatment of depression in inpatients: a  
4 systematic review and meta-analysis. *Clin Psychol Rev* 2011;31(3):353-360.
- 5  
6 Cuijpers P, de Beurs DP, van Spijker BA, et al. The effects of psychotherapy for adult depression on  
7 suicidality and hopelessness: A systematic review and meta-analysis. *J Affect Disord*  
8 2013;144(3):183-190.
- 9  
10 Cuijpers P, Driessen E, Hollon SD, et al. The efficacy of non-directive supportive therapy for adult  
11 depression: A meta-analysis. *Clin Psychol Rev* 2012;32:280-291.
- 12  
13 Cuijpers P, Geraedts AS, van Oppen P, et al. Interpersonal Psychotherapy for Depression: A Meta-  
14 Analysis. *Am J Psychiatry* 2011;168:581-592.
- 15  
16 Cuijpers P, Huibers M, Ebert DD, et al. How much psychotherapy is needed to treat depression? A  
17 metaregression analysis. *J Affect Disord* 2013;149(1-3):1-13.
- 18  
19 Cuijpers P, Reynolds III CF, Donker T, et al. Personalized treatment of adult depression: Medication,  
20 psychotherapy, or both? A systematic review. *Depress Anxiety* 2012;29:855-864.
- 21  
22 Cuijpers P, van Straten A, Hollon SD, et al. The contribution of active medication to  
23 combined treatments of psychotherapy and pharmacotherapy for adult depression: a meta-analysis  
24 *Acta Psychiatr Scand* 2010;121:415-423.
- 25  
26 Cuijpers P, van Straten A, Schuurman J, et al. Psychotherapy for chronic major depression and  
27 dysthymia: A meta-analysis *Clin Psychol Rev* 2010;30:51-62.
- 28  
29 Daigle MS, Pouliot L, Chagnon F, et al. Suicide attempts: Prevention of repetition. *Can J Psychiatry*  
30 2011;56(10):621-629.
- 31  
32 Dickens C, Cherrington A, Adeyemi I, et al. Characteristics of Psychological Interventions That  
33 Improve Depression in People With Coronary Heart Disease: A Systematic Review and Meta-  
34 Regression. *Psychosom Med* 2013;75:211-221.
- 35  
36 Dossa NI, Hatem M. Cognitive-Behavioral Therapy versus Other PTSD Psychotherapies as  
37 Treatment for Women Victims of War-Related Violence: A Systematic Review. *Scientific World Journal*  
38 2012;2012:181847. doi:10.1100/2012/181847. Epub 2012 Apr 19.
- 39  
40 Driessen E, Cuijpers P, de Maat SCM, et al. The efficacy of short-term psychodynamic psychotherapy  
41 depression: a meta-analysis. *Clin Psychol Rev* 2010;30(1):25-36.
- 42  
43 Ekers D, Webster LAD. An overview of the effectiveness of psychological therapy for depression and  
44 stepped care service delivery models. *J Res Nurs* 2013;18(2):171-184,
- 45  
46 Faller H, Schuler M, Richard M, et al. Effects of psycho-oncologic interventions on emotional distress  
47 and quality of life in adult patients with cancer: systematic review and meta-analysis. *J Clin Oncol*  
48 2013;31(6):782-93.
- 49  
50 Feng CY, Chu H, Chen CH, et al. The Effect of Cognitive Behavioral Group Therapy for Depression: A  
51 Meta-Analysis 2000-2010. *Worldviews Evid Based Nurs* 2012;9(1):2-17.
- 52  
53 Fritzsche A, Clamor A, von Leupoldt A. Effects of medical and psychological treatment  
54 of depression in patients with COPD e A review *Respir Med* 2011;105:1422-1433.
- 55  
56 Gibbon S, Duggan C, Stoffers J, et al. Psychological interventions for antisocial personality disorder.  
57 *Cochrane Database Syst Rev* 2010;6: CD007668. doi:10.1002/14651858.CD007668.pub2.
- 58  
59 Goncalves DC, Byrne GJ. Interventions for generalized anxiety disorder in older adults: Systematic  
60 review and meta-analysis *J Anxiety Disord* 2012;26:1-11.
- 61  
62 Goodson J, Helstrom A, Halpern JM, et al. Treatment of posttraumatic stress disorder in US combat  
63 veterans: a meta-analytic review. *Psychol Rep* 2011;109(2):573-599.

1  
2  
3 Gould RL, Coulson MC, Howard RJ. Efficacy of Cognitive Behavioral Therapy for Anxiety Disorders in  
4 Older People: A Meta-Analysis and Meta-Regression of Randomized Controlled Trials. *J Am Geriatr*  
5 *Soc* 2012;60(2):218-29. DOI: 10.1111/j.1532-5415.2011.03824.xJAGS 60:218–229, 2012.

6  
7 Guidi J, Fava GA, Fava M, et al. Efficacy of the sequential integration of psychotherapy and  
8 pharmacotherapy in major depressive disorder: a preliminary meta-analysis. *Psychol Med*  
9 2011;41:321–331.

10  
11 Gwozdziwycz N, Mehl-Madrona L. Meta-analysis of the use of narrative exposure therapy for the  
12 effects of trauma among refugee populations. *Perm J* 2013;17(1):70-76.

13  
14 Hanrahan F, Field AP, Jones FW, et al. A meta-analysis of cognitive therapy for worry in generalized  
15 anxiety disorder. *Clin Psychol Rev* 2013;33(1):120-32.

16  
17 Hans E, Hiller W. Effectiveness of and Dropout From Outpatient Cognitive Behavioral Therapy for  
18 Adult Unipolar Depression: A Meta-Analysis of Nonrandomized Effectiveness Studies. *J Consult Clin*  
19 *Psychol* 2013;81(1):75•88.

20  
21 Hansen K, Höfling V, Kröner-Borowik T, et al. Efficacy of psychological interventions aiming to reduce  
22 chronic nightmares: a meta-analysis. *Clin Psychol Rev* 2013;33(1):146-55.

23  
24 Hart SL, Hoyt MA, Diefenbach M, et al. Meta-Analysis of Efficacy of Interventions for Elevated  
25 Depressive Symptoms in Adults Diagnosed With Cancer. *J Natl Cancer Inst* 2012;104:990–1004.

26  
27 Haug T, Nordgreen T, Öst LG, et al. Self-help treatment of anxiety disorders: A meta-analysis and  
28 meta-regression of effects and potential moderators *Clin Psychol Rev* 2012;32:425–445.

29  
30 Hetrick SE, Purcell R, Garner B, et al. Combined pharmacotherapy and psychological therapies for  
31 post traumatic stress disorder (PTSD) *Cochrane Database Syst Rev* 2010;7:CD007316.  
32 DOI:10.1002/14651858.CD007316.pub2.

33  
34 Ho MSK, Lee CW. Cognitive behaviour therapy versus eye movement desensitization and  
35 reprocessing for post-traumatic disorder – is it all in the homework then? *Eur Rev Appl Psychol*  
36 2012;62:253–260.

37  
38 Hobbs JDJ, Kushner MG, Lee SS, et al. Meta-analysis of Supplemental Treatment for Depressive and  
39 Anxiety Disorders in Patients Being Treated for Alcohol Dependence. *Am J Addict* 2011;20:319–329.

40  
41 Hofmann SG, Sawyer AT, Witt AA, et al. The effect of mindfulness-based therapy on anxiety and  
42 depression: A meta-analytic review. *J Consult Clin Psychol* 2010;78(2):169-183.

43  
44 Huntley AL, Araya R, Salisbury C. Group psychological therapies for depression in the community:  
45 systematic review and meta-analysis. *Br J Psychiatry* 2012;200:184–190. doi:  
46 10.1192/bjp.bp.111.092049

47  
48 Imel ZE, Laska, K, Jakupcak M, et al. Meta-Analysis of Dropout in Treatments for Posttraumatic  
49 Stress Disorder. *J Consult Clin Psychol* 2013;81(3)394-404.

50  
51 IsHak WW, Ha K, Kapitanski N, et al. The Impact of Psychotherapy, Pharmacotherapy, and Their  
52 Combination on Quality of Life in Depression. *Harv Rev Psychiatry* 2011;19:277–289.

53  
54 Jakobsen JC, Hansen JL, Simonsen E, et al. The effect of adding psychodynamic therapy to  
55 antidepressants in patients with major depressive disorder. A systematic review of randomized clinical  
56 trials with meta-analyses and trial sequential analyses *J Affect Disord* 2012;137:4–14.

57  
58 Jakobsen JC, Hansen JL, Simonsen S, et al. Effects of cognitive therapy versus interpersonal  
59 psychotherapy in patients with major depressive disorder: a systematic review of randomized clinical  
60 trials with meta-analyses and trial sequential analyses. *Psychol Med* 2012;42:1343–1357.  
doi:10.1017/S0033291711002236.

- 1  
2  
3 Krishna M, Honagodu A, Rajendra R, et al. A systematic review and meta-analysis of group  
4 psychotherapy for sub-clinical depression in older adults. *Int J of Geriatr Psychiatry* 2013;28(9):881-  
5 888.
- 6  
7 Krishna M, Jauhari A, Lepping P, et al. Is group psychotherapy effective in older adults with  
8 depression? A systematic review. *Int J of Geriatr Psychiatry*. 2011;26(4):331-340.
- 9  
10 Leisenring F, Rabung S. Long-term psychodynamic psychotherapy in complex mental disorders:  
11 update of a meta-analysis. *Br J Psychiatry* 2011;199(1):15-22.
- 12  
13 Luciano M, Del Vecchio V, Giacco D, et al. A 'family affair'? The impact of family psychoeducational  
14 interventions on depression. *Expert Rev. Neurother* 2012;12(1):83-92.
- 15  
16 Markowitz SM, Gonzalez JS, Wilkinson JL, et al. A Review of Treating Depression in Diabetes:  
17 Emerging Findings. *Psychosomatics* 2011;52:1-18.
- 18  
19 Mavrides N, Nemeroff C. Treatment of depression in cardiovascular disease. *Depress Anxiety*  
20 2013;30(4):328-41.
- 21  
22 Nenova M, Morris L, Paul L, et al. Psychosocial Interventions With Cognitive-Behavioral Components  
23 for the Treatment of Cancer-Related Traumatic Stress Symptoms: A Review of Randomized  
24 Controlled Trials. *J Cogn Psychother* 2013;27(3)258-284.
- 25  
26 Nickerson A, Bryant RA, Silove D, et al. A critical review of psychological treatments of posttraumatic  
27 stress disorder in refugees. *Clin Psychol Rev* 2011;31:399-417.
- 28  
29 Oestergaard S, Møldrup C. Optimal duration of combined psychotherapy and pharmacotherapy for  
30 patients with moderate and severe depression: A meta-analysis. *J Affect Disord* 2011;131:24-36.
- 31  
32 Olatunji BO, Davis ML, Powers MB, et al. Cognitive-behavioral therapy for obsessive-compulsive  
33 disorder: A meta-analysis of treatment outcome and moderators. *J Psychiatr Res* 2013;47(1):33-41.
- 34  
35 Opris D, Pinteá S, Garcia-Palacios A, et al. Virtual reality exposure therapy in anxiety disorders: A  
36 quantitative meta-analysis. *Depress Anxiety* 2012;29(2):85-93.
- 37  
38 Palic S, Elklit A. Psychosocial treatment of post-traumatic stress disorder in adult refugees: a  
39 systematic review of prospective treatment outcome studies and a critique. *J Affect Disord*  
40 2011;131(1-3):8-23.
- 41  
42 Piet J, Hougaard E. The effect of mindfulness-based cognitive therapy for prevention of relapse in  
43 recurrent major depressive disorder: a systematic review and meta-analysis. *Clin Psychol Rev*  
44 2011;31(6):1032-1040.
- 45  
46 Possemato K, The current state of intervention research for posttraumatic stress disorder within the  
47 primary care setting. *J Clin Psychol Med Settings* 2011;18(3):268-280.
- 48  
49 Powers MB, Halpern JM, Ferenschak MP, et al. A meta-analytic review of prolonged exposure for  
50 posttraumatic stress disorder. *Clin Psychol Rev* 2010;30(6):635-641.
- 51  
52 Rakofsky JJ, Dunlop BW, Treating Nonspecific Anxiety and Anxiety Disorders in Patients With Bipolar  
53 Disorder: A Review. *J Clin Psychiatry* 2011;72(1):81-91.
- 54  
55 Richards D, Richardson T. Computer-based psychological treatments for depression: A systematic  
56 review and meta-analysis *Clin Psychol Rev* 2012;32:329-342.
- 57  
58 Rizzo M, Creed F, Goldberg D, et al. A systematic review of non-pharmacological treatments for  
59 depression in people with chronic physical health problems. *J Psychosom Res* 2011;71(1):18-27.
- 60  
61 Roberts NP, Kitchiner NJ, Kenardy J, et al. Early psychological interventions to treat acute traumatic  
62 stress symptoms. *Cochrane Database Syst Rev* 2010;3:CD007944.  
63 doi:10.1002/14651858.CD007944.pub2.

- 1  
2  
3 Rosenberg Edwards A. Psychotherapy and Pharmacotherapy for Social Anxiety Disorder: A  
4 Comprehensive Meta-Analysis. *Dissertation abstracts international: Section B: the Sciences and*  
5 *Engineering* 2011;72(4-B):2433-2601.
- 6  
7 Roshanaei-Moghaddam B, Pauly MC, Atkins DC, et al. Relative effects of CBT and pharmacotherapy  
8 in depression versus anxiety: Is medication somewhat better for depression, and CBT somewhat  
9 better for anxiety? *Depress Anxiety* 2011;28:560–567.
- 10  
11 Samad Z, Brealey S, Gilbody S. The effectiveness of behavioural therapy for the treatment of  
12 depression in older adults: a meta-analysis. *Int J of Geriatr Psychiatry* 2011;26(12):1211-1220.
- 13  
14 Sanchez-Meca J, Rosa-Alcázar AI, Marín-Martínez F, et al. Psychological treatment of panic disorder  
15 with or without agoraphobia: a meta-analysis. *Clin Psychol Rev* 2010;30(1):37-50.
- 16  
17 Schoenfeld FB, DeViva JC, Manber R. Treatment of sleep disturbances in posttraumatic stress  
18 disorder: A review. *J Rehabil Res Dev* 2012;49(5):729–752.
- 19  
20 Sempértegui GA, Karreman A, Arntz A, et al. Schema therapy for borderline personality disorder: a  
21 comprehensive review of its empirical foundations, effectiveness and implementation possibilities. *Clin*  
22 *Psychol Rev* 2013;33(3):426-47.
- 23  
24 Sloan DM, Bovin MJ, Schnurr PP. Review of group treatment for PTSD. *J Rehabil Res Dev*  
25 2012;49(5):689-701.
- 26  
27 Sloan DM, Feinstein BA, Gallagher MW, et al. Efficacy of Group Treatment for Posttraumatic Stress  
28 Disorder Symptoms: A Meta-Analysis. *Psychol Trauma* 2013;5(2):176-183.
- 29  
30 Sloan DM, Gallagher MW, Feinstein BA, et al. Efficacy of telehealth treatments for posttraumatic  
31 stress-related symptoms: a meta-analysis. *Cogn Behav Ther* 2011;40(2):111-125.
- 32  
33 Spielmans GI, Berman MI, Usitalo AN. Psychotherapy Versus Second-Generation Antidepressants in  
34 the Treatment of Depression A Meta-Analysis. *J Nerv Ment Dis* 2011;199:142–149.
- 35  
36 Spijker J, van Straten A, Bockting CL, et al. Psychotherapy, Antidepressants, and Their Combination  
37 for Chronic Major Depressive Disorder: A Systematic Review. *Can J Psychiatry* 2013;58(7):386-392.
- 38  
39 Stagg EK, Lazenby M. Best Practices for the Nonpharmacological Treatment of Depression at the End  
40 of Life. *Am J Hosp Palliat Care* 2012;29(3):183-194.
- 41  
42 Steenkamp MM, Litz BT Psychotherapy for military-related posttraumatic stress disorder: review of the  
43 evidence. *Clin Psychol Rev* 2013;33(1):45-53.
- 44  
45 Stoffers JM, Völlm BA, Rucker G, et al. Psychological therapies for people with borderline personality  
46 disorder (Review). *Cochrane Database Syst Rev* 2012;8:CD005652.  
47 doi:10.1002/14651858.CD005652.pub2.
- 48  
49 Van Dam D, Vedel E, Ehring T, et al. Psychological treatments for concurrent posttraumatic stress  
50 disorder and substance use disorder: A systematic review. *Clin Psychol Rev* 2012;32:202–214.
- 51  
52 Van der Feltz-Cornelis CM, Nuyen J, Stoop C, et al. Effect of interventions for major depressive  
53 disorder and significant depressive symptoms in patients with diabetes mellitus: a systematic review  
54 and meta-analysis *Gen Hosp Psychiatry* 2010;32:380–395.
- 55  
56 Van der Heiden C. Metacognitions in generalized anxiety disorder: theoretical and practical  
57 perspectives. *Expert Rev Neurother* 2013;13(2):135-141.
- 58  
59 Van Emmerik AA, Reijntjes A, Kamphuis JH. Writing Therapy for Posttraumatic Stress: A Meta-  
60 Analysis. *Psychother Psychosom* 2013;82:82-88.
- Van Hees ML, Rotter T, Ellermann T, et al. The effectiveness of individual interpersonal  
psychotherapy as a treatment for major depressive disorder in adult outpatients: A systematic review.  
*BMC Psychiatry* 2013;13:22. doi:10.1186/1471-244X-13-22.



1  
2  
3  
4 Van Straten A, Geraedts A, Verdonck-de Leeuw IM, et al. Psychological treatment of depressive  
5 symptoms in patients with medical disorders: a meta-analysis. *J Psychosom Res* 2010;69(1):23-32.

6  
7 Vøllestad J, Nielsen MB, Nielsen GH Mindfulness- and acceptance-based interventions for anxiety  
8 disorders: A systematic review and meta-analysis. *Br J Clin Psychol* 2012;51:239–260.

9  
10 Watts BV, Schnurr PP, Mayo L, et al. Meta-Analysis of the Efficacy of Treatments for Posttraumatic  
11 Stress Disorder. *J Clin Psychiatry* 2013;74(6):541-550.

12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

Supplement Table 4: Journals in which the 95 reviews were published

Journal	2010	2011	2012	2013	Total number
Clin Psychol Rev	4	3	5	8	20
Depress Anxiety	-	1	3	1	5
J Affect Disord	-	2	1	2	5
Cochrane Database Syst Rev	3	-	1	-	4
Br J Psychiatry	1	1	1	-	3
Can J Psychiatry	-	1	-	2	3
Int J of Geriatr Psychiatry	-	2	-	1	3
J Clin Psychiatry	-	1	1	1	3
Expert Rev Neurother	-	-	1	1	2
Harv Rev Psychiatry	-	1	1	-	2
J Consult Clin Psychol	1	-	-	1	2
J Psychosom Res	1	1	-	-	2
Psychol Med	-	1	1	-	2
Acta Psychiatr Scand	1	-	-	-	1
Am J Addict	-	1	-	-	1
Am J Hosp Palliat Care	-	-	1	-	1
Am J Psychiatry	-	1	-	-	1
BMC Psychiatry	-	-	-	1	1
Brain inj	-	-	-	1	1
Br J Clin Psychol	-	-	1	-	1
Can J Occup Ther	-	-	-	1	1
Clin Gerontol	-	-	-	1	1
Cogn Behav Ther	-	1	-	-	1
Dissertations Abstracts international: Section B: The Sciences and Engineering	-	1	-	-	1
Eur Rev Appl Psychol	-	-	1	-	1
Gen Hosp Psychiatry	1	-	-	-	1
J Am Geriatr Soc	-	-	1	-	1
J Anxiety Disord	-	-	1	-	1

J Clin Oncol	-	-	-	1	1
J Clin Psychol Med Settings	-	1	-	-	1
J Cogn Psychother	-	-	-	1	1
J Natl Cancer Inst	-	-	1	-	1
J Nerv Ment Dis	-	1	-	-	1
J Psychiatr Res	-	-	-	1	1
J Rehabil Res Dev	-	-	1	-	1
J Res Nurs	-	-	-	1	1
Neuropharmacology	-	-	1	-	1
Nord J Psychiatry	-	1	-	-	1
Perm J	-	-	-	1	1
Prog Neuropsychopharmacol Biol Psychiatry	-	-	-	1	1
Psychiatr Clin North Am	-	-	1	-	1
Psychiatry	-	1	-	-	1
Psychol Rep	-	1	-	-	1
Psychol Trauma	-	-	-	1	1
Psychosom Med	-	-	-	1	1
Psychosomatics	-	1	-	-	1
Psychother Psychosom	-	-	-	1	1
Respir Med	-	1	-	-	1
Scientific World Journal	-	-	1	-	1
Worldviews Evid Based Nurs	-	-	1	-	1



Supplement Table 5: Mandatory disclosure of Conflicts of Interest by Journal at the time of publication of the respective review.

Journal	Personal COI	Financial COI	Non-Financial COI
Acta Psychiatr Scand	no	Yes	No
Am J Addict	no	Yes	Yes
Am J Hosp Palliat Care	no	yes	No
Am J Psychiatry	no	yes	No
BMC Psychiatry	no	no	No
Brain Inj	yes	yes	No
Br J Clin Psychol	no	no	No
Br J Psychiatry	yes	yes	Yes
Can J Occup Ther	no	no	No
Can J Psychiatry	yes	yes	Yes
Clin Gerontol	no	no	No
Clin Psychol Rev	yes	yes	Yes
Cochrane Database Syst Rev	yes	yes	Yes
Cogn Behav Ther	no	no	No
Depress Anxiety	yes	yes	No
Dissertations Abstracts international: Section B: The Sciences and Engineering	no	no	No
Eur Rev Appl Psychol	yes	yes	Yes
Expert Rev Neurother	yes	yes	Yes
Gen Hosp Psychiatry	yes	yes	Yes
Harv Rev Psychiatry	yes	yes	No
Int J of Geriatr Psychiatry	yes	yes	No
J Affect Disord	yes	yes	Yes
J Am Geriatr Soc	yes	yes	Yes
J Anxiety Disord	yes	yes	Yes
J Clin Oncol	yes	yes	No
J Clin Psychiatry	yes	yes	No

J Clin Psychol Med Settings	no	yes	No
J Cogn Psychother	unclear	unclear	Unclear
J Consult Clin Psychol	yes	yes	No
J Natl Cancer Inst	no	yes	No
J Nerv Ment Dis	yes	yes	Yes
J Psychiatr Res	yes	yes	No
J Psychosom Res	yes	yes	Yes
J Rehabil Res Dev	yes	yes	No
J Res Nurs	no	yes	No
Neuropharmacology	yes	yes	Yes
Nord J Psychiatry	no	yes	No
Perm J	yes	yes	No
Prog Neuropsychopharmacol Biol Psychiatry	yes	yes	Yes
Psychiatr Clin North Am	no	yes	No
Psychiatry	no	no	No
Psychol Med	yes	yes	No
Psychol Rep	no	no	No
Psychol Trauma	yes	yes	Yes
Psychosom Med	yes	yes	No
Psychosomatics	no	yes	No
Psychother Psychosom	no	yes	No
Respir Med	yes	yes	Yes
Scientific World Journal	no	no	No
Worldviews Evid Based Nurs	no	yes	No

Supplement Table 6: References of the own primary studies included into 34 reviews by the review authors

Abbass AA, Campbell S, Magee K, et al. Intensive short-term dynamic psychotherapy to reduce rates of emergency department return visits for patients with medically unexplained symptoms: preliminary evidence from a pre-post intervention study. *CJEM* 2009;11(6):529–534.

Abbass A. Intensive short-term dynamic psychotherapy in a private psychiatric office: Clinical and cost effectiveness. *Am J Psychother* 2002;56:225–232.

Abbass A. Intensive short-term dynamic psychotherapy of treatment-resistant depression: a pilot study. *Depress Anxiety* 2006;23:449–452.

Abbass A. Modified short-term dynamic psychotherapy in patients with bipolar disorder. Preliminary report of a case series. *Can Child Psychiatry Rev* 2002;11(1):19–22.

Abbass A. Office based research in intensive short-term dynamic psychotherapy (ISTDP): data from the first 6 years of practice. *Ad Hoc Bull Short Term Dyn Psychother* 2002;6(2):5–14.

Abbass A, Sheldon A, Gyra A, et al. Intensive short-term dynamic psychotherapy for DSM-IV personality disorders. *J Nerv Ment Dis* 2008;196:211–216.

Abbass A. Small-group videotape training for psychotherapy skill development. *Acad Psychiatry* 2004;28:151–155.

Andersson G, Waara J, Jonsson U, et al. Internet-based self-help versus one-session exposure in the treatment of spider phobia: a randomized controlled trial. *Cogn Behav Ther* 2009;38:114–120.

Araya R, Rojas G, Fritsch R, et al. Treating depression in primary care in low-income women in Santiago, Chile: a randomised controlled trial. *Lancet* 2003;361:995–1000.

Arntz A, Dietzel R, Dreessen L. Assumptions in borderline personality disorder, specificity, stability and relationship with etiological factors. *Behav Res Ther* 1999;37(6):545–557.

Arntz A, Dreessen L, Schouten E, et al. Beliefs in personality disorders: A test with the Personality Disorder Belief Questionnaire. *Behav Res Ther* 2004;42(10):1215–1225.

Arntz A, Klokman J, Sieswerda S. An experimental test of the schema mode model of borderline personality disorder. *J Behav Ther Exp Psychiatry* 2005;36(3):226–239.

Arntz A, Weertman A, Salet S. Interpretation bias in Cluster-C and borderline personality disorders. *Behav Res Ther* 2011;49(8):472–481.

Beck JG, Coffey SF, Foy DW, et al. Group cognitive behavior therapy for chronic posttraumatic stress disorder: An initial randomized pilot study. *Behav Ther* 2009;40:82–92.

Bisson JI, Shepherd JP, Joy D, et al. Early cognitive-behavioural therapy for post-traumatic stress symptoms after physical injury. *Br J Psychiatry* 2004;184:63–69.

Bormann JE, Thorp SR, Wetherell JL, et al. Meditation-Based Mantram Intervention for Veterans With Posttraumatic Stress Disorder: A Randomized Trial. *Psychol Trauma* 2012, March. Advance online publication. doi: 10.1037/a0027522.

Botella C, Garcia-Palacios A, Villa H, et al. Virtual reality exposure in the treatment of panic disorder and agoraphobia: a controlled study. *Clin Psychol Psychother* 2007;14:164–175.

Chard KM. An evaluation of cognitive processing therapy for the treatment of posttraumatic stress disorder related to childhood sexual abuse. *J Consult Clin Psychol* 2005;73(5):965–971.

Chard KM, Schumm JA, McIlvain SM, et al. Exploring the efficacy of a residential treatment for veterans with PTSD and traumatic brain injury. *J Trauma Stress* 2011;24(3):347–351.

- 1  
2  
3  
4 Chard KM, Schumm JA, Owens GP, et al. A comparison of OEF and OIF veterans and Vietnam veterans  
5 receiving cognitive processing therapy. *J Trauma Stress* 2010;23(1):25–32.
- 6  
7 De Jonghe F, Hendriksen M, van Aalst G, et al. Psychotherapy alone and combined with pharmacotherapy  
8 in the treatment of depression. *Br J Psychiatry* 2004;185:37-45.
- 9  
10 Dickhaut V, Arntz A. Combined group and individual schema therapy for borderline personality disorder: A  
11 pilot study. *J Behav Ther Exp Psychiatr* 2014;45:242-251.
- 12  
13 Dimidjian S, Hollon SD, Dobson KS, et al. Randomized trial of behavioral activation, cognitive therapy, and  
14 antidepressant medication in the acute treatment of adults with major depression. *J Consult Clin Psychol*  
15 2006;74:658–670.
- 16  
17 DuHamel KN, Mosher CE, Winkel G, et al. Randomized clinical trial of Telephone – administered cognitive-  
18 behavioral therapy to reduce posttraumatic stress disorder and distress symptoms after hematopoietic  
19 stem-cell transplantation. *J Clin Oncol* 2010;28(23):3754-3761.
- 20  
21 Ekers D, Richards D, Gilbody S. A meta-analysis of behavioural therapy for depression. *Psychol Med*  
22 2008;38(5):611-623.
- 23  
24 Fava GA, Rafanelli C, Grandi S, et al. Six-year outcome for cognitive behavioral treatment of residual  
25 symptoms in major depression. *Am J Psychiatry* 1998;155:1443–1445.
- 26  
27 Fava GA, Ruini C, Rafanelli C, et al. Six-year outcome of cognitive behavior therapy for prevention of  
28 recurrent depression. *Am J Psychiatry* 2004;161:1872–1876.
- 29  
30 Fiorillo A, Malangone C, Del Vecchio VC, et al. Maj The effect of family psychoeducational interventions on  
31 patients with depression. *Eur Psychiatry* 2011;26:7.
- 32  
33 Foa EB, Dancu CV, Hembree EA, et al. A Comparison of exposure therapy, stress inoculation training, and  
34 their combination for reducing posttraumatic stress disorder in female assault victims. *J Consult Clin*  
35 *Psychol* 1999;67(2):194-200.
- 36  
37 Foa EB, Hembree EA, Cahill SP, et al. Randomized trial of prolonged exposure for posttraumatic stress  
38 disorder with and without cognitive restructuring: outcome at academic and community clinics. *J Consult*  
39 *Clin Psychol* 2005;73(5):953-964.
- 40  
41 Foa EB, Rothbaum BO, Riggs DS, et al. Treatment of posttraumatic stress disorder in rape victims : A  
42 comparison between cognitive-behavioral procedures and counseling. *J Consult Clin Psychol*  
43 1991;59(5):715-723.
- 44  
45 Friedman MJ, Marmar CR, Baker DG, et al. Randomized, double-blind comparison of sertraline and  
46 placebo for posttraumatic stress disorder in a Department of Veterans Affairs setting. *J Clin Psychiatry*  
47 2007;68(5):711- 720.
- 48  
49 Furmark T, Carlbring P, Hedman E, et al. Guided and unguided self-help for social anxiety disorder:  
50 randomized controlled trial. *Br J Psychiatry* 2009;195(5):440-447.
- 51  
52 Garcia-Palacios A, Hoffman H, Carlin A, et al. Virtual reality in the treatment of spider phobia: a controlled  
53 study. *Behav Res Ther* 2002;40:983–993.
- 54  
55 Giesen-Bloo J, van Dyck R, Spinhoven P, et al. Outpatient psychotherapy for borderline personality disorder  
56 randomized trial of schema-focused therapy vs. transference-focused psychotherapy. *Arch Gen Psychiatry*  
57 2006;63(6):649–658.
- 58  
59 Gilboa-Schechtman E, Foa EB, Shafran N, et al. Prolonged exposure vs dynamic therapy for adolescent  
60 PTSD: A pilot randomized controlled trial. *J Am Acad Child Adolesc Psychiatry* 2010;49(10):1034-1042.
- Gray MJ, Schorr Y, Nash W, et al. Adaptive disclosure: An open trial of a novel exposure-based intervention  
for service members with combat-related psychological stress injuries. *Behav Ther* 2012;43:407–415.
- Hellstrom K, Öst LG. One-session therapist directed exposure vs. 2 forms of manual directed self-exposure  
in the treatment of spider phobia. *Behav Res Ther* 1995;33:959–965.

1  
2  
3 Huband N, McMurrin M, Evans C, et al. Social problem-solving plus psychoeducation for adults with  
4 personality disorder : pragmatic randomised controlled trial. *Br J Psychiatry* 2007;190:307-313.

5  
6 Joling KJ, van Hout HP, van't Veer-Tazelaar PJ, et al. How effective is bibliotherapy for very old adults with  
7 subthreshold depression? A randomized controlled trial. *Am J Geriatr Psychiatry* 2011;19(3):256-265.

8  
9 Katon WJ, Von Korff M, Lin EH, et al. The Pathways Study: a randomized trial of collaborative care in  
10 patients with diabetes and depression. *Arch Gen Psychiatry* 2004;61:1042-1049.

11  
12 Lee CW, Gavriel H, Drummond PD, et al. Treatment of PTSD: stress inoculation training with prolonged  
13 exposure compared to EMDR. *J Clin Psychol* 2002;58(9):1071-1089.

14  
15 Li M, Chen K, Mo Z. Use of qigong therapy in the detoxification of heroin addicts. *Altern Ther Health Med*  
16 2002;8:50-59.

17  
18 Lobbestael J, Arntz A, Cima M, et al. Effects of induced anger in patients with antisocial personality  
19 disorder. *Psychol Med* 2009;39(4):557-568.

20  
21 Lobbestael J, Arntz A. Emotional, cognitive and physiological correlates of abuse-related stress in  
22 borderline and antisocial personality disorder. *Behav Res Ther* 2010;48(2):116-124.

23  
24 Lobbestael J, Arntz A, Sieswerda S. Schema modes and childhood abuse in borderline and antisocial  
25 patients. *J Behav Ther Exp Psychiatry* 2005;36(3):240-253.

26  
27 Lobbestael J, Arntz A. The state dependency of cognitive schemas in antisocial patients. *Psychiatry Res*  
28 2012;198:452-456.

29  
30 Markowitz JC, Kocsis JH, Bleiberg KL, et al. A comparative trial of psychotherapy and pharmacotherapy for  
31 "pure" dysthymic patients. *J Affect Dis* 2005;89:167-175.

32  
33 Markowitz JC, Kocsis JH, Christos P, et al. Pilot study of interpersonal psychotherapy for dysthymic patients  
34 with secondary alcohol abuse or dependence. *J Nerv Ment Dis* 2008;196:468-474.

35  
36 Markowitz JC, Kocsis JH, Fishman B, et al. Treatment of depressive symptoms in human immunodeficiency  
37 virus-positive patients. *Arch Gen Psychiatry* 1998;55:452-457.

38  
39 McDonagh A, Friedman M, McHugo G, et al. Randomized trial of cognitivebehavioral  
40 therapy for chronic posttraumatic stress disorder in adult female survivors of childhood sexual abuse. *J*  
41 *Consult Clin Psycho* 2005;73(3):515-524.

42  
43 Monson CM, Schnurr PP, Resick PA, et al. Cognitive processing therapy for veterans with military-related  
44 posttraumatic stress disorder. *J Consult Clin Psychol* 2006;74(5):898-907.

45  
46 Nacasch N, Foa EB, Huppert JD, et al. The efficacy of prolonged exposure therapy for combat and terror-  
47 related PTSD: A randomized control comparison with treatment as usual. *Am J Psychiatry* 2011;72(9):1174-  
48 1180.

49  
50 Nadort M, Arntz A, Smit JH, et al. Implementation of outpatient schema therapy for borderline personality  
51 disorder with versus without crisis support of the therapist outside office hours: A randomized trial. *Behav*  
52 *Res Ther* 2009;47:961-973.

53  
54 Nadort M, van Dyck R, Smit JA, et al. Three preparatory studies for promoting implementation of outpatient  
55 schema therapy for borderline personality disorder in general mental health care. *Behav Res Ther*  
56 2009;47(11):938-945.

57  
58 Neylan TC, Lenoci M, Maglione ML, et al. The effect of nefazodone on subjective and objective sleep  
59 quality in posttraumatic stress disorder. *J Clin Psychiatry* 2003;64(4):445-450.

60  
Neylan TC, Lenoci M, Samuelson KW, et al. No improvement of post-traumatic stress disorder symptoms  
with guanfacine treat-ment. *Am J Psychiatry* 2006;163(12):2186-2188.

Nordin S, Carlbring P, Cuijpers P, et al. Expanding the limits of bibliotherapy for panic disorder:  
Randomized trial of self-help without support but with a clear deadline. *Behav Ther* 2010;41(3):267-276.

1  
2  
3 Öst LG, Salkovskis PM, Hellstrom K. One-session therapist-directed exposure vs. Self-exposure in the  
4 treatment of spider phobia. *Behav Ther* 1991;22:407-422.

5 Palic S, Elkit A. An explorative outcome study of CBT-based multidisciplinary treatment in a diverse group  
6 of refugees from a Danish treatment centre for rehabilitation of traumatized refugees. *Torture*  
7 2009;19(3):248-270.

8  
9 Perlis RH, Nierenberg AA, Alpert JE, et al. Effects of adding cognitive therapy to fluoxetine dose increase  
10 on risk of relapse and residual symptoms in continuation treatment of major depressive disorder. *J Clin*  
11 *Psychopharmacol* 2002;22:474-480.

12  
13 Reiss N, Lieb K, Arntz A, et al. Responding to the treatment challenge of patients with severe BPD: results  
14 of three pilot studies of inpatient schema therapy. *Behav Cog Psychother* 2014;42:355-367.

15 Resick PA, Galovski TE, O'Brien Uhlmansiek M, et al. A randomized clinical trial to dismantle components  
16 of cognitive processing therapy for posttraumatic stress disorder in female victims of interper-sonal violence.  
17 *J Consult Clin Psychol* 2008;76(2):243-258.

18 Resick PA, Nishith P, Weaver TL, et al. A comparison of cognitive-processing therapy with pro-longed  
19 exposure and a waiting condition for the treatment of chronic posttraumatic stress disorder in female rape  
20 vic-tims. *J Consult Clin Psychol* 2002;70(4):867-879.

21  
22 Schindler A, Hiller W. Therapieeffekte und Responseraten bei unipolar deperssiven Patienten einer  
23 verhaltenstherapeutischen Hochschulambulanz [Therapy effects and response rates of cognitive-bahavioral  
24 treatment for unipolar depressive patients in an outpatient clinic] *Zeitschrift für Klinische Psychologie und*  
25 *Psychotherapie: Forschung und Praxis* 2010;39:107-115.

26  
27 Schnurr PP, Friedman MJ, Engel CC, et al. Cognitive behavioral therapy for posttraumatic stress disorder in  
28 women: a randomized controlled trial. *JAMA* 2007;297(8):820-830.

29 Schnurr PP, Friedman MJ, Foy DW, et al. Randomized trial of traumafocused group therapy for  
30 posttraumatic stress disorder: results li•om a department of veterans affairs eooperative study. *Arch Gen*  
31 *Psychiatry* 2003;60(5):481-489.

32  
33 Schnurr PP, Friedman MJ, Lavori PW, et al. Design of Department of Veterans Affairs Cooperative Study  
34 No. 420: Group treatment of posttraumatic stress disorder. *Control Clin Trials* 2001;22(1):74-88.

35 Shelton RC, Haman KL, Rapaport MH, et al. A randomized, double-blind, active-control study of sertraline  
36 versus venlafaxine XR in major depressive disorder. *J Clin Psychiatry* 2006;67:1674-1681.

37  
38 Sieswerda S, Arntz A, Kindt M. Successful psychotherapy reduces hypervigilance in borderline personality  
39 disorder. *Behav Cog Psychotherapy* 2007;35(4):387-402.

40  
41 Sieswerda S, Arntz A, Mertens I, et al. Hypervigilance in patients with borderline personality disorder:  
42 Specificity, automaticity, and predictors. *Behav Res Ther* 2007;45(5):1011-1024.

43  
44 Spinhoven P, Giesen-Bloo J, van Dyck R, et al. Can assessors and therapists predict the outcome of long-  
45 term psychotherapy in borderline personality disorder? *J Clin Psychol* 2008;64(6):667-686.

46  
47 Spinhoven P, Giesen-Bloo J, van Dyck R, et al. The therapeutic alliance in schema-focused therapy and  
48 transference-focused psychotherapy for borderline personality disorder. *J Consult Clin Psychol*  
49 2007;75(1):104-115.

50  
51 Swanson LM, Favorite TK, Horin E, et al. A combined group treatment for nightmares and insomnia in  
52 combat veterans: A pilot study. *J Trauma Stress* 2009;22(6):639-642.

53  
54 Taylor DT, Meader N, Bird V, et al. Pharmacology subgroup of the National Institute for Health and Clinical  
55 Excellence Guideline Development Group for Depression in Chronic Physical Health Problems.  
56 Pharmacological interventions for people with depression and chronic physical health problems: Systematic  
57 review and meta-analyses of safety and efficacy. *Br J Psychiatry* 2011;198:179-188.

58  
59 Van Asselt ADI, Dirksen CD, Arntz A, et al. Outpatient psychotherapy for borderline personality disorder:  
60 Cost effectiveness of schema-focused therapy versus transference focused psychotherapy. *Br J Psychiatry*  
2008;192:450-457.



1  
2  
3 Van der Heiden C, Muris P, van der Molen HT. Randomized controlled trial on the effectiveness of  
4 metacognitive therapy and intolerance-of-uncertainty therapy for generalized anxiety disorder. *Behav Res*  
5 *Ther* 2012;50(2):100-109.

6 Van Emmerik AAP, Kamphuis JH, Ernmelkamp PMG. Treating acute stress disorder and posttraumatic  
7 stress disorder with cognitive behavioral therapy or structured writing therapy: a randomized controlled trial.  
8 *Psychother Psychosom* 2008;77:93-100.

9  
10 Vilhauer JS, Young S, Kealoha C, et al. Treating major depression by creating positive expectations for the  
11 future: a pilot study for the effectiveness of future directed therapy (FDT) on symptom severity and quality of  
12 life. *CNS Neurosci Ther* 2012;18(2):102-109.

13 Watts BV, Landon B, Groft A, et al. A sham controlled study of repetitive transcranial magnetic stimulation  
14 for posttraumatic stress disorder. *Brain Stimul* 2012;5(1):38-43.

15  
16 Willemse GRWM, Smit F, Cuijpers P, et al. Minimal-contact psychotherapy for sub-threshold depression in  
17 primary care. *Br J Psychiatry* 2004;185: 416-421.

18 Williams Jr JW, Katon W, Lin EH, et al. The effectiveness of depression care management on  
19 diabetes-related outcomes in older patients. *Ann Intern Med* 2004;140:1015-1024.

Lieb et al., BMJ Open submission Checklist of items to include when reporting a systematic review or meta-analysis

Section/topic	#	Checklist item	Reported on page #
<b>TITLE</b>			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
<b>ABSTRACT</b>			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
<b>INTRODUCTION</b>			
Rationale	3	Describe the rationale for the review in the context of what is already known.	4
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	
<b>METHODS</b>			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	n.a.
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	5
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	5
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	Suppl Tables 1 and 2



Section/topic	#	Checklist item	Reported on page #
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	5 and Fig. 1
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	5
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	n.a.
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	7
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	n.a.
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., $I^2$ ) for each meta-analysis.	n.a.
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	n.a.
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	n.a.
<b>RESULTS</b>			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	Fig. 1
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	n.a.
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome-level assessment (see Item 12).	n.a.
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group and (b) effect estimates and	n.a.

Section/topic	#	Checklist item	Reported on page #
		confidence intervals, ideally with a forest plot.	
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	n.a.
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	9
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression) (see Item 16).	n.a.
<b>DISCUSSION</b>			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., health care providers, users, and policy makers).	10f.
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review level (e.g., incomplete retrieval of identified research, reporting bias).	12
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	13
<b>FUNDING</b>			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	13

# BMJ Open

## Conflicts of interest and spin in reviews of psychological therapies: A systematic review

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2015-010606.R1
Article Type:	Research
Date Submitted by the Author:	29-Jan-2016
Complete List of Authors:	Lieb, Klaus; University Medical Center Mainz, Psychiatry and Psychotherapy Osten Sacken, Jan; University Medical Center Mainz, Psychiatry and Psychotherapy Stoffers-Winterling, Jutta; University Medical Center Mainz, Psychiatry and Psychotherapy Reiss, Neele; Goethe University, Differential Psychology and Psychological Assessment Barth, Juergen; University of Bern,
<b>Primary Subject Heading</b>:	Medical publishing and peer review
Secondary Subject Heading:	Ethics, Medical publishing and peer review, Research methods, Pharmacology and therapeutics
Keywords:	Bias, psychotherapy, conflict of interest, systematic review

SCHOLARONE™  
Manuscripts

## Conflicts of interest and spin in reviews of psychological therapies: A systematic review

Revision to BMJ Open

Klaus Lieb, Jan von der Osten-Sacken, Jutta Stoffers-Winterling, Neele Reiss, Jürgen Barth

Department of Psychiatry and Psychotherapy, University Medical Center Mainz, Untere Zahlbacher Str. 8, 55131 Mainz, Germany Klaus Lieb full professor, Jan von der Osten-Sacken cand. med., Jutta Stoffers-Winterling psychologist Department of Psychiatry and Psychotherapy, University Medical Center Mainz, Untere Zahlbacher Str. 8, 55131 Mainz, Germany Neele Reiss assistant professor, Department of Differential Psychology and Psychological Assessment, Goethe-University Frankfurt, Theodor-W.-Adorno-Platz 1, 60629 Frankfurt am Main, Germany Jürgen Barth research director Institute for Complementary and Integrative Medicine, University Hospital Zurich and University Zurich, Sonneggstr. 6, 8006 Zurich, Switzerland

### Corresponding author:

Univ.-Prof. Dr. Klaus Lieb

klaus.lieb@unimedizin-mainz.de

Phone +49 6131 17-7335

Fax +49 6131 229974

www.unimedizin-mainz.de/psychiatrie

## Abstract

**Objective** To explore conflicts of interest (COI) and their reporting in systematic reviews of psychological therapies and to evaluate spin in the conclusions of the reviews.

**Methods** MEDLINE and PsycINFO databases were searched for systematic reviews published between 2010 and 2013 that assessed effects of psychological therapies for anxiety, depressive or personality disorders and included at least one randomized controlled trial (RCT). Required COI disclosure by journal, disclosed COI by review authors and the inclusion of own primary studies by review authors were extracted. Researcher allegiance, i.e. that researchers concluded favourably about the interventions they have studied, as well as spin, i.e. differences between results and conclusions of the reviews, were rated by two independent raters.

**Results** 936 references were retrieved, 95 reviews fulfilled eligibility criteria. 59 compared psychological therapies with other forms of psychological therapies, and 36 psychological therapies with pharmacological interventions. Financial, non-financial, and personal COI were disclosed in 22, 4, and 1 review, respectively. Two of 86 own primary studies of review authors included in 34 reviews were disclosed by review authors. In 15 of the reviews, authors showed an allegiance effect to the evaluated psychological therapy that was never disclosed. Spin in review conclusions was found in 27 of 95 reviews. Reviews with a conclusion in favour of psychological therapies (vs. pharmacological interventions) were at high risk for a spin in conclusions (OR = 8.31 [1.41 to 49.05]). Spin was related in trend to the inclusion of own primary studies in the systematic review (OR = 2.08 [CI 0.83 to 5.18] p = .11) and researcher allegiance (OR = 2.63 [0.84 to 8.16] p = 0.16).

**Conclusions** Non-financial COI, especially the inclusion of own primary studies into reviews and researcher allegiance, are frequently seen in systematic reviews of psychological therapies and need more transparency and better management.

## Article summary

### Strengths and limitations of this study

- This study addresses a widely neglected research topic, i.e. spin introduced by non-financial conflicts of interest, e.g. the researcher allegiance to a specific therapy, in reviews on psychotherapy studies.
- Although authors of reviews of psychological therapies frequently show COI (which mainly are not declared), the relationship to spin in review conclusions is less clear and has to be interpreted with caution.
- The selection of studies up to 2013 does not reflect possible changes in COI declarations in recent years. However, the authors are not aware of changes in COI declaration requirements regarding non-financial COI in 2014 or 2015.

## Introduction

Conflicts of interest (COI) are defined as a set of circumstances that creates a risk that a professional judgement or action regarding a primary interest will be unduly influenced by a secondary interest<sup>1 2</sup>. Research on COI has so far mainly focused on financial COI such as close financial relationships between researchers or medical doctors and pharmaceutical companies or the financing of drug trials by pharmaceutical companies<sup>3-7</sup>. Such research has shown that studies funded by pharmaceutical companies more often yield results or conclusions in favour of the sponsoring company as compared to non-industry-funded trials<sup>8 9</sup>, that close relationships of researchers to pharmaceutical companies are linked to biased assessments of drug safety and efficacy<sup>10 11</sup>, that positive trials are more likely to be published than trials unfavourable to sponsors<sup>12</sup>, and that COI are underreported in meta-analyses of pharmacological treatments<sup>13 14</sup>.

The influence of non-financial COI, however, on the framing of research questions, the data analysis and interpretation of results, or the decision which results are being published, has been much less extensively studied<sup>15</sup>. With respect to outcome research of psychological therapies, researcher allegiance constitutes an important non-financial COI. Allegiance covers the belief of a researcher in the superiority of a treatment<sup>16 17</sup>. Allegiance may be due to a special training in one specific psychological therapy, the involvement in previous efficacy research about this psychological therapy or the involvement in development of etiological models via basic research.<sup>18-20</sup> Empirical studies showed a strong impact of researcher allegiance on outcome in psychotherapy studies: A recent meta-meta-analysis showed a robust and moderate allegiance outcome association ( $r = .26$ )<sup>21</sup>, and such an association is also present in equally effective treatments<sup>22</sup>. Taking allegiance into account for the explanation of effect differences between two active treatments studies with balanced allegiance for two different treatments show no difference in the effectiveness<sup>23</sup>.

Since nothing is known about the extent and nature of non-financial COI in systematic reviews of psychological therapies, the aim of this study was to investigate how often non-financial COI are present and disclosed in systematic reviews of psychological therapies and to analyze whether these COI increase the risk of spin in the conclusions of the reviews.



## Methods

### Search strategy and eligibility criteria of systematic reviews

We searched the MEDLINE and PsycINFO databases for systematic reviews or meta-analyses of randomised controlled trials (RCT) on psychological therapies. Reviews were selected if they fulfilled the following inclusion criteria: 1) Inclusion of psychological therapies to treat patients with anxiety disorders, personality disorders and/or major depressive disorders in adults, 2) Active control groups with either other forms of psychological therapy or pharmacological interventions, 3) Inclusion of at least one randomised study, 4) English language. Searches were last run on February 3<sup>rd</sup> 2014, covering the publication period of January 2010 to December 2013. For exact MEDLINE and PsycINFO search strategies, confer supplement tables 1 and 2.

### Screening and inclusion of systematic reviews and primary studies

Retrieved references were initially screened for inclusion by title and abstract by two independent researchers. In a second step, full texts of relevant reviews were retrieved and assessed for inclusion by two independent researchers. These reviews were used to rate conflicts of interest and their disclosure (see below).

Primary studies included in these reviews were identified from the reference list of the systematic reviews and retrieved if one of the co-authors of the review was an author of the respective primary study. These primary studies were then used to rate researcher allegiance (see below).

### Assessment of disclosed and undisclosed COI

All disclosed COI were extracted: financial COI (honoraria e.g. for consulting, lectures, scientific articles, training courses or money for research projects), non-financial COI (e.g. researcher allegiance to a psychological therapy, special qualification in a psychological therapy,

enthusiasm for a psychological therapy in scientific publications, lectures and research, or inclusion of own primary studies in reviews), and personal COI (e.g. employee or private relationship to an employee of a company - regularly addressed as relationships to pharmaceutical companies). If no COI was reported, the websites of the respective journals as well as the guidelines for authors were screened for requirements of COI disclosures at the time of the publication of the review. In addition, we assessed whether review authors included own studies on psychological therapies into their review and whether this inclusion was disclosed.

### **Rating of researcher allegiance**

In case that a review author included at least one own primary study (which he or she co-authored) into the review, we retrieved these primary studies and rated the researcher allegiance according to information presented in the primary study (note that a rating of researcher allegiance was not possible in the reviews since these do not provide essential information to rate researcher allegiance according to established standards.<sup>18-20</sup>). Researcher allegiance was rated in 73 of the 86 included primary studies since 13 reviews did not compare psychological therapies to other treatments and were therefore excluded.

Researcher allegiance was defined to be present, if the author a) recommended the respective psychological therapy over another therapy and was b) either involved in the development of the respective psychological therapy or c) was involved in research of/development of the etiological model of the psychological therapy. Two independent researchers (JOS, JB) assessed allegiance in the primary studies and disagreements were resolved with a third rater (KL). If researcher allegiance was rated to be present in at least one of the primary studies included in a review, this review was rated as afflicted by researcher allegiance. Kappa statistics showed substantial inter-rater reliability ( $k = 0.62$ ; agreement 82%).

### **Assessment of spin in review conclusions**

To assess spin in review conclusions, we evaluated whether the conclusion of the review as expressed in the abstract or the discussion section was inconsistent or consistent to the

empirical results described in the results section of the review. If the conclusion was consistent with the empirical results, the review was considered as showing no spin. If it was inconsistent, the review was rated as showing spin. Two researchers (KL, JOS), who both were blind to the author names of the review as well as the Journal having published the review, independently assessed review conclusions and results and rated whether a spin in review conclusions was present or not. If no consensus was achieved, disagreements were resolved by a third person (JB). Kappa statistics showed substantial inter-rater reliability ( $k = 0.70$ ; agreement 87%).

### Statistical analyses

The percentage of disclosed COI, researcher allegiance and reviews with spin was calculated. For the first two indicators, the number of reviews was the denominator, the latter indicator was calculated with the number of studies as denominator. The association of researcher allegiance with a spin in the conclusion of reviews is presented as Odds ratio with 95% confidence interval. The same procedure was used for the association of the inclusion of own primary studies of the authors in the review and the disclosure of COI with a spin in the review.

### Results

Our search yielded 936 references. After screening and retrieving full text articles, 95 reviews remained which met our inclusion criteria. A detailed flow chart with a schedule of the reasons for exclusions is found in Fig. 1. The reviews and meta-analyses addressed anxiety disorders ( $n = 42$ ), depressive disorders ( $n = 48$ ), and/or personality disorders ( $n = 13$ ) and allowed conclusions about the following interventions: 59 reviews compared psychological therapies with other forms of psychological therapies, and 36 compared psychological therapies with pharmacological interventions.

- Insert Fig. 1 about here -

### **Required COI disclosure by journal and disclosed COI**

The references of the 95 reviews included in this study are listed in Supplement Table 3. Supplement Table 4 gives an overview how many reviews were published per year in which journal. 40 of the 50 journals regularly requested a disclosure of COI at the time of publication of the respective review. Supplement Table 5 demonstrates which journal asked for which kind of COI disclosure in the respective year of publication of the review article. In sum: Of the 50 publishing journals, 40 requested a disclosure of financial COI (80%), 28 of personal COI (56%), and 17 of non-financial COI (34%).

In 37 of 95 reviews (38.9%), the authors disclosed that no competing interests exist. Authors in 25 of 95 reviews (26.3%) made COI statements as follows: Own study included in the review (n = 2), research activities in relation to one psychological therapy (n = 2), research support (n = 18), author has served as consultant (n = 4), served as speaker on congresses (n = 1), get honoraria (n = 5), have holdings (n = 2), have patents (n = 1), served as a trainer for a psychological therapy (n = 1), being influenced as employer (n = 1). In other words, financial, non-financial, and personal COI were disclosed in 22 reviews (23.1%), 4 reviews (4.2%), and 1 review (1%), respectively. One of the disclosures of financial COI was given in a Journal which does not request declaration of COI; the non-financial and personal COI were all given in Journals requesting such disclosures. In 33 of 95 reviews (34.7%) no COI statement was made.

### **Inclusion of own studies into the reviews and researcher allegiance**

We also looked at the frequency of the inclusion of own primary studies into the review and the allegiance of the researcher. 34 of 95 reviews (35.8%) included at least one primary study of one of the review authors. In sum, 86 primary studies (all addressing psychological therapies) were identified which were included in 34 reviews (see Supplement Table 6 for references of these included studies). 20 reviews included 1 study, 4 reviews 6 studies, 4 reviews 3 studies, 4 reviews 2 studies, 1 review 4 studies and 1 review 18 studies. In 15 of the 34 reviews which included at least one own primary study, we found a researcher allegiance.

1  
2  
3 Since both the inclusion of own primary studies and researcher allegiance can be described as  
4 non-financial COI, we further assessed the disclosure of such COI in relation to the requests of  
5 the journal to declare non-financial COI. Regarding the inclusion of own studies into the review,  
6  
7 we found: Of 34 reviews including own primary studies, inclusion of own studies by review  
8  
9 authors was declared in 2 reviews according to the policy of the journal which specifically asked  
10  
11 for inclusion of own studies, was not declared in 16 reviews published in journals requesting the  
12  
13 disclosure of non-financial COI (but not defining inclusion of own studies as non-financial COI  
14  
15 specifically), and was not declared in 16 reviews published in journals not requesting the  
16  
17 disclosure of non-financial COI at all. Regarding researcher allegiance, we found that researcher  
18  
19 allegiance was never disclosed: Of 15 reviews with a researcher allegiance, researcher  
20  
21 allegiance was not declared in 9 reviews published in journals requesting the disclosure of non-  
22  
23 financial COI (but not defining researcher allegiance as non-financial COI specifically), and was  
24  
25 not declared in 6 reviews published in journals not requesting the disclosure of non-financial COI  
26  
27 at all.  
28  
29  
30  
31  
32

### 33 **Spin in review conclusions**

34  
35 Spin in the interpretation of review results was rated to be present in 27 of 95 reviews (28%).  
36  
37 Within the 36 reviews comparing psychological therapies to pharmacological interventions, 9  
38  
39 (25%) showed a spin. In reviews comparing psychological therapies and pharmacological  
40  
41 interventions, spin in favour of a specific psychological therapy was more often present as  
42  
43 compared to spin in favour of a pharmacological intervention (Fig. 2). Reviews with a favourable  
44  
45 conclusion about psychological therapies (vs. pharmacological interventions) are at high risk for  
46  
47 a spin in conclusions (OR = 8.31 [1.41 to 49.05]), whereas favourable conclusions about effects  
48  
49 of pharmacological interventions showed no spin in our sample (OR = 1.00 [0.16 to 6.14]. Also  
50  
51 the conclusion of equal effects of psychological therapies and pharmacological interventions  
52  
53 does not face a risk of spin (OR = 0.12 [0.01 to 1.08]. The conclusion of the equality of effects of  
54  
55 psychological therapies, however, showed a trend for a spin, which means that for the primary  
56  
57  
58  
59  
60

1  
2  
3 outcome of interest the review more often states equality despite inequality of treatment effects  
4  
5 (OR = 2.69 [0.86 to 8.41].  
6  
7

8  
9 - Insert Fig. 2 about here -  
10

11  
12 We further explored whether spin in review conclusions is associated with a disclosed COI, the  
13 inclusion of own primary studies of the authors or the researcher allegiance of the authors. To do  
14 so, we first investigated these associations in all 95 reviews (Tab. 1). Conclusions with spin were  
15 not associated to disclosed COI. However, spin in conclusions was associated in trend to the  
16 inclusion of own studies in the systematic review. Reviews with inclusion of own primary studies  
17 showed more often spin than reviews without inclusion of own primary studies of the review  
18 authors (OR = 2.08 [CI 0.83 to 5.18] p = .11; Tab. 1). The odds for spin in conclusions in  
19 systematic reviews including studies with researcher allegiance was similarly increased, but  
20 statistically non-significant (OR=2.63[0.84 to 8.12], p = .16; Tab. 1).  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31

32  
33 - Insert Tab. 1 about here -  
34  
35

36  
37 Since we were especially interested in spin in favour of psychological therapies, we also  
38 investigated whether spin in review conclusions in favour of psychological therapies is  
39 associated with a disclosed COI, the inclusion of own primary studies of the authors or the  
40 researcher allegiance of the authors (Tab. 2). However, none of the associations were  
41 statistically significant or showed trends.  
42  
43  
44  
45  
46  
47  
48

49 - Insert Tab. 2 about here -  
50  
51

## 52 53 Discussion

54  
55 This study is – at least to our knowledge - the first that systematically assessed the extent and  
56 nature of reporting of financial and non-financial COI in systematic reviews of psychological  
57  
58  
59  
60

1  
2  
3 therapies and that investigated how often these conflicts are disclosed and whether they may  
4 lead to spin in review conclusions. Financial and non-financial COI were disclosed only in 23.1%  
5 and 4.2% of the reviews, respectively, although non-financial COI were much more often  
6 detectable: Review authors had included 86 own studies in approximately 1/3<sup>rd</sup> of the reviews  
7 and authors of at least 16% of the reviews had allegiance for the evaluated psychological  
8 therapy. Spin in review conclusions was found in 27 of 95 reviews (28%) and was associated in  
9 trend to a non-financial COI, i.e. the inclusion of own primary studies in the systematic review.  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19

### 20 **Disclosure of financial, non-financial and personal COI**

21 The disclosure of financial COI was requested by 80% of the journals which published the  
22 reviews in our study, but only 22 reviews (23.2%) disclosed any financial COI. This may be  
23 explained by two reasons: Firstly, systematic reviews focussing on effectiveness of  
24 psychological therapies are most often written by psychologists who have rather seldom  
25 financial ties to pharmaceutical companies as compared to physicians who often show these  
26 relationships<sup>3-7</sup>, and secondly, the minority of reviews (36 of 95 reviews) compared psychological  
27 therapies to pharmacological interventions (in 10 of those reviews, financial COI were  
28 disclosed). Although psychologists may mostly judge themselves as free of financial COI,  
29 however, researcher allegiance as well as the inclusion of own studies into a review (which we  
30 both rated as non-financial COI) may well lead to financial gains indirectly.<sup>15</sup> Since psychologists  
31 who develop new psychological treatments are often the ones who distribute and train other  
32 psychologists in those therapies, the demonstration of effectiveness of a specific psychotherapy  
33 in a review may potentially lead to high financial incentives. The promotion of the respective  
34 therapy might be easier and the number of trained psychotherapists with high course fee  
35 increases. Showing the effectiveness of a treatment can be also an important step for patents  
36 and for the implementation in treatment guidelines. The fact that researchers developing and  
37 evaluating the effectiveness of psychological therapies are mostly allied to a specific  
38 psychotherapy (e.g. cognitive behavioural therapy or psychoanalysis), makes the issue of COI in  
39 psychology therapy research very complex and much more complicated than in pharmacological  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 research. Psychologists who realize that the effect of the therapy to which they are allied is less  
4 beneficial than another therapy cannot easily switch to another therapy – in contrast to a medical  
5 doctor who can directly prescribe another drug if a drug proves to be less effective than  
6 previously thought. Therefore, researcher allegiance might be present in primary studies in any  
7 case to some extent, but needs to be carefully declared in systematic reviews.  
8  
9

10  
11 Non-financial COI were disclosed only in a very small number of reviews (4.2%) although non-  
12 financial COI such as the inclusion of own primary studies of the review authors (in 34 of 95  
13 reviews) and researcher allegiance (in 15 of 95 reviews) were detectable in a considerable  
14 number of them. This low disclosure rate may be explained by three factors: Firstly, only a  
15 minority of journals (34% at the time of assessment) requests a disclosure of non-financial COI –  
16 and all 4 declarations of non-financial COI were done in these journals; secondly, only two  
17 journals (Perm J, Cochrane Database Syst Rev) specifically asked the authors for the inclusion  
18 of own primary studies and only two others (Psychol Trauma, J Psychiatr Res) asked for  
19 circumstances related to the presence of researcher allegiance at the point of our assessment;  
20 thirdly, researchers may not see the necessity to declare such COI although present and  
21 requested by the journal asking for non-financial COI. We conclude from this finding that the  
22 necessity to declare non-financial COI should be made more transparent in journal articles. The  
23 following strategies may be effective: Journals should consequently ask their authors to disclose  
24 any non-financial COI, should exactly define such conflicts and should include examples of  
25 common causes of non-financial COI such as the inclusion of own primary studies into review  
26 articles or researcher allegiance. Even the International Committee of Medical Journal Editors  
27 (ICMJE) mainly focuses on financial COI and their disclosure but gives little emphasis on and  
28 advice to the disclosure of non-financial COI.  
29

30  
31 Similar to non-financial COI, also personal COI were very seldom disclosed (only in one review).  
32 This is probably due to the common definition of personal COI meaning any relationship to a  
33 person working in a pharmaceutical company. This of course is a less relevant COI for  
34 psychotherapist assessing treatment effects of psychological therapies. However,  
35 psychotherapists, especially the ones who develop new therapies, are very often personally  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 involved in institutes promoting the distribution and training of new psychological therapies. Such  
4  
5 personal COI may indirectly lead to considerable financial gains.  
6  
7  
8  
9

### 10 11 12 13 **Spin in review conclusions**

14  
15 Previous research of our group and others has identified different risks increasing the likelihood  
16  
17 of bias in psychotherapeutic outcome research.<sup>21 24</sup> In our study, we investigated whether  
18  
19 researcher allegiance, an important risk factor of moderate effect size<sup>21</sup>, the inclusion of own  
20  
21 primary studies into the review or any declared COI may be associated to spin in review  
22  
23 conclusions, which we found in 27 of the 95 reviews. Both reviews with inclusion of own primary  
24  
25 studies and reviews with researcher allegiance showed more often a spin (statistical trend).  
26  
27 Since researcher allegiance has been shown to be significantly related to outcome of  
28  
29 psychological therapies<sup>21</sup>, authors should be transparent in disclosing their own  
30  
31 psychotherapeutic training background and the inclusion of own outcome studies in systematic  
32  
33 reviews to make an assessment of COI and allegiance easier. The allegiance indicators of our  
34  
35 study might be an initial step for such a statement (development of treatment or basic research  
36  
37 on the etiological model for a specific treatment).  
38  
39  
40

### 41 42 **Shortcomings**

43  
44 This study has several shortcomings. Firstly, we restricted our search to systematic reviews and  
45  
46 meta-analyses of anxiety disorders, personality disorders and major depressive disorders. This  
47  
48 may limit the generalizability of our findings. Secondly, our study is limited to published reports  
49  
50 from 2010 onwards. This limits generalizability to earlier reviews, but is justified since COI  
51  
52 reporting has become more regular nowadays and authors might not have been asked for a COI  
53  
54 statement in earlier submissions. Thirdly, our indicators of COI and allegiance are based on  
55  
56 publications and reporting quality on some indicators was rather low. The inter-rater reliability of  
57  
58 both ratings might be much better if reporting standards in journals would be implemented.  
59  
60

1  
2  
3 Fourth, we only checked the disclosed COI, but did not investigate whether authors might have  
4 more COI than the disclosed ones. We also did not investigate which authors of a review might  
5 be responsible for the evaluation and interpretation of studies addressing different types of  
6 interventions (i.e. pharmacotherapy and psychotherapy), since such investigations are at high  
7 risk of being inaccurate and incomplete.  
8  
9  
10  
11  
12

### 13 **Conclusions and suggestions for the management of COI in psychotherapy outcome** 14 **research**

15 We conclude that non-financial COI, especially the inclusion of own primary studies into reviews  
16 and researcher allegiance, are frequently seen in systematic reviews of psychological therapies  
17 and need more transparency. Most policies and Journal requirements for COI disclosure focus  
18 on the importance of financial COI for risks of bias and fail to capture the risk of spin associated  
19 with an allegiance. Therefore, if Journals place more emphasis on the declaration of non-  
20 financial COI, declaration rates of non-financial COI by authors will most likely increase. If spin  
21 effects of non-financial COI in psychotherapy outcome research are confirmed in further studies,  
22 journals should do more than simply providing transparency of COI in order to better manage the  
23 impact of COI on research outcomes and publications<sup>15</sup>. Strategies to mitigate biases may  
24 include the detection and removal of spin at the editorial stage, using independent authors and  
25 reviewers interpreting the findings of meta-analyses, the rejection of systematic reviews that  
26 demonstrate selective citation biases, and providing free access to all data of systematic reviews  
27 to ensure that systematic reviews can be more easily replicated.  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48

### 49 **Acknowledgements**

50 The study was funded by intramural funds from the University Medical Center Mainz, Department of  
51 Psychiatry and Psychotherapy, Mainz, Germany; there was no extramural funding. We thank V.  
52 Stancheva for helping in study extraction.  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

BMJ Open: first published as 10.1136/bmjopen-2015-010606 on 26 April 2016. Downloaded from <http://bmjopen.bmj.com/> on October 31, 2024 by guest. Protected by copyright.

### Contributorship statement

KL designed the study, analysed data, monitored study extraction, data analysis and interpretation, and drafted and revised the paper. He is guarantor. JOS and NR extracted and analysed data and revised the draft of the manuscript, JSW analysed data and revised the draft of the manuscript. JB analysed data, monitored study extraction, data analysis and interpretation, and revised the paper. All authors gave final approval of the version to be published. All authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

### Transparency declaration

The guarantor affirms that the manuscript is an honest, accurate, and transparent account of the study being reported and that no important aspects of the study have been omitted.

### Declaration of competing interests

All authors have completed the ICMJE uniform disclosure form at [www.icmje.org/coi\\_disclosure.pdf](http://www.icmje.org/coi_disclosure.pdf) and declare: no support from any organisation for the submitted work; KL and JB are active in research on conflicts of interest in medicine and psychology, and JB was involved in the development of indicators of allegiance. All authors declare that they had no financial or personal relationships with pharmaceutical companies within the last 3 years. KL, NR, JSW and JB are psychotherapists trained in CBT, KL and NR also in schematherapy. NR and JB, but not KL and JSW, did receive money from institutes providing training in schematherapy and CBT within the last three years. JSW and KL are coauthors on two reviews included into the study (Gibbon et al., 2010 and Stoffers et al., 2012), and NR and KL are coauthors on one primary study (Reiss et al., 2014) included in one of the reviews.

**License for publication statement**

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, a worldwide licence to the Publishers and its licensees in perpetuity, in all forms, formats and media (whether known now or created in the future), to i) publish, reproduce, distribute, display and store the Contribution, ii) translate the Contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or, abstracts of the Contribution, iii) create any other derivative work(s) based on the Contribution, iv) to exploit all subsidiary rights in the Contribution, v) the inclusion of electronic links from the Contribution to third party material where-ever it may be located; and, vi) licence any third party to do any or all of the above.

**Data sharing statement**

No additional data available.

## References

1. Thompson DF. The Challenge of Conflict of Interest in Medicine. *Z Evid Fortbild Qual Gesundheitswes* 2009;**103**(3):136-40.
2. Lo B, Fields (ed.) *Conflict of Interest in Medical Research, Education, and Practice*, Institute of Medicine 2009.
3. Campbell EG. Doctors and drug companies - scrutinizing influential relationships. *N Engl J Med* 2007;**357**(18):1796-7.
4. Campbell EG, Rao SR, DesRoches CM, et al. Physician professionalism and changes in physician-industry relationships from 2004 to 2009. *Arch Intern Med* 2010;**170**(20):1820-6.
5. Campbell EG, Weissman JS, Ehringhaus S, et al. Institutional academic industry relationships. *JAMA* 2007;**298**(15):1779-86.
6. Lieb K, Brandtönes S. A survey of german physicians in private practice about contacts with pharmaceutical sales representatives. *Dt Arztebl Int* 2010;**107**(22):392.
7. Lieb K, Scheurich A. Contact between Doctors and the Pharmaceutical Industry, Their Perceptions, and the Effects on Prescribing Habits. *PloS one* 2014;**9**(10):e110130.
8. Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. *JAMA* 2003;**289**(4):454-65.
9. Schott G, Pahl H, Limbach U, et al. The financing of drug trials by pharmaceutical companies and its consequences. Part 1: a qualitative, systematic review of the literature on possible influences on the findings, protocols, and quality of drug trials. *Dt Arztebl Int* 2010;**107**(16):279-85.
10. Wang AT, McCoy CP, Murad MH, et al. Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review. *BMJ* 2010;**340**:e1344.
11. Dunn AG, Arachi D, Hudgins J, et al. Financial conflicts of interest and conclusions about neuraminidase inhibitors for influenza: an analysis of systematic reviews. *Ann Intern Med* 2014;**161**(7):513-8.
12. Roest AM, de Jonge P, Williams CD, et al. Reporting Bias in Clinical Trials Investigating the Efficacy of Second-Generation Antidepressants in the Treatment of Anxiety Disorders: A Report of 2 Meta-analyses. *JAMA psychiatry* 2015;**72**(5):500-10.
13. Roseman M, Milette K, Bero LA, et al. Reporting of conflicts of interest in meta-analyses of trials of pharmacological treatments. *JAMA* 2011;**305**(10):1008-17.
14. Roseman M, Turner EH, Lexchin J, et al. Reporting of conflicts of interest from drug trials in Cochrane reviews: cross sectional study. *BMJ* 2012;**345**:e5155.
15. Clark AM, Choby A, Ainsworth K, et al. Addressing conflict of interest in non-pharmacological research. *Int J Clin Pract*. 2015;**69**(3):270-2.
16. Leykin Y, DeRubeis RJ. Allegiance in Psychotherapy Outcome Research: Separating Association From Bias. 2009.
17. Lambert MJ. Are differential treatment effects inflated by researcher therapy allegiance? Could Clever Hans count? *Clinical Psychology: Science and Practice* 1999;**6**(1):127-30.
18. Gaffan EA, Tsaousis I, Kemp-Wheeler SM. Researcher allegiance and meta-analysis: the case of cognitive therapy for depression. *J Consult Clin Psychol*. 1995;**63**(6):966-80.
19. Munder T, Gerger H, Trelle S, et al. Testing the allegiance bias hypothesis: a meta-analysis. *Psychother Res* 2011;**21**(6):670-84.
20. Miller S, Wampold B, Varhely K. Direct comparisons of treatment modalities for youth disorders: a meta-analysis. *Psychother Res* 2008;**18**(1):5-14.
21. Munder T, Brutsch O, Leonhart R, et al. Researcher allegiance in psychotherapy outcome research: an overview of reviews. *Clin Psychol Rev* 2013;**33**(4):501-11.



- 1  
2  
3 22. Munder T, Fluckiger C, Gerger H, et al. Is the allegiance effect an epiphenomenon of true  
4 efficacy differences between treatments? a meta-analysis. *J Couns Psychol*  
5 2012;**59**(4):631-7.  
6 23. Cuijpers P, Driessen E, Hollon SD, et al. The efficacy of non-directive supportive therapy for  
7 adult depression: a meta-analysis. *Clin Psychol Rev* 2012;**32**(4):280-91.  
8 24. Cuijpers P, van Straten A, Bohlmeijer E, et al. The effects of psychotherapy for adult  
9 depression are overestimated: a meta-analysis of study quality and effect size. *Psychol*  
10 *Med* 2010;**40**(2):211-23.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## Tables

Tab. 1 Association between disclosed COI and other forms of COI (i.e. inclusion of primary studies in reviews, researcher allegiance) and spin in review conclusions in all 95 reviews.

	Review with spin in conclusion	Review without spin in conclusion	Odds Ratio [95% confidence interval]
Inclusion of own primary study	13	21	2.08 [0.83 to 5.18]
No inclusion of own primary study	14	47	
Researcher allegiance	7	8	2.63 [0.84 to 8.16]
No researcher allegiance	20	60	
COI disclosed	9	16	1.63 [0.61 to 4.32]
No COI disclosed	18	52	
Inclusion of own primary study, researcher allegiance and/or COI declared	16	31	1.74 [0.70 to 4.29]
None of the three	11	37	

Tab. 2: Association between disclosed COI and other forms of COI (i.e. inclusion of primary studies in reviews, researcher allegiance) and spin in review conclusions in the reviews rated as having spin in favour of psychological therapies as compared to all other reviews.

	Review rated as “spin” in favour of psychological therapies	Review rated as “no spin” or “spin” against psychological therapies	Odds Ratio [95% confidence interval]
Inclusion of own primary study	6	28	1.24 [0.40 to 3.83]
No inclusion of own primary study	9	52	
Researcher allegiance	2	13	0.79 [0.16 to 3.94]
No researcher allegiance	13	67	
COI disclosed	4	21	1.02 [0.29 to 3.56]
No COI disclosed	11	59	
Inclusion of own primary study, researcher allegiance and/or COI disclosed	7	40	0.88 [0.29 to 2.64]
None of the three	8	40	

Lieb et al., BMJ Open bmjopen-2015-010606.R1

Figure 1: Flow chart of study selection




Fig. 1  
210x297mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Lieb et al., BMJ Open bmjopen-2015-010606.R1

Figure 2: Risk of spin in review conclusions in comparisons of different treatments (Tx1 vs. Tx2).




Fig. 2  
210x297mm (300 x 300 DPI)

## Supplements

### Conflicts of interest and bias in systematic reviews of psychological therapies

Revision to BMJ Open

Klaus Lieb, Jan von der Osten-Sacken, Jutta Stoffers-Winterling, Neele Reiss,  
Jürgen Barth

Supplement Table 1: MEDLINE EBSCO exact search strategy (last run on February 3<sup>rd</sup>, 2014)

#	
S1	(MH "Psychotherapy+")
S2	(MH "Anxiety Disorders+")*
S3	(S1 AND S2)
S4	(S1 AND S2) – Date of publication: 20100101-20131231; Publication Type: Meta-Analysis, Review

\* This search is exemplary for anxiety disorders. Separate searches were done for depressive and personality disorders, using controlled vocabulary (MH "Depressive Disorders+") or (MH "Personality Disorders+"), resp.

Supplement Table 2: PsycINFO EBSCO exact search strategy (last run on February 3<sup>rd</sup>, 2014)

#	
S1	DE "Psychotherapy" OR DE "Adlerian Psychotherapy" OR DE "Adolescent Psychotherapy" OR DE "Analytical Psychotherapy" OR DE "Autogenic Training" OR DE "Behavior Therapy" OR DE "Brief Psychotherapy" OR DE "Brief Relational Therapy" OR DE "Child Psychotherapy" OR DE "Client Centered Therapy" OR DE "Cognitive Behavior Therapy" OR DE "Conversion Therapy" OR DE "Eclectic Psychotherapy" OR DE "Emotion Focused Therapy" OR DE "Existential Therapy" OR DE "Experiential Psychotherapy" OR DE "Expressive Psychotherapy" OR DE "Eye Movement Desensitization Therapy" OR DE "Feminist Therapy" OR DE "Geriatric Psychotherapy" OR DE "Gestalt Therapy" OR DE "Group Psychotherapy" OR DE "Guided Imagery" OR DE "Humanistic Psychotherapy" OR DE "Hypnotherapy" OR DE "Individual Psychotherapy" OR DE "Insight Therapy" OR DE "Integrative Psychotherapy" OR DE "Interpersonal Psychotherapy" OR DE "Logotherapy" OR DE "Narrative Therapy" OR DE "Network Therapy" OR DE "Persuasion Therapy" OR DE "Primal Therapy" OR DE "Psychoanalysis" OR DE "Psychodrama" OR DE "Psychodynamic Psychotherapy" OR DE "Psychotherapeutic Counseling" OR DE "Rational Emotive Behavior Therapy" OR DE "Reality Therapy" OR DE "Relationship Therapy" OR DE "Solution Focused Therapy" OR DE "Supportive Psychotherapy" OR DE "Transactional Analysis"
S2	DE "Anxiety Disorders" OR DE "Acute Stress Disorder" OR DE "Castration Anxiety" OR DE "Death Anxiety" OR DE "Generalized Anxiety Disorder" OR DE "Obsessive Compulsive Disorder" OR DE "Panic Disorder" OR DE "Phobias" OR DE "Posttraumatic Stress Disorder" OR DE "Separation Anxiety"
S3	(S1 AND S2)
S4	(S1 AND S2) – Published date: 20100101-20131231; Methodology: -Systematic Review, -Meta Analysis

\* This search is exemplary for anxiety disorders. Separate searches were done for depressive and personality disorders, using controlled vocabulary (DE "Major Depression" OR DE "Anaclitic Depression" OR DE "Dysthymic Disorder" OR DE "Endogenous Depression" OR DE "Postpartum Depression" OR DE "Reactive Depression" OR DE "Recurrent Depression" OR DE "Treatment Resistant Depression") or (DE "Personality Disorders" OR DE "Antisocial Personality Disorder" OR DE "Avoidant Personality Disorder" OR DE "Borderline Personality Disorder" OR DE "Dependent Personality Disorder" OR DE "Histrionic Personality Disorder" OR DE "Narcissistic Personality Disorder" OR DE "Obsessive Compulsive Personality Disorder" OR DE "Paranoid Personality Disorder" OR DE "Passive Aggressive Personality Disorder" OR DE "Sadomasochistic Personality" OR DE "Schizoid Personality Disorder" OR DE "Schizotypal Personality Disorder"), resp.



## Supplement Table 3: References of the 95 reviews included in this study

Abbass A, Town J, Driessen E. Intensive short-term dynamic psychotherapy: A systematic review and meta-analysis of outcome research. *Harv Rev Psychiatry* 2012;20(2):97-108.

Abbass A, Town J, Driessen E. The efficacy of short-term psychodynamic psychotherapy for depressive disorders with comorbid personality disorder. *Psychiatry* 2011;74(1):58-71.

Baardseth TP, Goldberg SB, Pace BT, et al. Cognitive-behavioral therapy versus other therapies: Redux. *Clin Psychol Rev* 2013;33(3):395-405.

Barker-Collo S, Starkey N, Theadom A. Treatment for depression following mild traumatic brain injury in adults: A meta-analysis. *Brain Inj* 2013;27(10):1124-1133.

Bartley CA, Hay M, Bloch MH. Meta-analysis: Aerobic exercise for the treatment of anxiety disorders. *Prog Neuropsychopharmacol Biol Psychiatry* 2013;45:34-39.

Barrera TL, Mott JM, Hofstein RF, et al. A meta-analytic review of exposure in group cognitive behavioral therapy for posttraumatic stress disorder. *Clin Psychol Rev* 2013;33(1):24-32.

Beltman MW, Oude Voshaar RC, Speckens AE. Cognitive-behavioural therapy for depression in people with a somatic disease: meta-analysis of randomized controlled trials. *Br J Psychiatry* 2010;197(1):11-19.

Bomyea J, Lang AJ. Emerging interventions for PTSD: Future directions for clinical care and research. *Neuropharmacology* 2012;62:607-616.

Bontempo A, Panza KE, Bloch MH. Meta-Analysis: D-cycloserine Augmentation of Behavioral Therapy for the Treatment of Anxiety Disorders. *J Clin Psychiatry* 2012;73(4):533-537.

Budge SL, Moore JT, Del Re AC, et al. The effectiveness of evidence-based treatments for personality disorders when comparing treatment-as-usual and bona fide treatments. *Clin Psychol Rev* 2013;33:1057-1066.

Busch FN, Sandberg LS. Combined treatment of depression. *Psychiatr Clin North Am* 2012;35:165-179.

Casement MD, Swanson LM. A meta-analysis of imagery rehearsal for post-trauma nightmares: Effects on nightmare frequency, sleep quality, and posttraumatic stress. *Clin Psychol Rev* 2012;32:566-574.

Chard KM, Ricksecker EG, Healy ET, et al. Dissemination and experience with cognitive processing therapy. *J Rehabil Res Dev* 2012;49(5):667-78.

Chen KW, Berger CC, Manheimer E, et al. Meditative therapies for reducing anxiety: A systematic review and meta-analysis of randomized controlled trials. *Dedress Anxiety* 2012;29:545-562.

Chugh-Gupta N, Baldassarre FG, Vrkljan BH. A systematic review of yoga for state anxiety: Considerations for occupational therapy. *Can J Occup Ther* 2013;80(3):150-170.

Cody RA, Drysdale K. The Effects of Psychotherapy on Reducing Depression in Residential Aged Care: A Meta-Analytic Review. *Clin Gerontol* 2013;36(1):46-69.

Cuijpers P, Andersson G, Donker T, et al. Psychological treatment of depression: Results of a series of meta-analyses. *Nord J Psychiatry* 2011;65(6):354-364.

Cuijpers P, Berking M, Andersson G, et al. A Meta-Analysis of Cognitive-Behavioral Therapy for Adult Depression, Alone and in Comparison With Other Treatments. *Can J Psychiatry* 2013;58(7):376-385.

- 1  
2  
3 Cuijpers P, Clignet F, van Meijel B, et al. Psychological treatment of depression in inpatients: a  
4 systematic review and meta-analysis. *Clin Psychol Rev* 2011;31(3):353-360.
- 5  
6 Cuijpers P, de Beurs DP, van Spijker BA, et al. The effects of psychotherapy for adult depression on  
7 suicidality and hopelessness: A systematic review and meta-analysis. *J Affect Disord*  
8 2013;144(3):183-190.
- 9  
10 Cuijpers P, Driessen E, Hollon SD, et al. The efficacy of non-directive supportive therapy for adult  
11 depression: A meta-analysis. *Clin Psychol Rev* 2012;32:280-291.
- 12  
13 Cuijpers P, Geraedts AS, van Oppen P, et al. Interpersonal Psychotherapy for Depression: A Meta-  
14 Analysis. *Am J Psychiatry* 2011;168:581-592.
- 15  
16 Cuijpers P, Huibers M, Ebert DD, et al. How much psychotherapy is needed to treat depression? A  
17 metaregression analysis. *J Affect Disord* 2013;149(1-3):1-13.
- 18  
19 Cuijpers P, Reynolds III CF, Donker T, et al. Personalized treatment of adult depression: Medication,  
20 psychotherapy, or both? A systematic review. *Depress Anxiety* 2012;29:855-864.
- 21  
22 Cuijpers P, van Straten A, Hollon SD, et al. The contribution of active medication to  
23 combined treatments of psychotherapy and pharmacotherapy for adult depression: a meta-analysis  
24 *Acta Psychiatr Scand* 2010;121:415-423.
- 25  
26 Cuijpers P, van Straten A, Schuurman J, et al. Psychotherapy for chronic major depression and  
27 dysthymia: A meta-analysis *Clin Psychol Rev* 2010;30:51-62.
- 28  
29 Daigle MS, Pouliot L, Chagnon F, et al. Suicide attempts: Prevention of repetition. *Can J Psychiatry*  
30 2011;56(10):621-629.
- 31  
32 Dickens C, Cherrington A, Adeyemi I, et al. Characteristics of Psychological Interventions That  
33 Improve Depression in People With Coronary Heart Disease: A Systematic Review and Meta-  
34 Regression. *Psychosom Med* 2013;75:211-221.
- 35  
36 Dossa NI, Hatem M. Cognitive-Behavioral Therapy versus Other PTSD Psychotherapies as  
37 Treatment for Women Victims of War-Related Violence: A Systematic Review. *Scientific World Journal*  
38 2012;2012:181847. doi:10.1100/2012/181847. Epub 2012 Apr 19.
- 39  
40 Driessen E, Cuijpers P, de Maat SCM, et al. The efficacy of short-term psychodynamic psychotherapy  
41 depression: a meta-analysis. *Clin Psychol Rev* 2010;30(1):25-36.
- 42  
43 Ekers D, Webster LAD. An overview of the effectiveness of psychological therapy for depression and  
44 stepped care service delivery models. *J Res Nurs* 2013;18(2):171-184,
- 45  
46 Fallor H, Schuler M, Richard M, et al. Effects of psycho-oncologic interventions on emotional distress  
47 and quality of life in adult patients with cancer: systematic review and meta-analysis. *J Clin Oncol*  
48 2013;31(6):782-93.
- 49  
50 Feng CY, Chu H, Chen CH, et al. The Effect of Cognitive Behavioral Group Therapy for Depression: A  
51 Meta-Analysis 2000-2010. *Worldviews Evid Based Nurs* 2012;9(1):2-17.
- 52  
53 Fritzsche A, Clamor A, von Leupoldt A. Effects of medical and psychological treatment  
54 of depression in patients with COPD e A review *Respir Med* 2011;105:1422-1433.
- 55  
56 Gibbon S, Duggan C, Stoffers J, et al. Psychological interventions for antisocial personality disorder.  
57 *Cochrane Database Syst Rev* 2010;6: CD007668. doi:10.1002/14651858.CD007668.pub2.
- 58  
59 Goncalves DC, Byrne GJ. Interventions for generalized anxiety disorder in older adults: Systematic  
60 review and meta-analysis *J Anxiety Disord* 2012;26:1-11.
- 61  
62 Goodson J, Helstrom A, Halpern JM, et al. Treatment of posttraumatic stress disorder in US combat  
63 veterans: a meta-analytic review. *Psychol Rep* 2011;109(2):573-599.

1  
2  
3 Gould RL, Coulson MC, Howard RJ. Efficacy of Cognitive Behavioral Therapy for Anxiety Disorders in  
4 Older People: A Meta-Analysis and Meta-Regression of Randomized Controlled Trials. *J Am Geriatr*  
5 *Soc* 2012;60(2):218-29. DOI: 10.1111/j.1532-5415.2011.03824.xJAGS 60:218–229, 2012.

6  
7 Guidi J, Fava GA, Fava M, et al. Efficacy of the sequential integration of psychotherapy and  
8 pharmacotherapy in major depressive disorder: a preliminary meta-analysis. *Psychol Med*  
9 2011;41:321–331.

10  
11 Gwozdziwycz N, Mehl-Madrona L. Meta-analysis of the use of narrative exposure therapy for the  
12 effects of trauma among refugee populations. *Perm J* 2013;17(1):70-76.

13  
14 Hanrahan F, Field AP, Jones FW, et al. A meta-analysis of cognitive therapy for worry in generalized  
15 anxiety disorder. *Clin Psychol Rev* 2013;33(1):120-32.

16  
17 Hans E, Hiller W. Effectiveness of and Dropout From Outpatient Cognitive Behavioral Therapy for  
18 Adult Unipolar Depression: A Meta-Analysis of Nonrandomized Effectiveness Studies. *J Consult Clin*  
19 *Psychol* 2013;81(1):75•88.

20  
21 Hansen K, Höfling V, Kröner-Borowik T, et al. Efficacy of psychological interventions aiming to reduce  
22 chronic nightmares: a meta-analysis. *Clin Psychol Rev* 2013;33(1):146-55.

23  
24 Hart SL, Hoyt MA, Diefenbach M, et al. Meta-Analysis of Efficacy of Interventions for Elevated  
25 Depressive Symptoms in Adults Diagnosed With Cancer. *J Natl Cancer Inst* 2012;104:990–1004.

26  
27 Haug T, Nordgreen T, Öst LG, et al. Self-help treatment of anxiety disorders: A meta-analysis and  
28 meta-regression of effects and potential moderators *Clin Psychol Rev* 2012;32:425–445.

29  
30 Hetrick SE, Purcell R, Garner B, et al. Combined pharmacotherapy and psychological therapies for  
31 post traumatic stress disorder (PTSD) *Cochrane Database Syst Rev* 2010;7:CD007316.  
32 DOI:10.1002/14651858.CD007316.pub2.

33  
34 Ho MSK, Lee CW. Cognitive behaviour therapy versus eye movement desensitization and  
35 reprocessing for post-traumatic disorder – is it all in the homework then? *Eur Rev Appl Psychol*  
36 2012;62:253–260.

37  
38 Hobbs JDJ, Kushner MG, Lee SS, et al. Meta-analysis of Supplemental Treatment for Depressive and  
39 Anxiety Disorders in Patients Being Treated for Alcohol Dependence. *Am J Addict* 2011;20:319–329.

40  
41 Hofmann SG, Sawyer AT, Witt AA, et al. The effect of mindfulness-based therapy on anxiety and  
42 depression: A meta-analytic review. *J Consult Clin Psychol* 2010;78(2):169-183.

43  
44 Huntley AL, Araya R, Salisbury C. Group psychological therapies for depression in the community:  
45 systematic review and meta-analysis. *Br J Psychiatry* 2012;200:184–190. doi:  
46 10.1192/bjp.bp.111.092049

47  
48 Imel ZE, Laska, K, Jakupcak M, et al. Meta-Analysis of Dropout in Treatments for Posttraumatic  
49 Stress Disorder. *J Consult Clin Psychol* 2013;81(3)394-404.

50  
51 IsHak WW, Ha K, Kapitanski N, et al. The Impact of Psychotherapy, Pharmacotherapy, and Their  
52 Combination on Quality of Life in Depression. *Harv Rev Psychiatry* 2011;19:277–289.

53  
54 Jakobsen JC, Hansen JL, Simonsen E, et al. The effect of adding psychodynamic therapy to  
55 antidepressants in patients with major depressive disorder. A systematic review of randomized clinical  
56 trials with meta-analyses and trial sequential analyses *J Affect Disord* 2012;137:4–14.

57  
58 Jakobsen JC, Hansen JL, Simonsen S, et al. Effects of cognitive therapy versus interpersonal  
59 psychotherapy in patients with major depressive disorder: a systematic review of randomized clinical  
60 trials with meta-analyses and trial sequential analyses. *Psychol Med* 2012;42:1343–1357.  
doi:10.1017/S0033291711002236.

- 1  
2  
3 Krishna M, Honagodu A, Rajendra R, et al. A systematic review and meta-analysis of group  
4 psychotherapy for sub-clinical depression in older adults. *Int J of Geriatr Psychiatry* 2013;28(9):881-  
5 888.
- 6  
7 Krishna M, Jauhari A, Lepping P, et al. Is group psychotherapy effective in older adults with  
8 depression? A systematic review. *Int J of Geriatr Psychiatry*. 2011;26(4):331-340.
- 9  
10 Leisenring F, Rabung S. Long-term psychodynamic psychotherapy in complex mental disorders:  
11 update of a meta-analysis. *Br J Psychiatry* 2011;199(1):15-22.
- 12  
13 Luciano M, Del Vecchio V, Giacco D, et al. A 'family affair'? The impact of family psychoeducational  
14 interventions on depression. *Expert Rev. Neurother* 2012;12(1):83-92.
- 15  
16 Markowitz SM, Gonzalez JS, Wilkinson JL, et al. A Review of Treating Depression in Diabetes:  
17 Emerging Findings. *Psychosomatics* 2011;52:1-18.
- 18  
19 Mavrides N, Nemeroff C. Treatment of depression in cardiovascular disease. *Depress Anxiety*  
20 2013;30(4):328-41.
- 21  
22 Nenova M, Morris L, Paul L, et al. Psychosocial Interventions With Cognitive-Behavioral Components  
23 for the Treatment of Cancer-Related Traumatic Stress Symptoms: A Review of Randomized  
24 Controlled Trials. *J Cogn Psychother* 2013;27(3)258-284.
- 25  
26 Nickerson A, Bryant RA, Silove D, et al. A critical review of psychological treatments of posttraumatic  
27 stress disorder in refugees. *Clin Psychol Rev* 2011;31:399-417.
- 28  
29 Oestergaard S, Møldrup C. Optimal duration of combined psychotherapy and pharmacotherapy for  
30 patients with moderate and severe depression: A meta-analysis. *J Affect Disord* 2011;131:24-36.
- 31  
32 Olatunji BO, Davis ML, Powers MB, et al. Cognitive-behavioral therapy for obsessive-compulsive  
33 disorder: A meta-analysis of treatment outcome and moderators. *J Psychiatr Res* 2013;47(1):33-41.
- 34  
35 Opris D, Pinteá S, Garcia-Palacios A, et al. Virtual reality exposure therapy in anxiety disorders: A  
36 quantitative meta-analysis. *Depress Anxiety* 2012;29(2):85-93.
- 37  
38 Palic S, Elklit A. Psychosocial treatment of post-traumatic stress disorder in adult refugees: a  
39 systematic review of prospective treatment outcome studies and a critique. *J Affect Disord*  
40 2011;131(1-3):8-23.
- 41  
42 Piet J, Hougaard E. The effect of mindfulness-based cognitive therapy for prevention of relapse in  
43 recurrent major depressive disorder: a systematic review and meta-analysis. *Clin Psychol Rev*  
44 2011;31(6):1032-1040.
- 45  
46 Possemato K, The current state of intervention research for posttraumatic stress disorder within the  
47 primary care setting. *J Clin Psychol Med Settings* 2011;18(3):268-280.
- 48  
49 Powers MB, Halpern JM, Ferenschak MP, et al. A meta-analytic review of prolonged exposure for  
50 posttraumatic stress disorder. *Clin Psychol Rev* 2010;30(6):635-641.
- 51  
52 Rakofsky JJ, Dunlop BW, Treating Nonspecific Anxiety and Anxiety Disorders in Patients With Bipolar  
53 Disorder: A Review. *J Clin Psychiatry* 2011;72(1):81-91.
- 54  
55 Richards D, Richardson T. Computer-based psychological treatments for depression: A systematic  
56 review and meta-analysis *Clin Psychol Rev* 2012;32:329-342.
- 57  
58 Rizzo M, Creed F, Goldberg D, et al. A systematic review of non-pharmacological treatments for  
59 depression in people with chronic physical health problems. *J Psychosom Res* 2011;71(1):18-27.
- 60  
61 Roberts NP, Kitchiner NJ, Kenardy J, et al. Early psychological interventions to treat acute traumatic  
62 stress symptoms. *Cochrane Database Syst Rev* 2010;3:CD007944.  
63 doi:10.1002/14651858.CD007944.pub2.

- 1  
2  
3 Rosenberg Edwards A. Psychotherapy and Pharmacotherapy for Social Anxiety Disorder: A  
4 Comprehensive Meta-Analysis. *Dissertation abstracts international: Section B: the Sciences and*  
5 *Engineering* 2011;72(4-B):2433-2601.
- 6  
7 Roshanaei-Moghaddam B, Pauly MC, Atkins DC, et al. Relative effects of CBT and pharmacotherapy  
8 in depression versus anxiety: Is medication somewhat better for depression, and CBT somewhat  
9 better for anxiety? *Depress Anxiety* 2011;28:560–567.
- 10  
11 Samad Z, Brealey S, Gilbody S. The effectiveness of behavioural therapy for the treatment of  
12 depression in older adults: a meta-analysis. *Int J of Geriatr Psychiatry* 2011;26(12):1211-1220.
- 13  
14 Sanchez-Meca J, Rosa-Alcázar AI, Marín-Martínez F, et al. Psychological treatment of panic disorder  
15 with or without agoraphobia: a meta-analysis. *Clin Psychol Rev* 2010;30(1):37-50.
- 16  
17 Schoenfeld FB, DeViva JC, Manber R. Treatment of sleep disturbances in posttraumatic stress  
18 disorder: A review. *J Rehabil Res Dev* 2012;49(5):729–752.
- 19  
20 Sempértegui GA, Karreman A, Arntz A, et al. Schema therapy for borderline personality disorder: a  
21 comprehensive review of its empirical foundations, effectiveness and implementation possibilities. *Clin*  
22 *Psychol Rev* 2013;33(3):426-47.
- 23  
24 Sloan DM, Bovin MJ, Schnurr PP. Review of group treatment for PTSD. *J Rehabil Res Dev*  
25 2012;49(5):689-701.
- 26  
27 Sloan DM, Feinstein BA, Gallagher MW, et al. Efficacy of Group Treatment for Posttraumatic Stress  
28 Disorder Symptoms: A Meta-Analysis. *Psychol Trauma* 2013;5(2):176-183.
- 29  
30 Sloan DM, Gallagher MW, Feinstein BA, et al. Efficacy of telehealth treatments for posttraumatic  
31 stress-related symptoms: a meta-analysis. *Cogn Behav Ther* 2011;40(2):111-125.
- 32  
33 Spielmans GI, Berman MI, Usitalo AN. Psychotherapy Versus Second-Generation Antidepressants in  
34 the Treatment of Depression A Meta-Analysis. *J Nerv Ment Dis* 2011;199:142–149.
- 35  
36 Spijker J, van Straten A, Bockting CL, et al. Psychotherapy, Antidepressants, and Their Combination  
37 for Chronic Major Depressive Disorder: A Systematic Review. *Can J Psychiatry* 2013;58(7):386-392.
- 38  
39 Stagg EK, Lazenby M. Best Practices for the Nonpharmacological Treatment of Depression at the End  
40 of Life. *Am J Hosp Palliat Care* 2012;29(3):183-194.
- 41  
42 Steenkamp MM, Litz BT Psychotherapy for military-related posttraumatic stress disorder: review of the  
43 evidence. *Clin Psychol Rev* 2013;33(1):45-53.
- 44  
45 Stoffers JM, Völlm BA, Rucker G, et al. Psychological therapies for people with borderline personality  
46 disorder (Review). *Cochrane Database Syst Rev* 2012;8:CD005652.  
47 doi:10.1002/14651858.CD005652.pub2.
- 48  
49 Van Dam D, Vedel E, Ehring T, et al. Psychological treatments for concurrent posttraumatic stress  
50 disorder and substance use disorder: A systematic review. *Clin Psychol Rev* 2012;32:202–214.
- 51  
52 Van der Feltz-Cornelis CM, Nuyen J, Stoop C, et al. Effect of interventions for major depressive  
53 disorder and significant depressive symptoms in patients with diabetes mellitus: a systematic review  
54 and meta-analysis *Gen Hosp Psychiatry* 2010;32:380–395.
- 55  
56 Van der Heiden C. Metacognitions in generalized anxiety disorder: theoretical and practical  
57 perspectives. *Expert Rev Neurother* 2013;13(2):135-141.
- 58  
59 Van Emmerik AA, Reijntjes A, Kamphuis JH. Writing Therapy for Posttraumatic Stress: A Meta-  
60 Analysis. *Psychother Psychosom* 2013;82:82-88.
- Van Hees ML, Rotter T, Ellermann T, et al. The effectiveness of individual interpersonal  
psychotherapy as a treatment for major depressive disorder in adult outpatients: A systematic review.  
*BMC Psychiatry* 2013;13:22. doi:10.1186/1471-244X-13-22.



1  
2  
3  
4 Van Straten A, Geraedts A, Verdonck-de Leeuw IM, et al. Psychological treatment of depressive  
5 symptoms in patients with medical disorders: a meta-analysis. *J Psychosom Res* 2010;69(1):23-32.

6  
7 Vøllestad J, Nielsen MB, Nielsen GH Mindfulness- and acceptance-based interventions for anxiety  
8 disorders: A systematic review and meta-analysis. *Br J Clin Psychol* 2012;51:239–260.

9  
10 Watts BV, Schnurr PP, Mayo L, et al. Meta-Analysis of the Efficacy of Treatments for Posttraumatic  
11 Stress Disorder. *J Clin Psychiatry* 2013;74(6):541-550.

12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

Supplement Table 4: Journals in which the 95 reviews were published

Journal	2010	2011	2012	2013	Total number
Clin Psychol Rev	4	3	5	8	20
Depress Anxiety	-	1	3	1	5
J Affect Disord	-	2	1	2	5
Cochrane Database Syst Rev	3	-	1	-	4
Br J Psychiatry	1	1	1	-	3
Can J Psychiatry	-	1	-	2	3
Int J of Geriatr Psychiatry	-	2	-	1	3
J Clin Psychiatry	-	1	1	1	3
Expert Rev Neurother	-	-	1	1	2
Harv Rev Psychiatry	-	1	1	-	2
J Consult Clin Psychol	1	-	-	1	2
J Psychosom Res	1	1	-	-	2
Psychol Med	-	1	1	-	2
Acta Psychiatr Scand	1	-	-	-	1
Am J Addict	-	1	-	-	1
Am J Hosp Palliat Care	-	-	1	-	1
Am J Psychiatry	-	1	-	-	1
BMC Psychiatry	-	-	-	1	1
Brain inj	-	-	-	1	1
Br J Clin Psychol	-	-	1	-	1
Can J Occup Ther	-	-	-	1	1
Clin Gerontol	-	-	-	1	1
Cogn Behav Ther	-	1	-	-	1
Dissertations Abstracts international: Section B: The Sciences and Engineering	-	1	-	-	1
Eur Rev Appl Psychol	-	-	1	-	1
Gen Hosp Psychiatry	1	-	-	-	1
J Am Geriatr Soc	-	-	1	-	1
J Anxiety Disord	-	-	1	-	1



J Clin Oncol	-	-	-	1	1
J Clin Psychol Med Settings	-	1	-	-	1
J Cogn Psychother	-	-	-	1	1
J Natl Cancer Inst	-	-	1	-	1
J Nerv Ment Dis	-	1	-	-	1
J Psychiatr Res	-	-	-	1	1
J Rehabil Res Dev	-	-	1	-	1
J Res Nurs	-	-	-	1	1
Neuropharmacology	-	-	1	-	1
Nord J Psychiatry	-	1	-	-	1
Perm J	-	-	-	1	1
Prog Neuropsychopharmacol Biol Psychiatry	-	-	-	1	1
Psychiatr Clin North Am	-	-	1	-	1
Psychiatry	-	1	-	-	1
Psychol Rep	-	1	-	-	1
Psychol Trauma	-	-	-	1	1
Psychosom Med	-	-	-	1	1
Psychosomatics	-	1	-	-	1
Psychother Psychosom	-	-	-	1	1
Respir Med	-	1	-	-	1
Scientific World Journal	-	-	1	-	1
Worldviews Evid Based Nurs	-	-	1	-	1

Supplement Table 5: Mandatory disclosure of Conflicts of Interest by Journal – last accessed  
June 8, 2014

Journal	Personal COI	Financial COI	Non- Financial COI	Inclusion of own primary study	Researcher allegiance
Acta Psychiatr Scand	no	Yes	No	No	No
Am J Addict	no	Yes	Yes	No	No
Am J Hosp Palliat Care	no	yes	No	No	No
Am J Psychiatry	no	yes	No	No	No
BMC Psychiatry	no	no	No	No	No
Brain Inj	yes	yes	No	No	No
Br J Clin Psychol	no	no	No	No	No
Br J Psychiatry	yes	yes	Yes	No	No
Can J Occup Ther	no	no	No	No	No
Can J Psychiatry	yes	yes	Yes	No	No
Clin Gerontol	no	no	No	No	No
Clin Psychol Rev	yes	yes	Yes	No	No
Cochrane Database Syst Rev	yes	yes	Yes	yes	No
Cogn Behav Ther	no	no	No	No	No
Depress Anxiety	yes	yes	No	No	No
Dissertations Abstracts international: Section B: The Sciences and Engineering	no	no	No	No	No
Eur Rev Appl Psychol	yes	yes	Yes	No	No
Expert Rev Neurother	yes	yes	Yes	No	No
Gen Hosp Psychiatry	yes	yes	Yes	No	No
Harv Rev Psychiatry	yes	yes	No	No	No
Int J of Geriatr Psychiatry	yes	yes	No	No	No
J Affect Disord	yes	yes	Yes	No	No
J Am Geriatr Soc	yes	yes	Yes	No	No

J Anxiety Disord	yes	yes	Yes	No	No
J Clin Oncol	yes	yes	No	No	No
J Clin Psychiatry	yes	yes	No	No	No
J Clin Psychol Med Settings	no	yes	No	No	No
J Cogn Psychother	unclear	unclear	Unclear	Unclear	Unclear
J Consult Clin Psychol	yes	yes	No	No	No
J Natl Cancer Inst	no	yes	No	No	No
J Nerv Ment Dis	yes	yes	Yes	No	No
J Psychiatr Res	yes	yes	No	No	yes
J Psychosom Res	yes	yes	Yes	No	No
J Rehabil Res Dev	yes	yes	No	No	No
J Res Nurs	no	yes	No	No	No
Neuropharmacology	yes	yes	Yes	No	No
Nord J Psychiatry	no	yes	No	No	No
Perm J	yes	yes	No	yes	No
Prog Neuropsychopharmacol Biol Psychiatry	yes	yes	Yes	No	No
Psychiatr Clin North Am	no	yes	No	No	No
Psychiatry	no	no	No	No	No
Psychol Med	yes	yes	No	No	No
Psychol Rep	no	no	No	No	No
Psychol Trauma	yes	yes	Yes	No	yes
Psychosom Med	yes	yes	No	No	No
Psychosomatics	no	yes	No	No	No
Psychother Psychosom	no	yes	No	No	No
Respir Med	yes	yes	Yes	No	No
Scientific World Journal	no	no	No	No	No
Worldviews Evid Based Nurs	no	yes	No	No	No

Supplement Table 6: References of the own primary studies included into 34 reviews by the review authors

Abbass AA, Campbell S, Magee K, et al. Intensive shortterm dynamic psychotherapy to reduce rates of emergency department return visits for patients with medically unexplained symptoms: preliminary evidence from a pre-post intervention study. *CJEM* 2009;11(6):529–534.

Abbass A. Intensive short-term dynamic psychotherapy in a private psychiatric office: Clinical and cost effectiveness. *Am J Psychother* 2002;56:225-232.

Abbass A. Intensive short-term dynamic psychotherapy of treatment-resistant depression: a pilot study. *Depress Anxiety* 2006;23:449–452.

Abbass A. Modified short-term dynamic psychotherapy in patients with bipolar disorder. Preliminary report of a case series. *Can Child Psychiatry Rev* 2002;11(1):19–22.

Abbass A. Office based research in intensive short-term dynamic psychotherapy (ISTDP): data from the first 6 years of practice. *Ad Hoc Bull Short Term Dyn Psychother* 2002;6(2):5–14.

Abbass A, Sheldon A, Gyra A, et al. Intensive short-term dynamic psychotherapy for DSM-IV personality disorders. *J Nerv Ment Dis* 2008;196:211–216.

Abbass A. Small-group videotape training for psychotherapy skill development. *Acad Psychiatry* 2004;28:151–155.

Andersson G, Waara J, Jonsson U, et al. Internet-based self-help versus one-session exposure in the treatment of spider phobia: a randomized controlled trial. *Cogn Behav Ther* 2009;38:114-120.

Araya R, Rojas G, Fritsch R, et al. Treating depression in primary care in low-income women in Santiago, Chile: a randomised controlled trial. *Lancet* 2003;361:995–1000.

Arntz A, Dietzel R, Dreessen L. Assumptions in borderline personality disorder, specificity, stability and relationship with etiological factors. *Behav Res Ther* 1999;37(6):545–557.

Arntz A, Dreessen L, Schouten E, et al. Beliefs in personality disorders: A test with the Personality Disorder Belief Questionnaire. *Behav Res Ther* 2004;42(10):1215–1225.

Arntz A, Klokman J, Sieswerda S. An experimental test of the schema mode model of borderline personality disorder. *J Behav Ther Exp Psychiatry* 2005;36(3):226–239.

Arntz A, Weertman A, Salet S. Interpretation bias in Cluster-C and borderline personality disorders. *Behav Res Ther* 2011;49(8):472–481.

Beck JG, Coffey SF, Foy DW, et al. Group cognitive behavior therapy for chronic posttraumatic stress disorder: An initial randomized pilot study. *Behav Ther* 2009;40:82–92.

Bisson JI, Shepherd JP, Joy D, et al. Early cognitive-behavioural therapy for post-traumatic stress symptoms after physical injury. *Br J Psychiatry* 2004;184:63-69.

Bormann JE, Thorp SR, Wetherell JL, et al. Meditation-Based Mantram Intervention for Veterans With Posttraumatic Stress Disorder: A Randomized Trial. *Psychol Trauma* 2012, March. Advance online publication. doi: 10.1037/a0027522.

Botella C, Garcia-Palacios A, Villa H, et al. Virtual reality exposure in the treatment of panic disorder and agoraphobia: a controlled study. *Clin Psychol Psychother* 2007;14:164–175.

Chard KM. An evaluation of cognitive processing therapy for the treatment of posttraumatic stress disorder related to childhood sexual abuse. *J Consult Clin Psychol* 2005;73(5):965–971.

Chard KM, Schumm JA, McIlvain SM, et al. Exploring the efficacy of a residential treatment for veterans with PTSD and traumatic brain injury. *J Trauma Stress* 2011;24(3):347–351.

- 1  
2  
3  
4 Chard KM, Schumm JA, Owens GP, et al. A comparison of OEF and OIF veterans and Vietnam veterans  
5 receiving cognitive processing therapy. *J Trauma Stress* 2010;23(1):25–32.
- 6  
7 De Jonghe F, Hendriksen M, van Aalst G, et al. Psychotherapy alone and combined with pharmacotherapy  
8 in the treatment of depression. *Br J Psychiatry* 2004;185:37-45.
- 9  
10 Dickhaut V, Arntz A. Combined group and individual schema therapy for borderline personality disorder: A  
11 pilot study. *J Behav Ther Exp Psychiatr* 2014;45:242-251.
- 12  
13 Dimidjian S, Hollon SD, Dobson KS, et al. Randomized trial of behavioral activation, cognitive therapy, and  
14 antidepressant medication in the acute treatment of adults with major depression. *J Consult Clin Psychol*  
15 2006;74:658–670.
- 16  
17 DuHamel KN, Mosher CE, Winkel G, et al. Randomized clinical trial of Telephone – administered cognitive-  
18 behavioral therapy to reduce posttraumatic stress disorder and distress symptoms after hematopoietic  
19 stem-cell transplantation. *J Clin Oncol* 2010;28(23):3754-3761.
- 20  
21 Ekers D, Richards D, Gilbody S. A meta-analysis of behavioural therapy for depression. *Psychol Med*  
22 2008;38(5):611-623.
- 23  
24 Fava GA, Rafanelli C, Grandi S, et al. Six-year outcome for cognitive behavioral treatment of residual  
25 symptoms in major depression. *Am J Psychiatry* 1998;155:1443–1445.
- 26  
27 Fava GA, Ruini C, Rafanelli C, et al. Six-year outcome of cognitive behavior therapy for prevention of  
28 recurrent depression. *Am J Psychiatry* 2004;161:1872–1876.
- 29  
30 Fiorillo A, Malangone C, Del Vecchio VC, et al. Maj The effect of family psychoeducational interventions on  
31 patients with depression. *Eur Psychiatry* 2011;26:7.
- 32  
33 Foa EB, Dancu CV, Hembree EA, et al. A Comparison of exposure therapy, stress inoculation training, and  
34 their combination for reducing posttraumatic stress disorder in female assault victims. *J Consult Clin*  
35 *Psychol* 1999;67(2):194-200.
- 36  
37 Foa EB, Hembree EA, Cahill SP, et al. Randomized trial of prolonged exposure for posttraumatic stress  
38 disorder with and without cognitive restructuring: outcome at academic and community clinics. *J Consult*  
39 *Clin Psychol* 2005;73(5):953-964.
- 40  
41 Foa EB, Rothbaum BO, Riggs DS, et al. Treatment of posttraumatic stress disorder in rape victims : A  
42 comparison between cognitive-behavioral procedures and counseling. *J Consult Clin Psychol*  
43 1991;59(5):715-723.
- 44  
45 Friedman MJ, Marmar CR, Baker DG, et al. Randomized, double-blind comparison of sertraline and  
46 placebo for posttraumatic stress disorder in a Department of Veterans Affairs setting. *J Clin Psychiatry*  
47 2007;68(5):711- 720.
- 48  
49 Furmark T, Carlbring P, Hedman E, et al. Guided and unguided self-help for social anxiety disorder:  
50 randomized controlled trial. *Br J Psychiatry* 2009;195(5):440-447.
- 51  
52 Garcia-Palacios A, Hoffman H, Carlin A, et al. Virtual reality in the treatment of spider phobia: a controlled  
53 study. *Behav Res Ther* 2002;40:983–993.
- 54  
55 Giesen-Bloo J, van Dyck R, Spinhoven P, et al. Outpatient psychotherapy for borderline personality disorder  
56 randomized trial of schema-focused therapy vs. transference-focused psychotherapy. *Arch Gen Psychiatry*  
57 2006;63(6):649–658.
- 58  
59 Gilboa-Schechtman E, Foa EB, Shafran N, et al. Prolonged exposure vs dynamic therapy for adolescent  
60 PTSD: A pilot randomized controlled trial. *J Am Acad Child Adolesc Psychiatry* 2010;49(10):1034-1042.
- Gray MJ, Schorr Y, Nash W, et al. Adaptive disclosure: An open trial of a novel exposure-based intervention  
for service members with combat-related psychological stress injuries. *Behav Ther* 2012;43:407–415.
- Hellstrom K, Öst LG. One-session therapist directed exposure vs. 2 forms of manual directed self-exposure  
in the treatment of spider phobia. *Behav Res Ther* 1995;33:959–965.

1  
2  
3 Huband N, McMurrin M, Evans C, et al. Social problem-solving plus psychoeducation for adults with  
4 personality disorder : pragmatic randomised controlled trial. *Br J Psychiatry* 2007;190:307-313.

5  
6 Joling KJ, van Hout HP, van't Veer-Tazelaar PJ, et al. How effective is bibliotherapy for very old adults with  
7 subthreshold depression? A randomized controlled trial. *Am J Geriatr Psychiatry* 2011;19(3):256-265.

8  
9 Katon WJ, Von Korff M, Lin EH, et al. The Pathways Study: a randomized trial of collaborative care in  
10 patients with diabetes and depression. *Arch Gen Psychiatry* 2004;61:1042-1049.

11  
12 Lee CW, Gavriel H, Drummond PD, et al. Treatment of PTSD: stress inoculation training with prolonged  
13 exposure compared to EMDR. *J Clin Psychol* 2002;58(9):1071-1089.

14  
15 Li M, Chen K, Mo Z. Use of qigong therapy in the detoxification of heroin addicts. *Altern Ther Health Med*  
16 2002;8:50-59.

17  
18 Lobbestael J, Arntz A, Cima M, et al. Effects of induced anger in patients with antisocial personality  
19 disorder. *Psychol Med* 2009;39(4):557-568.

20  
21 Lobbestael J, Arntz A. Emotional, cognitive and physiological correlates of abuse-related stress in  
22 borderline and antisocial personality disorder. *Behav Res Ther* 2010;48(2):116-124.

23  
24 Lobbestael J, Arntz A, Sieswerda S. Schema modes and childhood abuse in borderline and antisocial  
25 patients. *J Behav Ther Exp Psychiatry* 2005;36(3):240-253.

26  
27 Lobbestael J, Arntz A. The state dependency of cognitive schemas in antisocial patients. *Psychiatry Res*  
28 2012;198:452-456.

29  
30 Markowitz JC, Kocsis JH, Bleiberg KL, et al. A comparative trial of psychotherapy and pharmacotherapy for  
31 "pure" dysthymic patients. *J Affect Dis* 2005;89:167-175.

32  
33 Markowitz JC, Kocsis JH, Christos P, et al. Pilot study of interpersonal psychotherapy for dysthymic patients  
34 with secondary alcohol abuse or dependence. *J Nerv Ment Dis* 2008;196:468-474.

35  
36 Markowitz JC, Kocsis JH, Fishman B, et al. Treatment of depressive symptoms in human immunodeficiency  
37 virus-positive patients. *Arch Gen Psychiatry* 1998;55:452-457.

38  
39 McDonagh A, Friedman M, McHugo G, et al. Randomized trial of cognitivebehavioral  
40 therapy for chronic posttraumatic stress disorder in adult female survivors of childhood sexual abuse. *J*  
41 *Consult Clin Psycho* 2005;73(3):515-524.

42  
43 Monson CM, Schnurr PP, Resick PA, et al. Cognitive processing therapy for veterans with military-related  
44 posttraumatic stress disorder. *J Consult Clin Psychol* 2006;74(5):898-907.

45  
46 Nacasch N, Foa EB, Huppert JD, et al. The efficacy of prolonged exposure therapy for combat and terror-  
47 related PTSD: A randomized control comparison with treatment as usual. *Am J Psychiatry* 2011;72(9):1174-  
48 1180.

49  
50 Nadort M, Arntz A, Smit JH, et al. Implementation of outpatient schema therapy for borderline personality  
51 disorder with versus without crisis support of the therapist outside office hours: A randomized trial. *Behav*  
52 *Res Ther* 2009;47:961-973.

53  
54 Nadort M, van Dyck R, Smit JA, et al. Three preparatory studies for promoting implementation of outpatient  
55 schema therapy for borderline personality disorder in general mental health care. *Behav Res Ther*  
56 2009;47(11):938-945.

57  
58 Neylan TC, Lenoci M, Maglione ML, et al. The effect of nefazodone on subjective and objective sleep  
59 quality in posttraumatic stress disorder. *J Clin Psychiatry* 2003;64(4):445-450.

60  
Neylan TC, Lenoci M, Samuelson KW, et al. No improvement of post-traumatic stress disorder symptoms  
with guanfacine treatment. *Am J Psychiatry* 2006;163(12):2186-2188.

Nordin S, Carlbring P, Cuijpers P, et al. Expanding the limits of bibliotherapy for panic disorder:  
Randomized trial of self-help without support but with a clear deadline. *Behav Ther* 2010;41(3):267-276.



- 1  
2  
3 Öst LG, Salkovskis PM, Hellstrom K. One-session therapist-directed exposure vs. Self-exposure in the  
4 treatment of spider phobia. *Behav Ther* 1991;22:407-422.
- 5  
6 Palic S, Elkit A. An explorative outcome study of CBT-based multidisciplinary treatment in a diverse group  
7 of refugees from a Danish treatment centre for rehabilitation of traumatized refugees. *Torture*  
8 2009;19(3):248-270.
- 9  
10 Perlis RH, Nierenberg AA, Alpert JE, et al. Effects of adding cognitive therapy to fluoxetine dose increase  
11 on risk of relapse and residual symptoms in continuation treatment of major depressive disorder. *J Clin*  
12 *Psychopharmacol* 2002;22:474-480.
- 13  
14 Reiss N, Lieb K, Arntz A, et al. Responding to the treatment challenge of patients with severe BPD: results  
15 of three pilot studies of inpatient schema therapy. *Behav Cog Psychother* 2014;42:355-367.
- 16  
17 Resick PA, Galovski TE, O'Brien Uhlmansiek M, et al. A randomized clinical trial to dismantle components  
18 of cognitive processing therapy for posttraumatic stress disorder in female victims of interper-sonal violence.  
19 *J Consult Clin Psychol* 2008;76(2):243-258.
- 20  
21 Resick PA, Nishith P, Weaver TL, et al. A comparison of cognitive-processing therapy with pro-longed  
22 exposure and a waiting condition for the treatment of chronic posttraumatic stress disorder in female rape  
23 vic-tims. *J Consult Clin Psychol* 2002;70(4):867-879.
- 24  
25 Schindler A, Hiller W. Therapieeffekte und Responseraten bei unipolar deperssiven Patienten einer  
26 verhaltenstherapeutischen Hochschulambulanz [Therapy effects and response rates of cognitive-bahavioral  
27 treatment for unipolar depressive patients in an outpatient clinic] *Zeitschrift für Klinische Psychologie und*  
28 *Psychotherapie: Forschung und Praxis* 2010;39:107-115.
- 29  
30 Schnurr PP, Friedman MJ, Engel CC, et al. Cognitive behavioral therapy for posttraumatic stress disorder in  
31 women: a randomized controlled trial. *JAMA* 2007;297(8):820-830.
- 32  
33 Schnurr PP, Friedman MJ, Foy DW, et al. Randomized trial of traumafocused group therapy for  
34 posttraumatic stress disorder: results li•om a department of veterans affairs eooperative study. *Arch Gen*  
35 *Psychiatry* 2003;60(5):481-489.
- 36  
37 Schnurr PP, Friedman MJ, Lavori PW, et al. Design of Department of Veterans Affairs Cooperative Study  
38 No. 420: Group treatment of posttraumatic stress disorder. *Control Clin Trials* 2001;22(1):74-88.
- 39  
40 Shelton RC, Haman KL, Rapaport MH, et al. A randomized, double-blind, active-control study of sertraline  
41 versus venlafaxine XR in major depressive disorder. *J Clin Psychiatry* 2006;67:1674-1681.
- 42  
43 Sieswerda S, Arntz A, Kindt M. Successful psychotherapy reduces hypervigilance in borderline personality  
44 disorder. *Behav Cog Psychotherapy* 2007;35(4):387-402.
- 45  
46 Sieswerda S, Arntz A, Mertens I, et al. Hypervigilance in patients with borderline personality disorder:  
47 Specificity, automaticity, and predictors. *Behav Res Ther* 2007;45(5):1011-1024.
- 48  
49 Spinhoven P, Giesen-Bloo J, van Dyck R, et al. Can assessors and therapists predict the outcome of long-  
50 term psychotherapy in borderline personality disorder? *J Clin Psychol* 2008;64(6):667-686.
- 51  
52 Spinhoven P, Giesen-Bloo J, van Dyck R, et al. The therapeutic alliance in schema-focused therapy and  
53 transference-focused psychotherapy for borderline personality disorder. *J Consult Clin Psychol*  
54 2007;75(1):104-115.
- 55  
56 Swanson LM, Favorite TK, Horin E, et al. A combined group treatment for nightmares and insomnia in  
57 combat veterans: A pilot study. *J Trauma Stress* 2009;22(6):639-642.
- 58  
59 Taylor DT, Meader N, Bird V, et al. Pharmacology subgroup of the National Institute for Health and Clinical  
60 Excellence Guideline Development Group for Depression in Chronic Physical Health Problems. Pharmacological interventions for people with depression and chronic physical health problems: Systematic review and meta-analyses of safety and efficacy. *Br J Psychiatry* 2011;198:179-188.
- Van Asselt ADI, Dirksen CD, Arntz A, et al. Outpatient psychotherapy for borderline personality disorder: Cost effectiveness of schema-focused therapy versus transference focused psychotherapy. *Br J Psychiatry* 2008;192:450-457.



1  
2  
3 Van der Heiden C, Muris P, van der Molen HT. Randomized controlled trial on the effectiveness of  
4 metacognitive therapy and intolerance-of-uncertainty therapy for generalized anxiety disorder. *Behav Res*  
5 *Ther* 2012;50(2):100-109.

6 Van Emmerik AAP, Kamphuis JH, Ernmelkamp PMG. Treating acute stress disorder and posttraumatic  
7 stress disorder with cognitive behavioral therapy or structured writing therapy: a randomized controlled trial.  
8 *Psychother Psychosom* 2008;77:93-100.

9  
10 Vilhauer JS, Young S, Kealoha C, et al. Treating major depression by creating positive expectations for the  
11 future: a pilot study for the effectiveness of future directed therapy (FDT) on symptom severity and quality of  
12 life. *CNS Neurosci Ther* 2012;18(2):102-109.

13 Watts BV, Landon B, Groft A, et al. A sham controlled study of repetitive transcranial magnetic stimulation  
14 for posttraumatic stress disorder. *Brain Stimul* 2012;5(1):38-43.

15  
16 Willemsse GRWM, Smit F, Cuijpers P, et al. Minimal-contact psychotherapy for sub-threshold depression in  
17 primary care. *Br J Psychiatry* 2004;185: 416-421.

18 Williams Jr JW, Katon W, Lin EH, et al. The effectiveness of depression care management on  
19 diabetes-related outcomes in older patients. *Ann Intern Med* 2004;140:1015-1024.

Lieb et al., BMJ Open submission Checklist of items to include when reporting a systematic review or meta-analysis

Section/topic	#	Checklist item	Reported on page #
<b>TITLE</b>			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
<b>ABSTRACT</b>			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
<b>INTRODUCTION</b>			
Rationale	3	Describe the rationale for the review in the context of what is already known.	4
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	
<b>METHODS</b>			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	n.a.
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	5
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	5
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	Suppl Tables 1 and 2

Section/topic	#	Checklist item	Reported on page #
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	5 and Fig. 1
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	5
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	n.a.
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	7
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	n.a.
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., $I^2$ ) for each meta-analysis.	n.a.
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	n.a.
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	n.a.
<b>RESULTS</b>			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	Fig. 1
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	n.a.
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome-level assessment (see Item 12).	n.a.
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group and (b) effect estimates and	n.a.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

Section/topic	#	Checklist item	Reported on page #
		confidence intervals, ideally with a forest plot.	
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	n.a.
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	9
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression) (see Item 16).	n.a.
<b>DISCUSSION</b>			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., health care providers, users, and policy makers).	10f.
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review level (e.g., incomplete retrieval of identified research, reporting bias).	12
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	13
<b>FUNDING</b>			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	13

# BMJ Open

## Conflicts of interest and spin in reviews of psychological therapies: A systematic review

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2015-010606.R2
Article Type:	Research
Date Submitted by the Author:	25-Feb-2016
Complete List of Authors:	Lieb, Klaus; University Medical Center Mainz, Psychiatry and Psychotherapy Osten Sacken, Jan; University Medical Center Mainz, Psychiatry and Psychotherapy Stoffers-Winterling, Jutta; University Medical Center Mainz, Psychiatry and Psychotherapy Reiss, Neele; Goethe University, Differential Psychology and Psychological Assessment Barth, Juergen; University of Bern,
<b>Primary Subject Heading</b>:	Medical publishing and peer review
Secondary Subject Heading:	Ethics, Medical publishing and peer review, Research methods, Pharmacology and therapeutics
Keywords:	bias, psychotherapy, conflict of interest, systematic review

SCHOLARONE™  
Manuscripts

1  
2  
3  
4 **Conflicts of interest and spin in reviews of psychological therapies: A systematic**  
5 **review**  
6  
7

8  
9  
10 Revision to BMJ Open  
11

12  
13  
14 Klaus Lieb, Jan von der Osten-Sacken, Jutta Stoffers-Winterling, Neele Reiss, Jürgen  
15 Barth  
16

17  
18  
19 Department of Psychiatry and Psychotherapy, University Medical Center Mainz, Untere Zahlbacher Str. 8,  
20 55131 Mainz, Germany Klaus Lieb full professor, Jan von der Osten-Sacken cand. med., Jutta Stoffers-  
21 Winterling psychologist Department of Psychiatry and Psychotherapy, University Medical Center Mainz,  
22 Untere Zahlbacher Str. 8, 55131 Mainz, Germany Neele Reiss assistant professor, Department of  
23 Differential Psychology and Psychological Assessment, Goethe-University Frankfurt, Theodor-W.-Adorno-  
24 Platz 1, 60629 Frankfurt am Main, Germany Jürgen Barth research director Institute for Complementary  
25 and Integrative Medicine, University Hospital Zurich and University Zurich, Sonneggstr. 6, 8006 Zurich,  
26 Switzerland  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36

37 **Corresponding author:**

38 Univ.-Prof. Dr. Klaus Lieb

39 klaus.lieb@unimedizin-mainz.de

40 Phone +49 6131 17-7335

41 Fax +49 6131 229974

42 www.unimedizin-mainz.de/psychiatrie  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Abstract

**Objective** To explore conflicts of interest (COI) and their reporting in systematic reviews of psychological therapies and to evaluate spin in the conclusions of the reviews.

**Methods** MEDLINE and PsycINFO databases were searched for systematic reviews published between 2010 and 2013 that assessed effects of psychological therapies for anxiety, depressive or personality disorders and included at least one randomized controlled trial (RCT). Required COI disclosure by journal, disclosed COI by review authors and the inclusion of own primary studies by review authors were extracted. Researcher allegiance, i.e. that researchers concluded favourably about the interventions they have studied, as well as spin, i.e. differences between results and conclusions of the reviews, were rated by two independent raters.

**Results** 936 references were retrieved, 95 reviews fulfilled eligibility criteria. 59 compared psychological therapies with other forms of psychological therapies, and 36 psychological therapies with pharmacological interventions. Financial, non-financial, and personal COI were disclosed in 22, 4, and 1 review, respectively. Two of 86 own primary studies of review authors included in 34 reviews were disclosed by review authors. In 15 of the reviews, authors showed an allegiance effect to the evaluated psychological therapy that was never disclosed. Spin in review conclusions was found in 27 of 95 reviews. Reviews with a conclusion in favour of psychological therapies (vs. pharmacological interventions) were at high risk for a spin in conclusions (OR = 8.31 [1.41 to 49.05]). Spin was related in trend to the inclusion of own primary studies in the systematic review (OR = 2.08 [CI 0.83 to 5.18]  $p = .11$ ) and researcher allegiance (OR = 2.63 [0.84 to 8.16]  $p = 0.16$ ).

**Conclusions** Non-financial COI, especially the inclusion of own primary studies into reviews and researcher allegiance, are frequently seen in systematic reviews of psychological therapies and need more transparency and better management.



## Article summary

### Strengths and limitations of this study

- This study addresses a widely neglected research topic, i.e. spin introduced by non-financial conflicts of interest, e.g. the researcher allegiance to a specific therapy, in reviews on psychotherapy studies.
- Although authors of reviews of psychological therapies frequently show COI (which mainly are not declared), the relationship to spin in review conclusions is less clear and has to be interpreted with caution.
- We decided to use the term “spin” instead of “bias”, although we cannot make claims about the nature of the influence which might be mere bias or more intentional spin.
- The selection of studies up to 2013 does not reflect possible changes in COI declarations in recent years. However, the authors are not aware of changes in COI declaration requirements regarding non-financial COI in 2014 or 2015.

## Introduction

Conflicts of interest (COI) are defined as a set of circumstances that creates a risk that a professional judgement or action regarding a primary interest will be unduly influenced by a secondary interest<sup>1 2</sup>. Research on COI has so far mainly focused on financial COI such as close financial relationships between researchers or medical doctors and pharmaceutical companies or the financing of drug trials by pharmaceutical companies<sup>3-7</sup>. Such research has shown that studies funded by pharmaceutical companies more often yield results or conclusions in favour of the sponsoring company as compared to non-industry-funded trials<sup>8 9</sup>, that close relationships of researchers to pharmaceutical companies are linked to biased assessments of drug safety and efficacy<sup>10 11</sup>, that positive trials are more likely to be published than trials unfavourable to sponsors<sup>12</sup>, and that COI are underreported in meta-analyses of pharmacological treatments<sup>13 14</sup>.

The influence of non-financial COI, however, on the framing of research questions, the data analysis and interpretation of results, or the decision which results are being published, has been much less extensively studied<sup>15</sup>. With respect to outcome research of psychological therapies, researcher allegiance constitutes an important non-financial COI. Allegiance covers the belief of a researcher in the superiority of a treatment<sup>16 17</sup>. Allegiance may be due to a special training in one specific psychological therapy, the involvement in previous efficacy research about this psychological therapy or the involvement in development of etiological models via basic research.<sup>18-20</sup> Empirical studies showed a strong impact of researcher allegiance on outcome in psychotherapy studies: A recent meta-meta-analysis showed a robust and moderate allegiance outcome association ( $r = .26$ )<sup>21</sup>, and such an association is also present in equally effective treatments<sup>22</sup>. Taking allegiance into account for the explanation of effect differences between two active treatments studies with balanced allegiance for two different treatments show no difference in the effectiveness<sup>23</sup>.

Since nothing is known about the extent and nature of non-financial COI in systematic reviews of psychological therapies, the aim of this study was to investigate how often non-financial COI are present and disclosed in systematic reviews of psychological therapies and to analyze whether these COI increase the risk of spin in the conclusions of the reviews.

## Methods

### Search strategy and eligibility criteria of systematic reviews

We searched the MEDLINE and PsycINFO databases for systematic reviews or meta-analyses of randomised controlled trials (RCT) on psychological therapies. Reviews were selected if they fulfilled the following inclusion criteria: 1) Inclusion of psychological therapies to treat patients with anxiety disorders, personality disorders and/or major depressive disorders in adults, 2) Active control groups with either other forms of psychological therapy or pharmacological interventions, 3) Inclusion of at least one randomised study, 4) English language. Searches were last run on February 3<sup>rd</sup> 2014, covering the publication period of January 2010 to December 2013. For exact MEDLINE and PsycINFO search strategies, confer supplement tables 1 and 2.

### Screening and inclusion of systematic reviews and primary studies

Retrieved references were initially screened for inclusion by title and abstract by two independent researchers. In a second step, full texts of relevant reviews were retrieved and assessed for inclusion by two independent researchers. These reviews were used to rate conflicts of interest and their disclosure (see below).

Primary studies included in these reviews were identified from the reference list of the systematic reviews and retrieved if one of the co-authors of the review was an author of the respective primary study. These primary studies were then used to rate researcher allegiance (see below).

### Assessment of disclosed and undisclosed COI

All disclosed COI were extracted: financial COI (honoraria e.g. for consulting, lectures, scientific articles, training courses or money for research projects), non-financial COI (e.g. researcher allegiance to a psychological therapy, special qualification in a psychological therapy,

enthusiasm for a psychological therapy in scientific publications, lectures and research, or inclusion of own primary studies in reviews), and personal COI (e.g. employee or private relationship to an employee of a company - regularly addressed as relationships to pharmaceutical companies). If no COI was reported, the websites of the respective journals as well as the guidelines for authors were screened for requirements of COI disclosures at the time of the publication of the review. In addition, we assessed whether review authors included own studies on psychological therapies into their review and whether this inclusion was disclosed.

### **Rating of researcher allegiance**

In case that a review author included at least one own primary study (which he or she co-authored) into the review, we retrieved these primary studies and rated the researcher allegiance according to information presented in the primary study (note that a rating of researcher allegiance was not possible in the reviews since these do not provide essential information to rate researcher allegiance according to established standards.<sup>18-20</sup>). Researcher allegiance was rated in 73 of the 86 included primary studies since 13 reviews did not compare psychological therapies to other treatments and were therefore excluded.

Researcher allegiance was defined to be present, if the author a) recommended the respective psychological therapy over another therapy and was b) either involved in the development of the respective psychological therapy or c) was involved in research of/development of the etiological model of the psychological therapy. Two independent researchers (JOS, JB) assessed allegiance in the primary studies and disagreements were resolved with a third rater (KL). If researcher allegiance was rated to be present in at least one of the primary studies included in a review, this review was rated as afflicted by researcher allegiance. Kappa statistics showed substantial inter-rater reliability ( $k = 0.62$ ; agreement 82%).

### **Assessment of spin in review conclusions**

To assess spin in review conclusions, we evaluated whether the conclusion of the review as expressed in the abstract or the discussion section was inconsistent or consistent to the

empirical results described in the results section of the review. If the conclusion was consistent with the empirical results, the review was considered as showing no spin. If it was inconsistent, the review was rated as showing spin. Two researchers (KL, JOS), who both were blind to the author names of the review as well as the Journal having published the review, independently assessed review conclusions and results and rated whether a spin in review conclusions was present or not. If no consensus was achieved, disagreements were resolved by a third person (JB). Kappa statistics showed substantial inter-rater reliability ( $k = 0.70$ ; agreement 87%).

### Statistical analyses

The percentage of disclosed COI, researcher allegiance and reviews with spin was calculated. For the first two indicators, the number of reviews was the denominator, the latter indicator was calculated with the number of studies as denominator. The association of researcher allegiance with a spin in the conclusion of reviews is presented as Odds ratio with 95% confidence interval. The same procedure was used for the association of the inclusion of own primary studies of the authors in the review and the disclosure of COI with a spin in the review.

### Results

Our search yielded 936 references. After screening and retrieving full text articles, 95 reviews remained which met our inclusion criteria. A detailed flow chart with a schedule of the reasons for exclusions is found in figure 1. The reviews and meta-analyses addressed anxiety disorders ( $n = 42$ ), depressive disorders ( $n = 48$ ), and/or personality disorders ( $n = 13$ ) and allowed conclusions about the following interventions: 59 reviews compared psychological therapies with other forms of psychological therapies, and 36 compared psychological therapies with pharmacological interventions.

- Insert figure 1 about here -

### Required COI disclosure by journal and disclosed COI

The references of the 95 reviews included in this study are listed in Supplement table 3. Supplement table 4 gives an overview how many reviews were published per year in which journal. 40 of the 50 journals regularly requested a disclosure of COI at the time of publication of the respective review. Supplement table 5 demonstrates which journal asked for which kind of COI disclosure in the respective year of publication of the review article. In sum: Of the 50 publishing journals, 40 requested a disclosure of financial COI (80%), 28 of personal COI (56%), and 17 of non-financial COI (34%).

In 37 of 95 reviews (38.9%), the authors disclosed that no competing interests exist. Authors in 25 of 95 reviews (26.3%) made COI statements as follows: Own study included in the review (n = 2), research activities in relation to one psychological therapy (n = 2), research support (n = 18), author has served as consultant (n = 4), served as speaker on congresses (n = 1), get honoraria (n = 5), have holdings (n = 2), have patents (n = 1), served as a trainer for a psychological therapy (n = 1), being influenced as employer (n = 1). In other words, financial, non-financial, and personal COI were disclosed in 22 reviews (23.1%), 4 reviews (4.2%), and 1 review (1%), respectively. One of the disclosures of financial COI was given in a Journal which does not request declaration of COI; the non-financial and personal COI were all given in Journals requesting such disclosures. In 33 of 95 reviews (34.7%) no COI statement was made.

### Inclusion of own studies into the reviews and researcher allegiance

We also looked at the frequency of the inclusion of own primary studies into the review and the allegiance of the researcher. 34 of 95 reviews (35.8%) included at least one primary study of one of the review authors. In sum, 86 primary studies (all addressing psychological therapies) were identified which were included in 34 reviews (see Supplement table 6 for references of these included studies). 20 reviews included 1 study, 4 reviews 6 studies, 4 reviews 3 studies, 4 reviews 2 studies, 1 review 4 studies and 1 review 18 studies. In 15 of the 34 reviews which included at least one own primary study, we found a researcher allegiance.

1  
2  
3 Since both the inclusion of own primary studies and researcher allegiance can be described as  
4 non-financial COI, we further assessed the disclosure of such COI in relation to the requests of  
5 the journal to declare non-financial COI. Regarding the inclusion of own studies into the review,  
6  
7 we found: Of 34 reviews including own primary studies, inclusion of own studies by review  
8  
9 authors was declared in 2 reviews according to the policy of the journal which specifically asked  
10  
11 for inclusion of own studies, was not declared in 16 reviews published in journals requesting the  
12  
13 disclosure of non-financial COI (but not defining inclusion of own studies as non-financial COI  
14  
15 specifically), and was not declared in 16 reviews published in journals not requesting the  
16  
17 disclosure of non-financial COI at all. Regarding researcher allegiance, we found that researcher  
18  
19 allegiance was never disclosed: Of 15 reviews with a researcher allegiance, researcher  
20  
21 allegiance was not declared in 9 reviews published in journals requesting the disclosure of non-  
22  
23 financial COI (but not defining researcher allegiance as non-financial COI specifically), and was  
24  
25 not declared in 6 reviews published in journals not requesting the disclosure of non-financial COI  
26  
27 at all.  
28  
29  
30  
31  
32

### 33 **Spin in review conclusions**

34  
35 Spin in the interpretation of review results was rated to be present in 27 of 95 reviews (28%).  
36  
37 Within the 36 reviews comparing psychological therapies to pharmacological interventions, 9  
38  
39 (25%) showed a spin. In reviews comparing psychological therapies and pharmacological  
40  
41 interventions, spin in favour of a specific psychological therapy was more often present as  
42  
43 compared to spin in favour of a pharmacological intervention (figure 2). Reviews with a  
44  
45 favourable conclusion about psychological therapies (vs. pharmacological interventions) are at  
46  
47 high risk for a spin in conclusions (OR = 8.31 [1.41 to 49.05]), whereas favourable conclusions  
48  
49 about effects of pharmacological interventions showed no spin in our sample (OR = 1.00 [0.16 to  
50  
51 6.14]. Also the conclusion of equal effects of psychological therapies and pharmacological  
52  
53 interventions does not face a risk of spin (OR = 0.12 [0.01 to 1.08]. The conclusion of the  
54  
55 equality of effects of psychological therapies, however, showed a trend for a spin, which means  
56  
57  
58  
59  
60



1  
2  
3 that for the primary outcome of interest the review more often states equality despite inequality  
4  
5 of treatment effects (OR = 2.69 [0.86 to 8.41].  
6  
7

8  
9 - Insert figure 2 about here -  
10

11  
12 We further explored whether spin in review conclusions is associated with a disclosed COI, the  
13 inclusion of own primary studies of the authors or the researcher allegiance of the authors. To do  
14 so, we first investigated these associations in all 95 reviews (table 1). Conclusions with spin  
15 were not associated to disclosed COI. However, spin in conclusions was associated in trend to  
16 the inclusion of own studies in the systematic review. Reviews with inclusion of own primary  
17 studies showed more often spin than reviews without inclusion of own primary studies of the  
18 review authors (OR = 2.08 [CI 0.83 to 5.18] p = .11; table 1). The odds for spin in conclusions in  
19 systematic reviews including studies with researcher allegiance was similarly increased, but  
20 statistically non-significant (OR=2.63[0.84 to 8.12], p = .16; table 1).  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31

32  
33 - Insert table 1 about here -  
34  
35

36  
37 Since we were especially interested in spin in favour of psychological therapies, we also  
38 investigated whether spin in review conclusions in favour of psychological therapies is  
39 associated with a disclosed COI, the inclusion of own primary studies of the authors or the  
40 researcher allegiance of the authors (table 2). However, none of the associations were  
41 statistically significant or showed trends.  
42  
43  
44  
45  
46  
47  
48

49 - Insert table 2 about here -  
50  
51

## 52 53 Discussion

54  
55 This study is – at least to our knowledge - the first that systematically assessed the extent and  
56 nature of reporting of financial and non-financial COI in systematic reviews of psychological  
57  
58  
59  
60



1  
2  
3 therapies and that investigated how often these conflicts are disclosed and whether they may  
4 lead to spin in review conclusions. Financial and non-financial COI were disclosed only in 23.1%  
5 and 4.2% of the reviews, respectively, although non-financial COI were much more often  
6 detectable: Review authors had included 86 own studies in approximately 1/3<sup>rd</sup> of the reviews  
7 and authors of at least 16% of the reviews had allegiance for the evaluated psychological  
8 therapy. Spin in review conclusions was found in 27 of 95 reviews (28%) and was associated in  
9 trend to a non-financial COI, i.e. the inclusion of own primary studies in the systematic review.  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19

### 20 **Disclosure of financial, non-financial and personal COI**

21 The disclosure of financial COI was requested by 80% of the journals which published the  
22 reviews in our study, but only 22 reviews (23.2%) disclosed any financial COI. This may be  
23 explained by two reasons: Firstly, systematic reviews focussing on effectiveness of  
24 psychological therapies are most often written by psychologists who have rather seldom  
25 financial ties to pharmaceutical companies as compared to physicians who often show these  
26 relationships<sup>3-7</sup>, and secondly, the minority of reviews (36 of 95 reviews) compared psychological  
27 therapies to pharmacological interventions (in 10 of those reviews, financial COI were  
28 disclosed). Although psychologists may mostly judge themselves as free of financial COI,  
29 however, researcher allegiance as well as the inclusion of own studies into a review (which we  
30 both rated as non-financial COI) may well lead to financial gains indirectly.<sup>15</sup> Since psychologists  
31 who develop new psychological treatments are often the ones who distribute and train other  
32 psychologists in those therapies, the demonstration of effectiveness of a specific psychotherapy  
33 in a review may potentially lead to high financial incentives. The promotion of the respective  
34 therapy might be easier and the number of trained psychotherapists with high course fee  
35 increases. Showing the effectiveness of a treatment can be also an important step for patents  
36 and for the implementation in treatment guidelines. The fact that researchers developing and  
37 evaluating the effectiveness of psychological therapies are mostly allied to a specific  
38 psychotherapy (e.g. cognitive behavioural therapy or psychoanalysis), makes the issue of COI in  
39 psychology therapy research very complex and much more complicated than in pharmacological  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 research. Psychotherapy researchers who realize that the effect of the therapy to which they are  
4 allied is less beneficial than another therapy cannot easily switch their research program to  
5 another therapy (since they have often been trained in that therapy for many years) – in contrast  
6 to a researcher addressing pharmacotherapy who can more easily change his or her research  
7 agenda to another drug if a drug proves to be less effective than previously thought. Therefore,  
8 researcher allegiance might be present in primary studies in any case to some extent, but needs  
9 to be carefully declared in systematic reviews.

10  
11 Non-financial COI were disclosed only in a very small number of reviews (4.2%) although non-  
12 financial COI such as the inclusion of own primary studies of the review authors (in 34 of 95  
13 reviews) and researcher allegiance (in 15 of 95 reviews) were detectable in a considerable  
14 number of them. This low disclosure rate may be explained by three factors: Firstly, only a  
15 minority of journals (34% at the time of assessment) requests a disclosure of non-financial COI –  
16 and all 4 declarations of non-financial COI were done in these journals; secondly, only two  
17 journals (Perm J, Cochrane Database Syst Rev) specifically asked the authors for the inclusion  
18 of own primary studies and only two others (Psychol Trauma, J Psychiatr Res) asked for  
19 circumstances related to the presence of researcher allegiance at the point of our assessment;  
20 thirdly, researchers may not see the necessity to declare such COI although present and  
21 requested by the journal asking for non-financial COI. We conclude from this finding that the  
22 necessity to declare non-financial COI should be made more transparent in journal articles. The  
23 following strategies may be effective: Journals should consequently ask their authors to disclose  
24 any non-financial COI, should exactly define such conflicts and should include examples of  
25 common causes of non-financial COI such as the inclusion of own primary studies into review  
26 articles or researcher allegiance. Even the International Committee of Medical Journal Editors  
27 (ICMJE) mainly focuses on financial COI and their disclosure but gives little emphasis on and  
28 advice to the disclosure of non-financial COI.

29  
30 Similar to non-financial COI, also personal COI were very seldom disclosed (only in one review).  
31 This is probably due to the common definition of personal COI meaning any relationship to a  
32 person working in a pharmaceutical company. This of course is a less relevant COI for  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 psychotherapist assessing treatment effects of psychological therapies. However,  
4  
5 psychotherapists, especially the ones who develop new therapies, are very often personally  
6  
7 involved in institutes promoting the distribution and training of new psychological therapies. Such  
8  
9 personal COI may indirectly lead to considerable financial gains.  
10

### 11 12 13 14 15 16 17 **Spin in review conclusions**

18  
19 Previous research of our group and others has identified different risks increasing the likelihood  
20  
21 of bias in psychotherapeutic outcome research.<sup>21 24</sup> In our study, we investigated whether  
22  
23 researcher allegiance, an important risk factor of moderate effect size<sup>21</sup>, the inclusion of own  
24  
25 primary studies into the review or any declared COI may be associated to spin in review  
26  
27 conclusions, which we found in 27 of the 95 reviews. Both reviews with inclusion of own primary  
28  
29 studies and reviews with researcher allegiance showed more often a spin (statistical trend).  
30  
31 Since researcher allegiance has been shown to be significantly related to outcome of  
32  
33 psychological therapies<sup>21</sup>, authors should be transparent in disclosing their own  
34  
35 psychotherapeutic training background and the inclusion of own outcome studies in systematic  
36  
37 reviews to make an assessment of COI and allegiance easier. The allegiance indicators of our  
38  
39 study might be an initial step for such a statement (development of treatment or basic research  
40  
41 on the etiological model for a specific treatment).  
42  
43  
44  
45

### 46 **Shortcomings**

47  
48 This study has several shortcomings. Firstly, we restricted our search to systematic reviews and  
49  
50 meta-analyses of anxiety disorders, personality disorders and major depressive disorders. This  
51  
52 may limit the generalizability of our findings. Secondly, our study is limited to published reports  
53  
54 from 2010 onwards. This limits generalizability to earlier reviews, but is justified since COI  
55  
56 reporting has become more regular nowadays and authors might not have been asked for a COI  
57  
58 statement in earlier submissions. Thirdly, our indicators of COI and allegiance are based on  
59  
60

1  
2  
3 publications and reporting quality on some indicators was rather low. The inter-rater reliability of  
4 both ratings might be much better if reporting standards in journals would be implemented.  
5  
6 Fourth, we only checked the disclosed COI, but did not investigate whether authors might have  
7 more COI than the disclosed ones. We also did not investigate which authors of a review might  
8 be responsible for the evaluation and interpretation of studies addressing different types of  
9 interventions (i.e. pharmacotherapy and psychotherapy), since such investigations are at high  
10 risk of being inaccurate and incomplete.  
11  
12  
13  
14  
15  
16  
17  
18  
19

### 20 **Conclusions and suggestions for the management of COI in psychotherapy outcome** 21 **research**

22 We conclude that non-financial COI, especially the inclusion of own primary studies into reviews  
23 and researcher allegiance, are frequently seen in systematic reviews of psychological therapies  
24 and need more transparency. Most policies and Journal requirements for COI disclosure focus  
25 on the importance of financial COI for risks of bias and fail to capture the risk of spin associated  
26 with an allegiance. Therefore, if Journals place more emphasis on the declaration of non-  
27 financial COI, declaration rates of non-financial COI by authors will most likely increase. If spin  
28 effects of non-financial COI in psychotherapy outcome research are confirmed in further studies,  
29 journals should do more than simply providing transparency of COI in order to better manage the  
30 impact of COI on research outcomes and publications<sup>15</sup>. Strategies to mitigate biases may  
31 include the detection and removal of spin at the editorial stage, using independent authors and  
32 reviewers interpreting the findings of meta-analyses, the rejection of systematic reviews that  
33 demonstrate selective citation biases, and providing free access to all data of systematic reviews  
34 to ensure that systematic reviews can be more easily replicated.  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### 58 **Acknowledgements**

1  
2  
3 The study was funded by intramural funds from the University Medical Center Mainz, Department of  
4 Psychiatry and Psychotherapy, Mainz, Germany; there was no extramural funding. We thank V.  
5  
6 Stancheva for helping in study extraction.  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

### Contributorship statement

KL designed the study, analysed data, monitored study extraction, data analysis and interpretation, and drafted and revised the paper. He is guarantor. JOS and NR extracted and analysed data and revised the draft of the manuscript, JSW analysed data and revised the draft of the manuscript. JB analysed data, monitored study extraction, data analysis and interpretation, and revised the paper. All authors gave final approval of the version to be published. All authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

### Transparency declaration

The guarantor affirms that the manuscript is an honest, accurate, and transparent account of the study being reported and that no important aspects of the study have been omitted.

### Declaration of competing interests

All authors have completed the ICMJE uniform disclosure form at [www.icmje.org/coi\\_disclosure.pdf](http://www.icmje.org/coi_disclosure.pdf) and declare: no support from any organisation for the submitted work; KL and JB are active in research on conflicts of interest in medicine and psychology, and JB was involved in the development of indicators of allegiance. All authors declare that they had no financial or personal relationships with pharmaceutical companies within the last 3 years. KL, NR, JSW and JB are psychotherapists trained in CBT, KL and NR also in schematherapy. NR and JB, but not KL and JSW, did receive money from institutes providing training in schematherapy and CBT within the last three years. JSW and KL are coauthors on two reviews included into the study (Gibbon et al., 2010 and Stoffers et al., 2012), and NR and KL are coauthors on one primary study (Reiss et al., 2014) included in one of the reviews.

**License for publication statement**

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, a worldwide licence to the Publishers and its licensees in perpetuity, in all forms, formats and media (whether known now or created in the future), to i) publish, reproduce, distribute, display and store the Contribution, ii) translate the Contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or, abstracts of the Contribution, iii) create any other derivative work(s) based on the Contribution, iv) to exploit all subsidiary rights in the Contribution, v) the inclusion of electronic links from the Contribution to third party material where-ever it may be located; and, vi) licence any third party to do any or all of the above.

**Data sharing statement**

Extra data is available by emailing [Klaus.lieb@unimedizin-mainz.de](mailto:Klaus.lieb@unimedizin-mainz.de).



## References

1. Thompson DF. The Challenge of Conflict of Interest in Medicine. *Z Evid Fortbild Qual Gesundheitswes* 2009;**103**(3):136-40.
2. Lo B, Fields (ed.) *Conflict of Interest in Medical Research, Education, and Practice*, Institute of Medicine 2009.
3. Campbell EG. Doctors and drug companies - scrutinizing influential relationships. *N Engl J Med* 2007;**357**(18):1796-7.
4. Campbell EG, Rao SR, DesRoches CM, et al. Physician professionalism and changes in physician-industry relationships from 2004 to 2009. *Arch Intern Med* 2010;**170**(20):1820-6.
5. Campbell EG, Weissman JS, Ehringhaus S, et al. Institutional academic industry relationships. *JAMA* 2007;**298**(15):1779-86.
6. Lieb K, Brandtönes S. A survey of german physicians in private practice about contacts with pharmaceutical sales representatives. *Dt Arztebl Int* 2010;**107**(22):392.
7. Lieb K, Scheurich A. Contact between Doctors and the Pharmaceutical Industry, Their Perceptions, and the Effects on Prescribing Habits. *PloS one* 2014;**9**(10):e110130.
8. Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. *JAMA* 2003;**289**(4):454-65.
9. Schott G, Pahl H, Limbach U, et al. The financing of drug trials by pharmaceutical companies and its consequences. Part 1: a qualitative, systematic review of the literature on possible influences on the findings, protocols, and quality of drug trials. *Dt Arztebl Int* 2010;**107**(16):279-85.
10. Wang AT, McCoy CP, Murad MH, et al. Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review. *BMJ* 2010;**340**:e1344.
11. Dunn AG, Arachi D, Hudgins J, et al. Financial conflicts of interest and conclusions about neuraminidase inhibitors for influenza: an analysis of systematic reviews. *Ann Intern Med* 2014;**161**(7):513-8.
12. Roest AM, de Jonge P, Williams CD, et al. Reporting Bias in Clinical Trials Investigating the Efficacy of Second-Generation Antidepressants in the Treatment of Anxiety Disorders: A Report of 2 Meta-analyses. *JAMA psychiatry* 2015;**72**(5):500-10.
13. Roseman M, Milete K, Bero LA, et al. Reporting of conflicts of interest in meta-analyses of trials of pharmacological treatments. *JAMA* 2011;**305**(10):1008-17.
14. Roseman M, Turner EH, Lexchin J, et al. Reporting of conflicts of interest from drug trials in Cochrane reviews: cross sectional study. *BMJ* 2012;**345**:e5155.
15. Clark AM, Choby A, Ainsworth K, et al. Addressing conflict of interest in non-pharmacological research. *Int J Clin Pract*. 2015;**69**(3):270-2.
16. Leykin Y, DeRubeis RJ. Allegiance in Psychotherapy Outcome Research: Separating Association From Bias. 2009.
17. Lambert MJ. Are differential treatment effects inflated by researcher therapy allegiance? Could Clever Hans count? *Clinical Psychology: Science and Practice* 1999;**6**(1):127-30.
18. Gaffan EA, Tsaousis I, Kemp-Wheeler SM. Researcher allegiance and meta-analysis: the case of cognitive therapy for depression. *J Consult Clin Psychol*. 1995;**63**(6):966-80.
19. Munder T, Gerger H, Trelle S, et al. Testing the allegiance bias hypothesis: a meta-analysis. *Psychother Res* 2011;**21**(6):670-84.
20. Miller S, Wampold B, Varhely K. Direct comparisons of treatment modalities for youth disorders: a meta-analysis. *Psychother Res* 2008;**18**(1):5-14.
21. Munder T, Brutsch O, Leonhart R, et al. Researcher allegiance in psychotherapy outcome research: an overview of reviews. *Clin Psychol Rev* 2013;**33**(4):501-11.

- 1  
2  
3 22. Munder T, Fluckiger C, Gerger H, et al. Is the allegiance effect an epiphenomenon of true  
4 efficacy differences between treatments? a meta-analysis. *J Couns Psychol*  
5 2012;**59**(4):631-7.  
6 23. Cuijpers P, Driessen E, Hollon SD, et al. The efficacy of non-directive supportive therapy for  
7 adult depression: a meta-analysis. *Clin Psychol Rev* 2012;**32**(4):280-91.  
8 24. Cuijpers P, van Straten A, Bohlmeijer E, et al. The effects of psychotherapy for adult  
9 depression are overestimated: a meta-analysis of study quality and effect size. *Psychol*  
10 *Med* 2010;**40**(2):211-23.  
11

#### 12 13 14 **Figure Legends:**

15  
16 Figure 1: Flow chart of study selection

17  
18 Figure 2: Risk of spin in review conclusions in comparisons of different treatments  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Tables

Table 1 Association between disclosed COI and other forms of COI (i.e. inclusion of primary studies in reviews, researcher allegiance) and spin in review conclusions in all 95 reviews.

	Review with spin in conclusion	Review without spin in conclusion	Odds Ratio [95% confidence interval]
Inclusion of own primary study	13	21	2.08 [0.83 to 5.18]
No inclusion of own primary study	14	47	
Researcher allegiance	7	8	2.63 [0.84 to 8.16]
No researcher allegiance	20	60	
COI disclosed	9	16	1.63 [0.61 to 4.32]
No COI disclosed	18	52	
Inclusion of own primary study, researcher allegiance and/or COI declared	16	31	1.74 [0.70 to 4.29]
None of the three	11	37	

Table 2: Association between disclosed COI and other forms of COI (i.e. inclusion of primary studies in reviews, researcher allegiance) and spin in review conclusions in the reviews rated as having spin in favour of psychological therapies as compared to all other reviews.

	Review rated as “spin” in favour of psychological therapies	Review rated as “no spin” or “spin” against psychological therapies	Odds Ratio [95% confidence interval]
Inclusion of own primary study	6	28	1.24 [0.40 to 3.83]
No inclusion of own primary study	9	52	
Researcher allegiance	2	13	0.79 [0.16 to 3.94]
No researcher allegiance	13	67	
COI disclosed	4	21	1.02 [0.29 to 3.56]
No COI disclosed	11	59	
Inclusion of own primary study, researcher allegiance and/or COI disclosed	7	40	0.88 [0.29 to 2.64]
None of the three	8	40	

Lieb et al., BMJ Open bmjopen-2015-010606.R1

Figure 1: Flow chart of study selection




Fig. 1  
210x297mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Lieb et al., BMJ Open bmjopen-2015-010606.R1

Figure 2: Risk of spin in review conclusions in comparisons of different treatments (Tx1 vs. Tx2).




Fig. 2  
210x297mm (300 x 300 DPI)

## Supplements

### Conflicts of interest and bias in systematic reviews of psychological therapies

Revision to BMJ Open

Klaus Lieb, Jan von der Osten-Sacken, Jutta Stoffers-Winterling, Neele Reiss,  
Jürgen Barth

Supplement Table 1: MEDLINE EBSCO exact search strategy (last run on February 3<sup>rd</sup>,  
2014)

#	
S1	(MH "Psychotherapy+")
S2	(MH "Anxiety Disorders+")*
S3	(S1 AND S2)
S4	(S1 AND S2) – Date of publication: 20100101-20131231; Publication Type: Meta-Analysis, Review

\* This search is exemplary for anxiety disorders. Separate searches were done for depressive and personality disorders, using controlled vocabulary (MH "Depressive Disorders+") or (MH "Personality Disorders+"), resp.



Supplement Table 2: PsycINFO EBSCO exact search strategy (last run on February 3<sup>rd</sup>, 2014)

#	
S1	DE "Psychotherapy" OR DE "Adlerian Psychotherapy" OR DE "Adolescent Psychotherapy" OR DE "Analytical Psychotherapy" OR DE "Autogenic Training" OR DE "Behavior Therapy" OR DE "Brief Psychotherapy" OR DE "Brief Relational Therapy" OR DE "Child Psychotherapy" OR DE "Client Centered Therapy" OR DE "Cognitive Behavior Therapy" OR DE "Conversion Therapy" OR DE "Eclectic Psychotherapy" OR DE "Emotion Focused Therapy" OR DE "Existential Therapy" OR DE "Experiential Psychotherapy" OR DE "Expressive Psychotherapy" OR DE "Eye Movement Desensitization Therapy" OR DE "Feminist Therapy" OR DE "Geriatric Psychotherapy" OR DE "Gestalt Therapy" OR DE "Group Psychotherapy" OR DE "Guided Imagery" OR DE "Humanistic Psychotherapy" OR DE "Hypnotherapy" OR DE "Individual Psychotherapy" OR DE "Insight Therapy" OR DE "Integrative Psychotherapy" OR DE "Interpersonal Psychotherapy" OR DE "Logotherapy" OR DE "Narrative Therapy" OR DE "Network Therapy" OR DE "Persuasion Therapy" OR DE "Primal Therapy" OR DE "Psychoanalysis" OR DE "Psychodrama" OR DE "Psychodynamic Psychotherapy" OR DE "Psychotherapeutic Counseling" OR DE "Rational Emotive Behavior Therapy" OR DE "Reality Therapy" OR DE "Relationship Therapy" OR DE "Solution Focused Therapy" OR DE "Supportive Psychotherapy" OR DE "Transactional Analysis"
S2	DE "Anxiety Disorders" OR DE "Acute Stress Disorder" OR DE "Castration Anxiety" OR DE "Death Anxiety" OR DE "Generalized Anxiety Disorder" OR DE "Obsessive Compulsive Disorder" OR DE "Panic Disorder" OR DE "Phobias" OR DE "Posttraumatic Stress Disorder" OR DE "Separation Anxiety"
S3	(S1 AND S2)
S4	(S1 AND S2) – Published date: 20100101-20131231; Methodology: -Systematic Review, -Meta Analysis

\* This search is exemplary for anxiety disorders. Separate searches were done for depressive and personality disorders, using controlled vocabulary (DE "Major Depression" OR DE "Anaclitic Depression" OR DE "Dysthymic Disorder" OR DE "Endogenous Depression" OR DE "Postpartum Depression" OR DE "Reactive Depression" OR DE "Recurrent Depression" OR DE "Treatment Resistant Depression") or (DE "Personality Disorders" OR DE "Antisocial Personality Disorder" OR DE "Avoidant Personality Disorder" OR DE "Borderline Personality Disorder" OR DE "Dependent Personality Disorder" OR DE "Histrionic Personality Disorder" OR DE "Narcissistic Personality Disorder" OR DE "Obsessive Compulsive Personality Disorder" OR DE "Paranoid Personality Disorder" OR DE "Passive Aggressive Personality Disorder" OR DE "Sadomasochistic Personality" OR DE "Schizoid Personality Disorder" OR DE "Schizotypal Personality Disorder"), resp.

## Supplement Table 3: References of the 95 reviews included in this study

Abbass A, Town J, Driessen E. Intensive short-term dynamic psychotherapy: A systematic review and meta-analysis of outcome research. *Harv Rev Psychiatry* 2012;20(2):97-108.

Abbass A, Town J, Driessen E. The efficacy of short-term psychodynamic psychotherapy for depressive disorders with comorbid personality disorder. *Psychiatry* 2011;74(1):58-71.

Baardseth TP, Goldberg SB, Pace BT, et al. Cognitive-behavioral therapy versus other therapies: Redux. *Clin Psychol Rev* 2013;33(3):395-405.

Barker-Collo S, Starkey N, Theadom A. Treatment for depression following mild traumatic brain injury in adults: A meta-analysis. *Brain Inj* 2013;27(10):1124-1133.

Bartley CA, Hay M, Bloch MH. Meta-analysis: Aerobic exercise for the treatment of anxiety disorders. *Prog Neuropsychopharmacol Biol Psychiatry* 2013;45:34-39.

Barrera TL, Mott JM, Hofstein RF, et al. A meta-analytic review of exposure in group cognitive behavioral therapy for posttraumatic stress disorder. *Clin Psychol Rev* 2013;33(1):24-32.

Beltman MW, Oude Voshaar RC, Speckens AE. Cognitive-behavioural therapy for depression in people with a somatic disease: meta-analysis of randomized controlled trials. *Br J Psychiatry* 2010;197(1):11-19.

Bomyea J, Lang AJ. Emerging interventions for PTSD: Future directions for clinical care and research *Neuropharmacology* 2012;62:607-616.

Bontempo A, Panza KE, Bloch MH. Meta-Analysis: D-cycloserine Augmentation of Behavioral Therapy for the Treatment of Anxiety Disorders. *J Clin Psychiatry* 2012;73(4):533–537.

Budge SL, Moore JT, Del Re AC, et al. The effectiveness of evidence-based treatments for personality disorders when comparing treatment-as-usual and bona fide treatments. *Clin Psychol Rev* 2013;33:1057–1066.

Busch FN, Sandberg LS. Combined treatment of depression *Psychiatr Clin North Am* 2012;35:165-179.

Casement MD, Swanson LM. A meta-analysis of imagery rehearsal for post-trauma nightmares: Effects on nightmare frequency, sleep quality, and posttraumatic stress. *Clin Psychol Rev* 2012;32:566–574.

Chard KM, Ricksecker EG, Healy ET, et al. Dissemination and experience with cognitive processing therapy. *J Rehabil Res Dev* 2012;49(5):667-78.

Chen KW, Berger CC, Manheimer E, et al. Meditative therapies for reducing anxiety: A systematic review and meta-analysis of randomized controlled trials. *Dedress Anxiety* 2012;29:545–562.

Chugh-Gupta N, Baldassarre FG, Vrkljan BH. A systematic review of yoga for state anxiety: Considerations for occupational therapy. *Can J Occup Ther* 2013;80(3):150-170.

Cody RA, Drysdale K. The Effects of Psychotherapy on Reducing Depression in Residential Aged Care: A Meta-Analytic Review. *Clin Gerontol* 2013;36(1):46-69.

Cuijpers P, Andersson G, Donker T, et al. Psychological treatment of depression: Results of a series of meta-analyses *Nord J Psychiatry* 2011;65(6):354-364.

Cuijpers P, Berking M, Andersson G, et al. A Meta-Analysis of Cognitive-Behavioral Therapy for Adult Depression, Alone and in Comparison With Other Treatments. *Can J Psychiatry* 2013;58(7):376-385.

- 1  
2  
3 Cuijpers P, Clignet F, van Meijel B, et al. Psychological treatment of depression in inpatients: a  
4 systematic review and meta-analysis. *Clin Psychol Rev* 2011;31(3):353-360.  
5  
6 Cuijpers P, de Beurs DP, van Spijker BA, et al. The effects of psychotherapy for adult depression on  
7 suicidality and hopelessness: A systematic review and meta-analysis. *J Affect Disord*  
8 2013;144(3):183-190.  
9  
10 Cuijpers P, Driessen E, Hollon SD, et al. The efficacy of non-directive supportive therapy for adult  
11 depression: A meta-analysis. *Clin Psychol Rev* 2012;32:280–291.  
12  
13 Cuijpers P, Geraedts AS, van Oppen P, et al. Interpersonal Psychotherapy for Depression: A Meta-  
14 Analysis. *Am J Psychiatry* 2011;168:581–592.  
15  
16 Cuijpers P, Huibers M, Ebert DD, et al. How much psychotherapy is needed to treat depression? A  
17 metaregression analysis. *J Affect Disord* 2013;149(1-3):1-13.  
18  
19 Cuijpers P, Reynolds III CF, Donker T, et al. Personalized treatment of adult depression: Medication,  
20 psychotherapy, or both? A systematic review. *Depress Anxiety* 2012;29:855–864.  
21  
22 Cuijpers P, van Straten A, Hollon SD, et al. The contribution of active medication to  
23 combined treatments of psychotherapy and pharmacotherapy for adult depression: a meta-analysis  
24 *Acta Psychiatr Scand* 2010;121:415–423.  
25  
26 Cuijpers P, van Straten A, Schuurman J, et al. Psychotherapy for chronic major depression and  
27 dysthymia: A meta-analysis *Clin Psychol Rev* 2010;30:51–62.  
28  
29 Daigle MS, Pouliot L, Chagnon F, et al. Suicide attempts: Prevention of repetition. *Can J Psychiatry*  
30 2011;56(10):621-629.  
31  
32 Dickens C, Cherrington A, Adeyemi I, et al. Characteristics of Psychological Interventions That  
33 Improve Depression in People With Coronary Heart Disease: A Systematic Review and Meta-  
34 Regression. *Psychosom Med* 2013;75:211-221.  
35  
36 Dossa NI, Hatem M. Cognitive-Behavioral Therapy versus Other PTSD Psychotherapies as  
37 Treatment for Women Victims of War-Related Violence: A Systematic Review. *Scientific World Journal*  
38 2012;2012:181847. doi:10.1100/2012/181847. Epub 2012 Apr 19.  
39  
40 Driessen E, Cuijpers P, de Maat SCM, et al. The efficacy of short-term psychodynamic psychotherapy  
41 depression: a meta-analysis. *Clin Psychol Rev* 2010;30(1):25-36.  
42  
43 Ekers D, Webster LAD. An overview of the effectiveness of psychological therapy for depression and  
44 stepped care service delivery models. *J Res Nurs* 2013;18(2):171-184,  
45  
46 Faller H, Schuler M, Richard M, et al. Effects of psycho-oncologic interventions on emotional distress  
47 and quality of life in adult patients with cancer: systematic review and meta-analysis. *J Clin Oncol*  
48 2013;31(6):782-93.  
49  
50 Feng CY, Chu H, Chen CH, et al. The Effect of Cognitive Behavioral Group Therapy for Depression: A  
51 Meta-Analysis 2000–2010. *Worldviews Evid Based Nurs* 2012;9(1):2-17.  
52  
53 Fritzsche A, Clamor A, von Leupoldt A. Effects of medical and psychological treatment  
54 of depression in patients with COPD e A review *Respir Med* 2011;105:1422-1433.  
55  
56 Gibbon S, Duggan C, Stoffers J, et al. Psychological interventions for antisocial personality disorder.  
57 *Cochrane Database Syst Rev* 2010;6: CD007668. doi:10.1002/14651858.CD007668.pub2.  
58  
59 Goncalves DC, Byrne GJ. Interventions for generalized anxiety disorder in older adults: Systematic  
60 review and meta-analysis *J Anxiety Disord* 2012;26:1–11.  
  
Goodson J, Helstrom A, Halpern JM, et al. Treatment of posttraumatic stress disorder in US combat  
veterans: a meta-analytic review. *Psychol Rep* 2011;109(2):573-599.

1  
2  
3 Gould RL, Coulson MC, Howard RJ. Efficacy of Cognitive Behavioral Therapy for Anxiety Disorders in  
4 Older People: A Meta-Analysis and Meta-Regression of Randomized Controlled Trials. *J Am Geriatr*  
5 *Soc* 2012;60(2):218-29. DOI: 10.1111/j.1532-5415.2011.03824.x *JAGS* 60:218–229, 2012.  
6

7 Guidi J, Fava GA, Fava M, et al. Efficacy of the sequential integration of psychotherapy and  
8 pharmacotherapy in major depressive disorder: a preliminary meta-analysis. *Psychol Med*  
9 2011;41:321–331.  
10

11 Gwozdziwycz N, Mehl-Madrona L. Meta-analysis of the use of narrative exposure therapy for the  
12 effects of trauma among refugee populations. *Perm J* 2013;17(1):70-76.  
13

14 Hanrahan F, Field AP, Jones FW, et al. A meta-analysis of cognitive therapy for worry in generalized  
15 anxiety disorder. *Clin Psychol Rev* 2013;33(1):120-32.  
16

17 Hans E, Hiller W. Effectiveness of and Dropout From Outpatient Cognitive Behavioral Therapy for  
18 Adult Unipolar Depression: A Meta-Analysis of Nonrandomized Effectiveness Studies. *J Consult Clin*  
19 *Psychol* 2013;81(1):75•88.  
20

21 Hansen K, Höfling V, Kröner-Borowik T, et al. Efficacy of psychological interventions aiming to reduce  
22 chronic nightmares: a meta-analysis. *Clin Psychol Rev* 2013;33(1):146-55.  
23

24 Hart SL, Hoyt MA, Diefenbach M, et al. Meta-Analysis of Efficacy of Interventions for Elevated  
25 Depressive Symptoms in Adults Diagnosed With Cancer. *J Natl Cancer Inst* 2012;104:990–1004.  
26

27 Haug T, Nordgreen T, Öst LG, et al. Self-help treatment of anxiety disorders: A meta-analysis and  
28 meta-regression of effects and potential moderators *Clin Psychol Rev* 2012;32:425–445.  
29

30 Hetrick SE, Purcell R, Garner B, et al. Combined pharmacotherapy and psychological therapies for  
31 post traumatic stress disorder (PTSD) *Cochrane Database Syst Rev* 2010;7:CD007316.  
32 DOI:10.1002/14651858.CD007316.pub2.  
33

34 Ho MSK, Lee CW. Cognitive behaviour therapy versus eye movement desensitization and  
35 reprocessing for post-traumatic disorder – is it all in the homework then? *Eur Rev Appl Psychol*  
36 2012;62:253–260.  
37

38 Hobbs JDJ, Kushner MG, Lee SS, et al. Meta-analysis of Supplemental Treatment for Depressive and  
39 Anxiety Disorders in Patients Being Treated for Alcohol Dependence. *Am J Addict* 2011;20:319–329.  
40

41 Hofmann SG, Sawyer AT, Witt AA, et al. The effect of mindfulness-based therapy on anxiety and  
42 depression: A meta-analytic review. *J Consult Clin Psychol* 2010;78(2):169-183.  
43

44 Huntley AL, Araya R, Salisbury C. Group psychological therapies for depression in the community:  
45 systematic review and meta-analysis. *Br J Psychiatry* 2012;200:184–190. doi:  
46 10.1192/bjp.bp.111.092049  
47

48 Imel ZE, Laska, K, Jakupcak M, et al. Meta-Analysis of Dropout in Treatments for Posttraumatic  
49 Stress Disorder. *J Consult Clin Psychol* 2013;81(3)394-404.  
50

51 IsHak WW, Ha K, Kapitanski N, et al. The Impact of Psychotherapy, Pharmacotherapy, and Their  
52 Combination on Quality of Life in Depression. *Harv Rev Psychiatry* 2011;19:277–289.  
53

54 Jakobsen JC, Hansen JL, Simonsen E, et al. The effect of adding psychodynamic therapy to  
55 antidepressants in patients with major depressive disorder. A systematic review of randomized clinical  
56 trials with meta-analyses and trial sequential analyses *J Affect Disord* 2012;137:4–14.  
57

58 Jakobsen JC, Hansen JL, Simonsen S, et al. Effects of cognitive therapy versus interpersonal  
59 psychotherapy in patients with major depressive disorder: a systematic review of randomized clinical  
60 trials with meta-analyses and trial sequential analyses. *Psychol Med* 2012;42:1343–1357.  
doi:10.1017/S0033291711002236.

- 1  
2  
3 Krishna M, Honagodu A, Rajendra R, et al. A systematic review and meta-analysis of group  
4 psychotherapy for sub-clinical depression in older adults. *Int J of Geriatr Psychiatry* 2013;28(9):881-  
5 888.  
6
- 7 Krishna M, Jauhari A, Lepping P, et al. Is group psychotherapy effective in older adults with  
8 depression? A systematic review. *Int J of Geriatr Psychiatry*. 2011;26(4):331-340.  
9
- 10 Leisenring F, Rabung S. Long-term psychodynamic psychotherapy in complex mental disorders:  
11 update of a meta-analysis. *Br J Psychiatry* 2011;199(1):15-22.  
12
- 13 Luciano M, Del Vecchio V, Giacco D, et al. A 'family affair'? The impact of family psychoeducational  
14 interventions on depression. *Expert Rev. Neurother* 2012;12(1):83-92.  
15
- 16 Markowitz SM, Gonzalez JS, Wilkinson JL, et al. A Review of Treating Depression in Diabetes:  
17 Emerging Findings. *Psychosomatics* 2011;52:1-18.  
18
- 19 Mavrides N, Nemeroff C. Treatment of depression in cardiovascular disease. *Depress Anxiety*  
20 2013;30(4):328-41.  
21
- 22 Nenova M, Morris L, Paul L, et al. Psychosocial Interventions With Cognitive-Behavioral Components  
23 for the Treatment of Cancer-Related Traumatic Stress Symptoms: A Review of Randomized  
24 Controlled Trials. *J Cogn Psychother* 2013;27(3)258-284.  
25
- 26 Nickerson A, Bryant RA, Silove D, et al. A critical review of psychological treatments of posttraumatic  
27 stress disorder in refugees. *Clin Psychol Rev* 2011;31:399-417.  
28
- 29 Oestergaard S, Møldrup C. Optimal duration of combined psychotherapy and pharmacotherapy for  
30 patients with moderate and severe depression: A meta-analysis. *J Affect Disord* 2011;131:24-36.  
31
- 32 Olatunji BO, Davis ML, Powers MB, et al. Cognitive-behavioral therapy for obsessive-compulsive  
33 disorder: A meta-analysis of treatment outcome and moderators. *J Psychiatr Res* 2013;47(1):33-41.  
34
- 35 Opris D, Pinteá S, Garcia-Palacios A, et al. Virtual reality exposure therapy in anxiety disorders: A  
36 quantitative meta-analysis. *Depress Anxiety* 2012;29(2):85-93.  
37
- 38 Palic S, Elklit A. Psychosocial treatment of post-traumatic stress disorder in adult refugees: a  
39 systematic review of prospective treatment outcome studies and a critique. *J Affect Disord*  
40 2011;131(1-3):8-23.  
41
- 42 Piet J, Hougaard E. The effect of mindfulness-based cognitive therapy for prevention of relapse in  
43 recurrent major depressive disorder: a systematic review and meta-analysis. *Clin Psychol Rev*  
44 2011;31(6):1032-1040.  
45
- 46 Possemato K, The current state of intervention research for posttraumatic stress disorder within the  
47 primary care setting. *J Clin Psychol Med Settings* 2011;18(3):268-280.  
48
- 49 Powers MB, Halpern JM, Ferenschak MP, et al. A meta-analytic review of prolonged exposure for  
50 posttraumatic stress disorder. *Clin Psychol Rev* 2010;30(6):635-641.  
51
- 52 Rakofsky JJ, Dunlop BW, Treating Nonspecific Anxiety and Anxiety Disorders in Patients With Bipolar  
53 Disorder: A Review. *J Clin Psychiatry* 2011;72(1):81-91.  
54
- 55 Richards D, Richardson T. Computer-based psychological treatments for depression: A systematic  
56 review and meta-analysis *Clin Psychol Rev* 2012;32:329-342.  
57
- 58 Rizzo M, Creed F, Goldberg D, et al. A systematic review of non-pharmacological treatments for  
59 depression in people with chronic physical health problems. *J Psychosom Res* 2011;71(1):18-27.  
60
- Roberts NP, Kitchiner NJ, Kenardy J, et al. Early psychological interventions to treat acute traumatic  
stress symptoms. *Cochrane Database Syst Rev* 2010;3:CD007944.  
doi:10.1002/14651858.CD007944.pub2.



- 1  
2  
3 Rosenberg Edwards A. Psychotherapy and Pharmacotherapy for Social Anxiety Disorder: A  
4 Comprehensive Meta-Analysis. *Dissertation abstracts international: Section B: the Sciences and*  
5 *Engineering* 2011;72(4-B):2433-2601.  
6
- 7 Roshanaei-Moghaddam B, Pauly MC, Atkins DC, et al. Relative effects of CBT and pharmacotherapy  
8 in depression versus anxiety: Is medication somewhat better for depression, and CBT somewhat  
9 better for anxiety? *Depress Anxiety* 2011;28:560–567.  
10
- 11 Samad Z, Brealey S, Gilbody S. The effectiveness of behavioural therapy for the treatment of  
12 depression in older adults: a meta-analysis. *Int J of Geriatr Psychiatry* 2011;26(12):1211-1220.  
13
- 14 Sanchez-Meca J, Rosa-Alcázar AI, Marín-Martínez F, et al. Psychological treatment of panic disorder  
15 with or without agoraphobia: a meta-analysis. *Clin Psychol Rev* 2010;30(1):37-50.  
16
- 17 Schoenfeld FB, DeViva JC, Manber R. Treatment of sleep disturbances in posttraumatic stress  
18 disorder: A review. *J Rehabil Res Dev* 2012;49(5):729–752.  
19
- 20 Sempértegui GA, Karreman A, Arntz A, et al. Schema therapy for borderline personality disorder: a  
21 comprehensive review of its empirical foundations, effectiveness and implementation possibilities. *Clin*  
22 *Psychol Rev* 2013;33(3):426-47.  
23
- 24 Sloan DM, Bovin MJ, Schnurr PP. Review of group treatment for PTSD. *J Rehabil Res Dev*  
25 2012;49(5):689-701.  
26
- 27 Sloan DM, Feinstein BA, Gallagher MW, et al. Efficacy of Group Treatment for Posttraumatic Stress  
28 Disorder Symptoms: A Meta-Analysis. *Psychol Trauma* 2013;5(2):176-183.  
29
- 30 Sloan DM, Gallagher MW, Feinstein BA, et al. Efficacy of telehealth treatments for posttraumatic  
31 stress-related symptoms: a meta-analysis. *Cogn Behav Ther* 2011;40(2):111-125.  
32
- 33 Spielmans GI, Berman MI, Usitalo AN. Psychotherapy Versus Second-Generation Antidepressants in  
34 the Treatment of Depression A Meta-Analysis. *J Nerv Ment Dis* 2011;199:142–149.  
35
- 36 Spijker J, van Straten A, Bockting CL, et al. Psychotherapy, Antidepressants, and Their Combination  
37 for Chronic Major Depressive Disorder: A Systematic Review. *Can J Psychiatry* 2013;58(7):386-392.  
38
- 39 Stagg EK, Lazenby M. Best Practices for the Nonpharmacological Treatment of Depression at the End  
40 of Life. *Am J Hosp Palliat Care* 2012;29(3):183-194.  
41
- 42 Steenkamp MM, Litz BT Psychotherapy for military-related posttraumatic stress disorder: review of the  
43 evidence. *Clin Psychol Rev* 2013;33(1):45-53.  
44
- 45 Stoffers JM, Völlm BA, Rucker G, et al. Psychological therapies for people with borderline personality  
46 disorder (Review), *Cochrane Database Syst Rev* 2012;8:CD005652.  
47 doi:10.1002/14651858.CD005652.pub2.  
48
- 49 Van Dam D, Vedel E, Ehrling T, et al. Psychological treatments for concurrent posttraumatic stress  
50 disorder and substance use disorder: A systematic review. *Clin Psychol Rev* 2012;32:202–214.  
51
- 52 Van der Feltz-Cornelis CM, Nuyen J, Stoop C, et al. Effect of interventions for major depressive  
53 disorder and significant depressive symptoms in patients with diabetes mellitus: a systematic review  
54 and meta-analysis *Gen Hosp Psychiatry* 2010;32:380–395.  
55
- 56 Van der Heiden C. Metacognitions in generalized anxiety disorder: theoretical and practical  
57 perspectives. *Expert Rev Neurother* 2013;13(2):135-141.  
58
- 59 Van Emmerik AA, Reijntjes A, Kamphuis JH. Writing Therapy for Posttraumatic Stress: A Meta-  
60 Analysis. *Psychother Psychosom* 2013;82:82-88.
- Van Hees ML, Rotter T, Ellermann T, et al. The effectiveness of individual interpersonal  
psychotherapy as a treatment for major depressive disorder in adult outpatients: A systematic review.  
*BMC Psychiatry* 2013;13:22. doi:10.1186/1471-244X-13-22.

1  
2  
3  
4 Van Straten A, Geraedts A, Verdonck-de Leeuw IM, et al. Psychological treatment of depressive  
5 symptoms in patients with medical disorders: a meta-analysis. *J Psychosom Res* 2010;69(1):23-32.  
6

7 Vøllestad J, Nielsen MB, Nielsen GH Mindfulness- and acceptance-based interventions for anxiety  
8 disorders: A systematic review and meta-analysis. *Br J Clin Psychol* 2012;51:239–260.  
9

10 Watts BV, Schnurr PP, Mayo L, et al. Meta-Analysis of the Efficacy of Treatments for Posttraumatic  
11 Stress Disorder. *J Clin Psychiatry* 2013;74(6):541-550.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only



Supplement Table 4: Journals in which the 95 reviews were published

Journal	2010	2011	2012	2013	Total number
Clin Psychol Rev	4	3	5	8	20
Depress Anxiety	-	1	3	1	5
J Affect Disord	-	2	1	2	5
Cochrane Database Syst Rev	3	-	1	-	4
Br J Psychiatry	1	1	1	-	3
Can J Psychiatry	-	1	-	2	3
Int J of Geriatr Psychiatry	-	2	-	1	3
J Clin Psychiatry	-	1	1	1	3
Expert Rev Neurother	-	-	1	1	2
Harv Rev Psychiatry	-	1	1	-	2
J Consult Clin Psychol	1	-	-	1	2
J Psychosom Res	1	1	-	-	2
Psychol Med	-	1	1	-	2
Acta Psychiatr Scand	1	-	-	-	1
Am J Addict	-	1	-	-	1
Am J Hosp Palliat Care	-	-	1	-	1
Am J Psychiatry	-	1	-	-	1
BMC Psychiatry	-	-	-	1	1
Brain inj	-	-	-	1	1
Br J Clin Psychol	-	-	1	-	1
Can J Occup Ther	-	-	-	1	1
Clin Gerontol	-	-	-	1	1
Cogn Behav Ther	-	1	-	-	1
Dissertations Abstracts international: Section B: The Sciences and Engineering	-	1	-	-	1
Eur Rev Appl Psychol	-	-	1	-	1
Gen Hosp Psychiatry	1	-	-	-	1
J Am Geriatr Soc	-	-	1	-	1
J Anxiety Disord	-	-	1	-	1

J Clin Oncol	-	-	-	1	1
J Clin Psychol Med Settings	-	1	-	-	1
J Cogn Psychother	-	-	-	1	1
J Natl Cancer Inst	-	-	1	-	1
J Nerv Ment Dis	-	1	-	-	1
J Psychiatr Res	-	-	-	1	1
J Rehabil Res Dev	-	-	1	-	1
J Res Nurs	-	-	-	1	1
Neuropharmacology	-	-	1	-	1
Nord J Psychiatry	-	1	-	-	1
Perm J	-	-	-	1	1
Prog Neuropsychopharmacol Biol Psychiatry	-	-	-	1	1
Psychiatr Clin North Am	-	-	1	-	1
Psychiatry	-	1	-	-	1
Psychol Rep	-	1	-	-	1
Psychol Trauma	-	-	-	1	1
Psychosom Med	-	-	-	1	1
Psychosomatics	-	1	-	-	1
Psychother Psychosom	-	-	-	1	1
Respir Med	-	1	-	-	1
Scientific World Journal	-	-	1	-	1
Worldviews Evid Based Nurs	-	-	1	-	1

Supplement Table 5: Mandatory disclosure of Conflicts of Interest by Journal – last accessed  
June 8, 2014

<b>Journal</b>	<b>Personal COI</b>	<b>Financial COI</b>	<b>Non- Financial COI</b>	<b>Inclusion of own primary study</b>	<b>Researcher allegiance</b>
Acta Psychiatr Scand	no	Yes	No	No	No
Am J Addict	no	Yes	Yes	No	No
Am J Hosp Palliat Care	no	yes	No	No	No
Am J Psychiatry	no	yes	No	No	No
BMC Psychiatry	no	no	No	No	No
Brain Inj	yes	yes	No	No	No
Br J Clin Psychol	no	no	No	No	No
Br J Psychiatry	yes	yes	Yes	No	No
Can J Occup Ther	no	no	No	No	No
Can J Psychiatry	yes	yes	Yes	No	No
Clin Gerontol	no	no	No	No	No
Clin Psychol Rev	yes	yes	Yes	No	No
Cochrane Database Syst Rev	yes	yes	Yes	yes	No
Cogn Behav Ther	no	no	No	No	No
Depress Anxiety	yes	yes	No	No	No
Dissertations Abstracts international: Section B: The Sciences and Engineering	no	no	No	No	No
Eur Rev Appl Psychol	yes	yes	Yes	No	No
Expert Rev Neurother	yes	yes	Yes	No	No
Gen Hosp Psychiatry	yes	yes	Yes	No	No
Harv Rev Psychiatry	yes	yes	No	No	No
Int J of Geriatr Psychiatry	yes	yes	No	No	No
J Affect Disord	yes	yes	Yes	No	No
J Am Geriatr Soc	yes	yes	Yes	No	No

J Anxiety Disord	yes	yes	Yes	No	No
J Clin Oncol	yes	yes	No	No	No
J Clin Psychiatry	yes	yes	No	No	No
J Clin Psychol Med Settings	no	yes	No	No	No
J Cogn Psychother	unclear	unclear	Unclear	Unclear	Unclear
J Consult Clin Psychol	yes	yes	No	No	No
J Natl Cancer Inst	no	yes	No	No	No
J Nerv Ment Dis	yes	yes	Yes	No	No
J Psychiatr Res	yes	yes	No	No	yes
J Psychosom Res	yes	yes	Yes	No	No
J Rehabil Res Dev	yes	yes	No	No	No
J Res Nurs	no	yes	No	No	No
Neuropharmacology	yes	yes	Yes	No	No
Nord J Psychiatry	no	yes	No	No	No
Perm J	yes	yes	No	yes	No
Prog Neuropsychopharmacol Biol Psychiatry	yes	yes	Yes	No	No
Psychiatr Clin North Am	no	yes	No	No	No
Psychiatry	no	no	No	No	No
Psychol Med	yes	yes	No	No	No
Psychol Rep	no	no	No	No	No
Psychol Trauma	yes	yes	Yes	No	yes
Psychosom Med	yes	yes	No	No	No
Psychosomatics	no	yes	No	No	No
Psychother Psychosom	no	yes	No	No	No
Respir Med	yes	yes	Yes	No	No
Scientific World Journal	no	no	No	No	No
Worldviews Evid Based Nurs	no	yes	No	No	No

1  
2  
3  
4  
5 Supplement Table 6: References of the own primary studies included into 34 reviews by the  
6 review authors  
7  
8

9  
10 Abbass AA, Campbell S, Magee K, et al. Intensive shortterm dynamic psychotherapy to reduce rates of  
11 emergency department return visits for patients with medically unexplained symptoms: preliminary evidence  
12 from a pre-post intervention study. *CJEM* 2009;11(6):529–534.

13  
14 Abbass A. Intensive short-term dynamic psychotherapy in a private psychiatric office: Clinical and cost  
15 effectiveness. *Am J Psychother* 2002;56:225-232.

16  
17 Abbass A. Intensive short-term dynamic psychotherapy of treatment-resistant depression: a pilot study.  
18 *Depress Anxiety* 2006;23:449–452.

19  
20 Abbass A. Modified short-term dynamic psychotherapy in patients with bipolar disorder. Preliminary report  
21 of a case series. *Can Child Psychiatry Rev* 2002;11(1):19–22.

22  
23 Abbass A. Office based research in intensive short-term dynamic psychotherapy (ISTDP): data from the first  
24 6 years of practice. *Ad Hoc Bull Short Term Dyn Psychother* 2002;6(2):5–14.

25  
26 Abbass A, Sheldon A, Gyra A, et al. Intensive short-term dynamic psychotherapy for DSM-IV personality  
27 disorders. *J Nerv Ment Dis* 2008;196:211–216.

28  
29 Abbass A. Small-group videotape training for psychotherapy skill development. *Acad Psychiatry*  
30 2004;28:151–155.

31  
32 Andersson G, Waara J, Jonsson U, et al. Internet-based self-help versus one-session exposure in the  
33 treatment of spider phobia: a randomized controlled trial. *Cogn Behav Ther* 2009;38:114-120.

34  
35 Araya R, Rojas G, Fritsch R, et al. Treating depression in primary care in low-income women in Santiago,  
36 Chile: a randomised controlled trial. *Lancet* 2003;361:995–1000.

37  
38 Arntz A, Dietzel R, Dreessen L. Assumptions in borderline personality disorder, specificity, stability and  
39 relationship with etiological factors. *Behav Res Ther* 1999;37(6):545–557.

40  
41 Arntz A, Dreessen L, Schouten E, et al. Beliefs in personality disorders: A test with the Personality Disorder  
42 Belief Questionnaire. *Behav Res Ther* 2004;42(10):1215–1225.

43  
44 Arntz A, Klokman J, Sieswerda S. An experimental test of the schema mode model of borderline personality  
45 disorder. *J Behav Ther Exp Psychiatry* 2005;36(3):226–239.

46  
47 Arntz A, Weertman A, Salet S. Interpretation bias in Cluster-C and borderline personality disorders. *Behav*  
48 *Res Ther* 2011;49(8):472–481.

49  
50 Beck JG, Coffey SF, Foy DW, et al. Group cognitive behavior therapy for chronic posttraumatic stress  
51 disorder: An initial randomized pilot study. *Behav Ther* 2009;40:82–92.

52  
53 Bisson JI, Shepherd JP, Joy D, et al. Early cognitive-behavioural therapy for post-traumatic stress  
54 symptoms after physical injury. *Br J Psychiatry* 2004;184:63-69.

55  
56 Bormann JE, Thorp SR, Wetherell JL, et al. Meditation-Based Mantram Intervention for Veterans With  
57 Posttraumatic Stress Disorder: A Randomized Trial. *Psychol Trauma* 2012, March. Advance online  
58 publication. doi: 10.1037/a0027522.

59  
60 Botella C, Garcia-Palacios A, Villa H, et al. Virtual reality exposure in the treatment of panic disorder and  
agoraphobia: a controlled study. *Clin Psychol Psychother* 2007;14:164–175.

Chard KM. An evaluation of cognitive processing therapy for the treatment of posttraumatic stress disorder  
related to childhood sexual abuse. *J Consult Clin Psychol* 2005;73(5):965–971.

Chard KM, Schumm JA, McIlvain SM, et al. Exploring the efficacy of a residential treatment for veterans  
with PTSD and traumatic brain injury. *J Trauma Stress* 2011;24(3):347–351.

1  
2  
3  
4 Chard KM, Schumm JA, Owens GP, et al. A comparison of OEF and OIF veterans and Vietnam veterans  
5 receiving cognitive processing therapy. *J Trauma Stress* 2010;23(1):25–32.

6  
7 De Jonghe F, Hendriksen M, van Aalst G, et al. Psychotherapy alone and combined with pharmacotherapy  
8 in the treatment of depression. *Br J Psychiatry* 2004;185:37-45.

9  
10 Dickhaut V, Arntz A. Combined group and individual schema therapy for borderline personality disorder: A  
11 pilot study. *J Behav Ther Exp Psychiatr* 2014;45:242-251.

12  
13 Dimidjian S, Hollon SD, Dobson KS, et al. Randomized trial of behavioral activation, cognitive therapy, and  
14 antidepressant medication in the acute treatment of adults with major depression. *J Consult Clin Psychol*  
15 2006;74:658–670.

16  
17 DuHamel KN, Mosher CE, Winkel G, et al. Randomized clinical trial of Telephone – administered cognitive-  
18 behavioral therapy to reduce posttraumatic stress disorder and distress symptoms after hematopoietic  
19 stem-cell transplantation. *J Clin Oncol* 2010;28(23):3754-3761.

20  
21 Ekers D, Richards D, Gilbody S. A meta-analysis of behavioural therapy for depression. *Psychol Med*  
22 2008;38(5):611-623.

23  
24 Fava GA, Rafanelli C, Grandi S, et al. Six-year outcome for cognitive behavioral treatment of residual  
25 symptoms in major depression. *Am J Psychiatry* 1998;155:1443–1445.

26  
27 Fava GA, Ruini C, Rafanelli C, et al. Six-year outcome of cognitive behavior therapy for prevention of  
28 recurrent depression. *Am J Psychiatry* 2004;161:1872–1876.

29  
30 Fiorillo A, Malangone C, Del Vecchio VC, et al. The effect of family psychoeducational interventions on  
31 patients with depression. *Eur Psychiatry* 2011;26:7.

32  
33 Foa EB, Dancu CV, Hembree EA, et al. A Comparison of exposure therapy, stress inoculation training, and  
34 their combination for reducing posttraumatic stress disorder in female assault victims. *J Consult Clin*  
35 *Psychol* 1999;67(2):194-200.

36  
37 Foa EB, Hembree EA, Cahill SP, et al. Randomized trial of prolonged exposure for posttraumatic stress  
38 disorder with and without cognitive restructuring: outcome at academic and community clinics. *J Consult*  
39 *Clin Psychol* 2005;73(5):953-964.

40  
41 Foa EB, Rothbaum BO, Riggs DS, et al. Treatment of posttraumatic stress disorder in rape victims : A  
42 comparison between cognitive-behavioral procedures and counseling. *J Consult Clin Psychol*  
43 1991;59(5):715-723.

44  
45 Friedman MJ, Marmar CR, Baker DG, et al. Randomized, double-blind comparison of sertraline and  
46 placebo for posttraumatic stress disorder in a Department of Veterans Affairs setting. *J Clin Psychiatry*  
47 2007;68(5):711- 720.

48  
49 Furmark T, Carlbring P, Hedman E, et al. Guided and unguided self-help for social anxiety disorder:  
50 randomized controlled trial. *Br J Psychiatry* 2009;195(5):440-447.

51  
52 Garcia-Palacios A, Hoffman H, Carlin A, et al. Virtual reality in the treatment of spider phobia: a controlled  
53 study. *Behav Res Ther* 2002;40:983–993.

54  
55 Giesen-Bloo J, van Dyck R, Spinhoven P, et al. Outpatient psychotherapy for borderline personality disorder  
56 randomized trial of schema-focused therapy vs. transference-focused psychotherapy. *Arch Gen Psychiatry*  
57 2006;63(6):649–658.

58  
59 Gilboa-Schechtman E, Foa EB, Shafran N, et al. Prolonged exposure vs dynamic therapy for adolescent  
60 PTSD: A pilot randomized controlled trial. *J Am Acad Child Adolesc Psychiatry* 2010;49(10):1034-1042.

Gray MJ, Schorr Y, Nash W, et al. Adaptive disclosure: An open trial of a novel exposure-based intervention  
for service members with combat-related psychological stress injuries. *Behav Ther* 2012;43:407–415.

Hellstrom K, Öst LG. One-session therapist directed exposure vs. 2 forms of manual directed self-exposure  
in the treatment of spider phobia. *Behav Res Ther* 1995;33:959–965.

- 1  
2  
3 Huband N, McMurran M, Evans C, et al. Social problem-solving plus psychoeducation for adults with  
4 personality disorder : pragmatic randomised controlled trial. *Br J Psychiatry* 2007;190:307-313.  
5
- 6 Joling KJ, van Hout HP, van't Veer-Tazelaar PJ, et al. How effective is bibliotherapy for very old adults with  
7 subthreshold depression? A randomized controlled trial. *Am J Geriatr Psychiatry* 2011;19(3):256-265.  
8
- 9 Katon WJ, Von Korff M, Lin EH, et al. The Pathways Study: a randomized trial of collaborative care in  
10 patients with diabetes and depression. *Arch Gen Psychiatry* 2004;61:1042–1049.  
11
- 12 Lee CW, Gavriel H, Drummond PD, et al. Treatment of PTSD: stress inoculation training with prolonged  
13 exposure compared to EMDR. *J Clin Psychol* 2002;58(9):1071–1089.  
14
- 15 Li M, Chen K, Mo Z. Use of qigong therapy in the detoxification of heroin addicts. *Altern Ther Health Med*  
16 2002;8:50–59.  
17
- 18 Lobbestael J, Arntz A, Cima M, et al. Effects of induced anger in patients with antisocial personality  
19 disorder. *Psychol Med* 2009;39(4):557–568.  
20
- 21 Lobbestael J, Arntz A. Emotional, cognitive and physiological correlates of abuse-related stress in  
22 borderline and antisocial personality disorder. *Behav Res Ther* 2010;48(2):116–124.  
23
- 24 Lobbestael J, Arntz A, Sieswerda S. Schema modes and childhood abuse in borderline and antisocial  
25 patients. *J Behav Ther Exp Psychiatry* 2005;36(3):240–253.  
26
- 27 Lobbestael J, Arntz A. The state dependency of cognitive schemas in antisocial patients. *Psychiatry Res*  
28 2012;198:452-456.  
29
- 30 Markowitz JC, Kocsis JH, Bleiberg KL, et al. A comparative trial of psychotherapy and pharmacotherapy for  
31 “pure” dysthymic patients. *J Affect Dis* 2005;89:167–175.  
32
- 33 Markowitz JC, Kocsis JH, Christos P, et al. Pilot study of interpersonal psychotherapy for dysthymic patients  
34 with secondary alcohol abuse or dependence. *J Nerv Ment Dis* 2008;196:468–474.  
35
- 36 Markowitz JC, Kocsis JH, Fishman B, et al. Treatment of depressive symptoms in human immunodeficiency  
37 virus-positive patients. *Arch Gen Psychiatry* 1998;55:452–457.  
38
- 39 McDonagh A, Friedman M, McHugo G, et al. Randomized trial of cognitivebehavioral  
40 therapy for chronic posttraumatic stress disorder in adult female survivors of childhood sexual abuse. *J*  
41 *Consult Clin Psycho* 2005;73(3):515-524.  
42
- 43 Monson CM, Schnurr PP, Resick PA, et al. Cognitive processing therapy for veterans with military-related  
44 posttraumatic stress disorder. *J Consult Clin Psychol* 2006;74(5):898–907.  
45
- 46 Nacasch N, Foa EB, Huppert JD, et al. The efficacy of prolonged exposure therapy for combat and terror-  
47 related PTSD: A randomized control comparison with treatment as usual. *Am J Psychiatry* 2011;72(9):1174-  
48 1180.  
49
- 50 Nadort M, Arntz A, Smit JH, et al. Implementation of outpatient schema therapy for borderline personality  
51 disorder with versus without crisis support of the therapist outside office hours: A randomized trial. *Behav*  
52 *Res Ther* 2009;47:961–973.  
53
- 54 Nadort M, van Dyck R, Smit JA, et al. Three preparatory studies for promoting implementation of outpatient  
55 schema therapy for borderline personality disorder in general mental health care. *Behav Res Ther*  
56 2009;47(11):938–945.  
57
- 58 Neylan TC, Lenoci M, Maglione ML, et al. The effect of nefazodone on subjective and objective sleep  
59 quality in posttraumatic stress disorder. *J Clin Psychiatry* 2003;64(4):445–450.  
60
- 61 Neylan TC, Lenoci M, Samuelson KW, et al. No improvement of post-traumatic stress disorder symptoms  
62 with guanfacine treat-ment. *Am J Psychiatry* 2006;163(12):2186–2188.  
63
- 64 Nordin S, Carlbring P, Cuijpers P, et al. Expanding the limits of bibliotherapy for panic disorder:  
65 Randomized trial of self-help without support but with a clear deadline. *Behav Ther* 2010;41(3):267-276.



1  
2  
3 Öst LG, Salkovskis PM, Hellstrom K. One-session therapist-directed exposure vs. Self-exposure in the  
4 treatment of spider phobia. *Behav Ther* 1991;22:407-422.

5  
6 Palic S, Elkit A. An explorative outcome study of CBT-based multidisciplinary treatment in a diverse group  
7 of refugees from a Danish treatment centre for rehabilitation of traumatized refugees. *Torture*  
8 2009;19(3):248-270.

9  
10 Perlis RH, Nierenberg AA, Alpert JE, et al. Effects of adding cognitive therapy to fluoxetine dose increase  
11 on risk of relapse and residual symptoms in continuation treatment of major depressive disorder. *J Clin*  
12 *Psychopharmacol* 2002;22:474-480.

13  
14 Reiss N, Lieb K, Arntz A, et al. Responding to the treatment challenge of patients with severe BPD: results  
15 of three pilot studies of inpatient schema therapy. *Behav Cog Psychother* 2014;42:355-367.

16  
17 Resick PA, Galovski TE, O'Brien Uhlmansiek M, et al. A randomized clinical trial to dismantle components  
18 of cognitive processing therapy for posttraumatic stress disorder in female victims of interper-sonal violence.  
19 *J Consult Clin Psychol* 2008;76(2):243-258.

20  
21 Resick PA, Nishith P, Weaver TL, et al. A comparison of cognitive-processing therapy with pro-longed  
22 exposure and a waiting condition for the treatment of chronic posttraumatic stress disorder in female rape  
23 vic-tims. *J Consult Clin Psychol* 2002;70(4):867-879.

24  
25 Schindler A, Hiller W. Therapieeffekte und Responseraten bei unipolar deperssiven Patienten einer  
26 verhaltenstherapeutischen Hochschulambulanz [Therapy effects and response rates of cognitive-bahavioral  
27 treatment for unipolar depressive patients in an outpatient clinic] *Zeitschrift für Klinische Psychologie und*  
28 *Psychotherapie: Forschung und Praxis* 2010;39:107-115.

29  
30 Schnurr PP, Friedman MJ, Engel CC, et al. Cognitive behavioral therapy for posttraumatic stress disorder in  
31 women: a randomized controlled trial. *JAMA* 2007;297(8):820-830.

32  
33 Schnurr PP, Friedman MJ, Foy DW, et al. Randomized trial of traumafocused group therapy for  
34 posttraumatic stress disorder: results li-om a department of veterans affairs eooperative study. *Arch Gen*  
35 *Psychiatry* 2003;60(5):481-489.

36  
37 Schnurr PP, Friedman MJ, Lavori PW, et al. Design of Department of Veterans Affairs Cooperative Study  
38 No. 420: Group treatment of posttraumatic stress disorder. *Control Clin Trials* 2001;22(1):74-88.

39  
40 Shelton RC, Haman KL, Rapaport MH, et al. A randomized, double-blind, active-control study of sertraline  
41 versus venlafaxine XR in major depressive disorder. *J Clin Psychiatry* 2006;67:1674-1681.

42  
43 Sieswerda S, Arntz A, Kindt M. Successful psychotherapy reduces hypervigilance in borderline personality  
44 disorder. *Behav Cog Psychotherapy* 2007;35(4):387-402.

45  
46 Sieswerda S, Arntz A, Mertens I, et al. Hypervigilance in patients with borderline personality disorder:  
47 Specificity, automaticity, and predictors. *Behav Res Ther* 2007;45(5):1011-1024.

48  
49 Spinhoven P, Giesen-Bloo J, van Dyck R, et al. Can assessors and therapists predict the outcome of long-  
50 term psychotherapy in borderline personality disorder? *J Clin Psychol* 2008;64(6):667-686.

51  
52 Spinhoven P, Giesen-Bloo J, van Dyck R, et al. The therapeutic alliance in schema-focused therapy and  
53 transference-focused psychotherapy for borderline personality disorder. *J Consult Clin Psychol*  
54 2007;75(1):104-115.

55  
56 Swanson LM, Favorite TK, Horin E, et al. A combined group treatment for nightmares and insomnia in  
57 combat veterans: A pilot study. *J Trauma Stress* 2009;22(6):639-642.

58  
59 Taylor DT, Meader N, Bird V, et al. Pharmacology subgroup of the National Institute for Health and Clinical  
60 Excellence Guideline Development Group for Depression in Chronic Physical Health Problems. Pharmacological interventions for people with depression and chronic physical health problems: Systematic review and meta-analyses of safety and efficacy. *Br J Psychiatry* 2011;198:179-188.

Van Asselt ADI, Dirksen CD, Arntz A, et al. Outpatient psychotherapy for borderline personality disorder: Cost effectiveness of schema-focused therapy versus transference focused psychotherapy. *Br J Psychiatry* 2008;192:450-457.



1  
2  
3 Van der Heiden C, Muris P, van der Molen HT. Randomized controlled trial on the effectiveness of  
4 metacognitive therapy and intolerance-of-uncertainty therapy for generalized anxiety disorder. *Behav Res*  
5 *Ther* 2012;50(2):100-109.  
6

7 Van Emmerik AAP, Kamphuis JH, Ernmelkamp PMG. Treating acute stress disorder and posttraumatic  
8 stress disorder with cognitive behavioral therapy or structured writing therapy: a randomized controlled trial.  
9 *Psychother Psychosom* 2008;77:93-100.

10 Vilhauer JS, Young S, Kealoha C, et al. Treating major depression by creating positive expectations for the  
11 future: a pilot study for the effectiveness of future directed therapy (FDT) on symptom severity and quality of  
12 life. *CNS Neurosci Ther* 2012;18(2):102-109.  
13

14 Watts BV, Landon B, Groft A, et al. A sham controlled study of repetitive transcranial magnetic stimulation  
15 for posttraumatic stress disorder. *Brain Stimul* 2012;5(1):38-43.  
16

17 Willemse GRWM, Smit F, Cuijpers P, et al. Minimal-contact psychotherapy for sub-threshold depression in  
18 primary care. *Br J Psychiatry* 2004;185: 416-421.  
19

20 Williams Jr JW, Katon W, Lin EH, et al. The effectiveness of depression care management on  
21 diabetes-related outcomes in older patients. *Ann Intern Med* 2004;140:1015-1024.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Lieb et al., BMJ Open submission Checklist of items to include when reporting a systematic review or meta-analysis

Section/topic	#	Checklist item	Reported on page #
<b>TITLE</b>			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
<b>ABSTRACT</b>			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
<b>INTRODUCTION</b>			
Rationale	3	Describe the rationale for the review in the context of what is already known.	4
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	
<b>METHODS</b>			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	n.a.
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	5
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	5
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	Suppl Tables 1 and 2

Section/topic	#	Checklist item	Reported on page #
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	5 and Fig. 1
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	5
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	n.a.
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	7
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	n.a.
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., $I^2$ ) for each meta-analysis.	n.a.
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	n.a.
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	n.a.
<b>RESULTS</b>			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	Fig. 1
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	n.a.
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome-level assessment (see Item 12).	n.a.
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group and (b) effect estimates and	n.a.

Section/topic	#	Checklist item	Reported on page #
		confidence intervals, ideally with a forest plot.	
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	n.a.
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	9
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression) (see Item 16).	n.a.
<b>DISCUSSION</b>			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., health care providers, users, and policy makers).	10f.
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review level (e.g., incomplete retrieval of identified research, reporting bias).	12
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	13
<b>FUNDING</b>			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	13